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Beborende bij bet proefschrift 
Characterization and regulation of Protocad/1erin-J: 
a novel gene for asthma 
1. De functie van Protocadberine-1 kan beter onderzocbt worden in cellen 
die gekweekt worden op Air Liquid Interface dan in cellen die 
gekweekt zijn in een monolayer (dit proefschrift). 
2. Protocadherine-1 is geen klassiek adhesiemolecuul, maar kan bet best 
worden gezien als een adhesiemolecuul met signaleringsmogelijkheden 
(dit proefschrifl:). 
3. De specificiteit van een antilicbaam voor immunohistocbemie of 
immunofluorescente kleuringen, zonder duidelijke positieve controle, 
kan slecbts met zekerbeid worden vastgesteld door middel van knock­
out muizen of knockdown experimenten (dit proefschrifl:). 
4. Het integreren van kennis over verschillende astmagenen, zoals PCDH I 
en SMAD3, kan leiden tot nieuwe inzicbten in de pathogenese van 
astma (dit proefschrift). 
5. Men moet niet de biologiscbe interpretatie van een gen-gen interactie 
verwarren met de interpretatie van een biologiscbe interactie tussen de 
eiwit-producten van twee genen. 
6. Mensen zijn objecten die gebrusht dienen te worden 
7. Een wetenscbapper is net zo afhankelijk van zijn toolbox als een 
timmerman. 
8. Op de racefiets beefl: ook de voorste van een peloton voordeel van bet 
fietsen in een groep (Bert Blocken, TU Eindhoven). 
9. Er wordt minder roofvis gevangen wanneer betzelfde kunstaas 
meermaals gepresenteerd wordt in bet betzelfde viswater. 
Henk Koning 21 november 2012 
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Chapter 1 
General Introduction and Aims of this Thesis 
CHAPTER I 
OVERVIEW 
In this thesis we aim to investigate the role of Protocadherin-1 in asthma pathogenesis. 
Therefore, this introduction first describes the general and clinical background of asthma and 
bronchial hyperresponsiveness (BHR) and the basic immunological background of asthma. 
Next the normal structure of airway wall is being discussed, followed by pathological features 
of asthma. Then the contribution of the inflammatory and structural changes of the airways to 
BHR will be discussed. Despite our current knowledge on the inflammatory and structural 
background of asthma, the exact mechanisms leading to BHR and asthma are unknown. 
Genetic studies are conducted in order to identify genes, the identity of which might inform 
on new mechanisms in asthma. Therefore in the last sections, the current genetic knowledge 
of BHR and asthma is described, and the family of protocadherins is introduced. Finally the 
rationale and the research questions of this thesis are presented. 
Asthma and Bronchial hyperresponsiveness 
Asthma is a common chronic disease of the airways affecting up to 300 million people 
world-wide, of different ages and ethnic backgrounds (1 ). Most of asthma has its onset in 
childhood (2). Asthma is characterized clinically by variable airway obstruction with a 
reversible component, and BHR triggered by smoke, cold air or allergens like house-dust mite 
(3). Asthma patients experience episodes of cough, wheezing and shortness of breath. 
Furthermore, airflow limitation may result in severe shortness of breath or induce 
exacerbations (4). Asthma is a phenotypically heterogeneous disease, which is preceded by 
varying patterns of wheezing in childhood (5). In addition, asthma has a marked variation in 
age at onset, severity and progression of the disease; some children with mild asthma can 
remit from the disease, while most of the severe asthmatic children still suffer from asthma in 
adulthood (6). Moreover, a proportion of asthmatics develops asthma at adult age, e.g. after 
menopause in females (7). 
To date, asthma is controlled by anti-inflammatory drugs such as glucocorticoids and 
leukotriene antagonists, whereas bronchoconstriction is effectively reduced with 
bronchodilators such as short- or long-acting �2-agonists and anticholinergics. Combination 
therapies of glucocorticoids and long acting �2-agonists may increase asthma control by 
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improving lung function and reducing exacerbations (8). For control of severe asthma, add-on 
therapy with anti-IgE can be considered (8). However, while these treatment options 
effectively suppress the symptoms of the disease, they fail to cure asthma. Furthermore, 
deterioration of clinical control may occur if these medications are discontinued (8). As the 
exact causes of asthma are unknown, a treatment option that can cure or prevent asthma has 
not yet been developed. 
One of the main characteristics of asthma is bronchial hyperresponsiveness (BHR). 
BHR is defined as a heightened responsiveness of the airways to a range of different non­
allergic stimuli, and is generally quantified by a provocative agent which induces a 20% fall 
(PC20) in the forced expiratory volume in one second (FEV1). Given the way BHR is 
expressed, BHR is associated with pre-challenge FEV 1• In the general population BHR has a 
population prevalence of up to 35%. BHR is present both in subjects with (symptomatic 
BHR) and without respiratory symptoms (asymptomatic BHR) (9). Asymptomatic BHR is a 
predictor for development of respiratory diseases, such as asthma ( I 0). 
BHR can be detected by administration of histamine or methacholine that act by 
stimulation of H 1- or muscarinic receptors of airway smooth muscle cells. Furthermore, 
indirect methods of determining BHR are available, such as exercise, exposure to cold air, 
hypertonic saline, mannitol, or adenosine-mono-phosphate (AMP) (I I). These indirect factors 
generally target immune cells like mast cells, which in tum release mediators like histamine, 
leukotrienes or prostaglandins stimulating airway smooth muscle contraction. Therefore, the 
indirect method of detecting BHR more closely reflects the inflammatory status of the 
airways, which is especially relevant when testing the effect of immunomodulating drugs on 
BHR (12, 13). In order to get a better understanding of the immunological background of 
BHR and asthma, a brief overview of the mechanisms in asthma is provided in the next 
section. 
Mechanisms in asthma: the interface of immunological and structural cells of 
the airway 
Immunological mechanisms in allergic asthma 
Most asthma is characterized by an underlying allergic response to inhaled innocuous 
substances called allergens. When allergens are inhaled and enter the airways, they are taken 
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up by dendritic cells (DCs). After DCs have taken up an antigen, they can migrate to the 
draining lymph nodes where naive T-cells reside, and present the antigen in the context of 
Major Histocompability Class (MHC)-II molecules. Migration of DCs towards the draining 
lymph nodes and antigen presentation by the DCs is regulated by the local tissue 
microenvironment, consisting of stromal cells like fibroblasts, endothelial and epithelial cells 
(14). House-dust mite allergens for example, activate pattern recognition receptors on airway 
epithelial cells. Epithelial cells in tum produce cytokines like TSLP, IL-33 and IL-25 that 
activate DCs, indicating that the airway epithelium plays a regulatory role in the induction of 
a response to inhaled antigens (15). Antigen-presenting DCs can either activate T-cells so that 
they differentiate towards effector phenotypes such as TH 1, T H2 and TH 17 cells, induce a 
tolerogenic or a regulatory T-cell phenotype. The outcome of the DC-T cell interaction in 
terms of T-cell phenotypes is a function of the DC activation state at the time of the cognate 
interaction and the cytokines present in the microenvironment (16). 
Once activated, TH I-cells produce interleukin (IL)-2, Tumor Necrosis Factor alpha 
(TNF-a), and interferon gamma (IFN-y), and are critical in the development of cell-mediated 
immunity, in which macrophages, natural killer cells (NK), and antigen-specific cytotoxic T­
lymphocytes work together to clear intracellular pathogens (16). 
T H2-cells produce a range of different interleukins such as IL-4, IL-5, IL-9, and IL-13. 
IL-4, together with IL-13, induces B-cells to produce lgE-antibodies against the selected 
antigen or allergen. Furthermore IL-4 induces maturation of mast cells, which start expressing 
specific receptors for these IgE molecules (FcERl-receptors). IL-5 specifically attracts 
eosinophils (17). IL-9 shares many features with IL-4, and assists in growth of T-lymphocytes 
and maturation of mast cells (18). In a sensitized individual, that has allergen-specific IgE 
antibodies, renewed exposure to an allergen will induce an allergic response. IgE-loaded mast 
cells become activated and degranulate, resulting in the immediate release of several pro­
inflammatory mediators like leukotrienes, and histamine, which trigger airways constriction. 
This early phase of the allergic reaction is characterized by increased vascular permeability 
and mucosal oedema ( 19). After 3-6 hours, this facilitates the entry of inflammatory cells, like 
T H2-cell and eosinophils into the lung parenchyma and airway epithelium. The activation of 
these cells and the subsequent release of pro-inflammatory cytokines, leukotrienes and 
damaging proteins like major basic protein, eosinophil cationic protein, and eosinophil 
peroxidase causes a second period of airway narrowing, the so-called late phase response to 
allergens (19, 20). TH 17-cells produce cytokines of the IL-17 family like IL-17 A and ILl  7-F. 
These cytokines act on a range of cell-types such as epithelial cells, endothelial cells and 
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fibroblasts, and induce the production of cytokines like IL-8 that subsequently attract 
neutrophils, amongst others assisting in the defense reaction against extracenular pathogens 
and fungi (21). 
Regulatory T-cens (Tregs) suppress the activity of effector T-cens and thereby 
maintain tolerance towards self-antigens and inhaled anergens (22). The induction of effector 
versus tolerogenic T-cen phenotypes is criticany dependent on the DC phenotype (immature 
and mature DCs) and the microenvironment at the time of antigen presentation, and 
determines the induction of tolerance versus immunity towards the inhaled anergen (23). In 
the absence of signals inducing DC maturation and expression of costimulatory markers, 
presentation of airway-derived antigens in the draining lymph nodes will result in regulatory 
T-cen (Treg) induction and tolerance. Tregs maintain tolerance in an antigen-specific fashion. 
Tregs can impair the capacity of DCs to prime naive T-cens towards effector phenotypes, 
thereby promoting the development of tolerogenic DCs. Furthermore, Tregs can directly 
inhibit the activity of effector T-cens (16). A dysbalance in Treg-activity may lead to a 
decreased suppressive activity and thereby to an increased inflammatory response (24). 
Asthma has originany been postulated to be a disease characterized by a T H2-type of 
inflammatory response (25). But as increased levels of ILi 7-A are detected in lungs of 
asthmatic patients compared to healthy controls, TH 17 effector cens may also play a role, and 
may explain the presence of low numbers of neutrophils in asthma (26). Furthermore, the 
presence of lower numbers of Treg cens in asthmatic patients compared to controls may lead 
to a decreased suppression of inflammatory cens and effector T-cens (22), thereby inducing 
an aggravated inflammatory response. Together with a continuing exposure to anergens, this 
may lead to a chronic inflammatory response in the airways. The chronic inflammatory 
response to seemingly harmless agents is in turn thought to contribute to the remode11ing of 
the asthmatic airways. To understand the process of airway remodelling in the asthmatic 
airways, the resident cens of the airway wan are described in the next section. 
Resident cells of the airway wall 
Under physiological conditions, the airway wan is lined by a pseudo-stratified 
epithelial cen boundary, protected by a mucous layer. This thin layer of viscous fluid is 
produced by secretory epithelial glands. Epithelial cens are located on top of the reticular 
basement membrane, a supportive structure consisting of collagen, laminin and proteoglycan 
molecules (27). The area below the basement membrane is ca11ed the lamina propria or 
submucosa, where fibroblasts are present. Fibroblasts are key players in the maintenance and 
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turnover of extracellular matrix components, the main constituents of the connective tissue of 
the submucosal layer (28). The submucosa is positioned in between the basement membrane 
and smooth muscle cell layer. Smooth muscle cells contribute to the contractility, and by 
producing extracellular matrix components, to the stability of the airway wall (29). This thesis 
focuses on two main cell-types in the airway wall important for asthma and BHR; the airway 
epithelium and airway smooth muscle cells. 
The airway epithelium is the first line of defence against invading pathogens, inhaled 
allergens or irritant agents, such as house-dust mite or smoke, respectively. It forms a physical 
barrier by maintaining a size- and ion selective impermeable connections between 
neighbouring epithelial cells, and by the production of a mucous layer. Epithelial cells 
connect to each other by tight-and adherens junctions, formed by adhesion molecules like 
Occludin, Claudins, JAMI, Zona-Occludins (ZO) 1, 2 and 3 (all of which localize to the tight­
junctions), and E-cadherin, �-catenin and plakoglobin (all of which localize to the adherens 
junctions) (30). Communication between cells takes place by gap junctions, which are build­
up by connexins, and facilitate the transport of molecules between cells (31) (Figure I). This 
thesis discusses the epithelial cells of the large airways, as these are studied most extensively, 
and are subject of our studies. In the airway epithelium of the large airways several cell types 
have been identified, which can be categorized into four main categories: basal, 
undifferentiated columnar, secretory and ciliated cells (32). Basal cells are strongly attached 
to the basement membrane by hemidesmosomes and integrins and thereby provide support for 
columnar or differentiated epithelial cells. Attachment of basal cells to the columnar or 
differentiated cells is facilitated by desmosomes (33). These structures consist of several 
integral membrane proteins like desmocollin and desmoglein, and adaptor molecules 
plakophilin and plakoglobin, which connect to intermediate filaments and thereby maintain 
the integrity of the airway epithelium (Figure I; (34)). Furthermore, basal cells are considered 
as the progenitor cell-type in the lung (35, 36). Secretory cells consist of mucous or goblet 
cells, and Clara cells, mainly secreting mucin granules, antimicrobial proteins and surfactant 
molecules (36, 37). Besides these cell types, a rare secretory cell exists in the large airway; the 
neuroendocrine-cell (NEC). NECs secrete surfactants, perform chemoreception (hypoxia 
sensing) and are involved in the regulation of lung maturation and growth (38, 39). Ciliated 
cells are the most prominent cell-type in the large airways and their coordinated ciliary 
beating results in mucociliary clearance. 
14 
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Figure 1: Structure of the airway epithelium 
Basal epithelial cells are connected by integrins ( a6P4) and hemidesmosomes to the basement 
membrane. Communication with columnar, ciliated or other differentiated cells takes place 
using gap-junctions consisting of connexins. Basal cells do not communicate with each other 
but provide strong support for differentiated cells. Basal cells are strongly connected to 
differentiated cells by desmosomes. Differentiated ( ciliated) cells communicate by gap­
junctions, and are strongly attached to each other by adherens junctions ( E-cadherin, P­
catenin and plakoglobin) and tight-junctions (Occludins, Claudins, JAMI, Z0-1, 2, 3 and 
Par3,6). Adaptor molecules like P-catenin (fi-cat), plakoglobin, Z0-1, 2, 3 and Par3, 6 
provide anchorage to the actin cytoskeleton. Adapted from Nawijn et al., Trends in 
Immunology, 201 I (30). 
Tight Junction: 
Adherens junction: 




Besides the physical barrier function, the airway epithelium has a sensory innate 
immune function. Airway epithelial cells can sense the presence of bacteria, viruses, fungi or 
components of these organisms, also known as pathogen-associated molecular patterns 
(PAMPs), via pattern recognition receptors, of which the family of Toll-like receptors (TLRs) 
are the most well-known receptors (40). Most of the TLRs can sense extracellular PAMPs, 
but some receptors can sense intracellular PAMPs as well by connection to endosomes (TLR-
3, 7 /8, 9) ( 41 ). TLR-receptor activation results in the expression of pro-inflammatory 
cytokines, like Interleukin-6 (IL-6), IL-8, TNFa, Interferons (42), TSLP (43), and chemokines 
like CCL5/RANTES (44). These pro-inflammatory cytokines can recruit inflammatory cells 
like macrophages and dendritic cells (DCs) for phagocytosis of bacteria and other pathogens, 
and T-cells for initiation of a T1-1 l or T 1-12-response. 
Furthermore the epithelium has an immune alarming function. Besides P AMPs, 
originating from infectious micro-organisms, pathogenic insults on the epithelium, injury or 
trauma of the airway epithelium can induce the release factors alarming the immune-system. 
These factors originate from the epithelial cells itself and are collectively called alarmins or 
damage associated molecular patterns (DAMPs) (45). Examples of endogenous epithelial 
alarm ins are high mobility group box 1 (HMGB I) ( 46) and IL-33 ( 47), which are both 
expressed in the nucleus of the airway epithelial cells. Release of these DAMPs can alert the 
immune system to tissue damage, and warn for possible infections, such that the appropriate 
immunological responses can be initiated ( 48). 
Finally, upon injury of the airway wall, epithelial cells increase the production of 
growth factors, like fibroblast growth factor (FGF)-2, insulin-like growth factor (IGF)-1, 
platelet-derived growth factor (PDGF), endothelin (ET)-1 and TGF-�2, and the expression of 
apically located growth factor receptors like Epidermal growth factor receptor (EGFR) (49). 
By secreting these factors and upregulating growth factor receptor expression levels, the 
epithelium communicates with fibroblasts in the submucosa. Under the influence of these 
factors, fibroblasts then become activated and may differentiate into myofibroblasts, which 
may migrate to the site of injury and secrete extracellular matrix components to assist in 
repair (50). Together with epithelial cells they constitute the epithelial mesenchymal trophic 
unit (EMTU). This EMTU and its EGF, FGF, and TGF receptor signalling between the 
epithelium and mesenchyme has been shown to be essential for embryonic lung development, 
and is reactivated upon airway epithelial injury (51 ). 
The airway smooth muscle (ASM) cells contribute to BHR and asthma due to their role 
in airways constriction. Under physiological conditions smooth muscle cell functions include 
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migration, differentiation and contraction. During lung development smooth muscle cells 
migrate and differentiate to add to the formation of the airway wall (52). Smooth muscle cells 
contain the contractile proteins actin, myosin, and tropomyosin. Smooth muscle cell 
contraction results from the interaction of actin filaments with myosin and tropomyosin 
filaments, in response to a change in calcium concentrations (53). In full-grown lungs of 
healthy persons, ASM is believed to perform peristalsis, a coordinated symmetrical 
contraction and relaxation of muscles, in order to assist in exhalation or mucous removal. 
Furthermore ASM is believed to promote blood flow and ventilation, to protect the peripheral 
lung and airway structure from toxic substances, and to stabilize the airways (54). Perhaps a 
novel role for ASMs lays in its communication with other cell-types of the lung; such as 
airway epithelial cells, where ASM can influence the repair process of the EMTU in mice by 
secreting the fibroblast growth factor IO (55). 
Remodelling of the airways in asthma 
Pathologically, asthma is characterized by airway inflammation and airway 
remodelling. The main inflammatory cells found in the airways of asthmatics are eosinophils 
and neutrophils, and to a lesser extent the mast cell (56), as was described before in the 
chapter regarding the basic inflammatory mechanisms in asthma. Remodelling refers to 
"modifications to the normal composition and structural organization of a certain tissue, 
which occurs in response to various mechanical or physiological forms of stress" (57). In 
asthma, airways remodelling is characterized by epithelial changes, subepithelial extracellular 
matrix deposition, smooth muscle hyperplasia and hypertrophy, increased numbers of 
activated fibroblasts, and vascular changes (57). The increase in extracellular matrix products, 
like collagen, fibronectin and tenascin produced by fibroblasts, can lead to thickening of the 
reticular basement membrane (RBM) (58-60). An increase in blood vessels in the asthmatic 
airways and increased microvascular permeability are also highly relevant mechanisms in the 
pathogenesis of asthma that are increasingly attracting attention (6 I). Changes to the airway 
epithelium and smooth muscle cell layer in asthma are described in detail below. 
What is wrong with the airway epithelium in asthma ? In the airway epithelium of 
asthma patients, several abnormalities have been observed when compared to healthy subjects 
that relate to structural differences, changes in epithelial cell-type, differences in cytokine and 
growth factor secretion, increased permeability and an aberrant responses to injury. As 
evidenced by histopathological studies, epithelial cells are shed from the basement membrane 
or disconnected from the basal epithelial cell-layer (62), and can be detected in sputum of 
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CHAPTER I asthmatic subjects as creola bodies (63). This epithelial desquamation has been under debate, as it might in part be the result of a sampling artefact (64), but stiII may reflect a weaker attachment of epithelial ceIIs to the basal ceIIs or basement membrane in asthmatic subjects (65). Besides epithelial denudation, lower expression levels of adhesion molecules have been described in asthmatic epithelium (66-68), altogether suggesting that the integrity of the epithelium is compromised. Interestingly, bronchial epithelial cultures of asthmatic subjects show a decreased barrier function in measurements of transepithelial electrical resistance (TEER) compared to healthy controls (67), and this increased permeability correlates with lower tight-junction molecule expression (69). As such, the observed decrease in adhesion molecule expression can be directly correlated to a decrease in epithelial barrier function of the asthmatic epithelium. Furthermore, ciliated airway epithelial ceIIs isolated from asthma patients exhibit a reduced ciliary beat frequency, especiaIIy in moderate and severe asthmatics (70) when compared to healthy controls. In the asthmatic epithelium there is an increase in goblet ceII numbers, mucin mRNA expression levels, and stored mucin (71 ). Together with the reduced clearance by ciliated ceIIs this could lead to excess of resident mucous in the airways, resulting in mucous plugs and more severe airway obstruction. These mucous plugs or casts can even result in fatal asthma attacks (72). In addition to these structural changes, asthmatic epithelial ceIIs intrinsicaIIy produce increased amounts of cytokines like IL-6 (specificaIIy by epithelial ceIIs of children) (73), IL-8 (68) or TSLP (adults) (74), thereby attracting higher numbers of inflammatory ceIIs l ike neutrophils, and maintaining a pro-inflammatory response. Asthmatic bronchial epithelial ceIIs also produce larger amounts of epidermal growth factor (EGF) (73), and TGF� (75), and upregulate expression levels of its receptors like EGFR (76). It is thought that the EMTU, important in lung development and repair, is abnormaIIy activated in asthma, due to the increase in the production of these growth factors and their receptors (77, 78). This might lead to a continuous repair of the airway epithelium. Epithelial repair upon injury consist of several processes, starting with migration of ceIIs to the site of injury, division of the migrated ceIIs and finaIIy differentiation towards either ciliated or secretory functional ceII types (79). The potential defects in repair and differentiation of the asthmatic airway epithelium may, in addition to the structural changes and increased inflammatory status of the epithelium, lead to a severely remodeIIed epithelium (80), as weII as an enhanced susceptibility to environmental chaIIenges such as viruses, aIIergens and cigarette smoke. 18 
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What is wrong with the airway smooth muscle in asthma ? In asthma, ASM has 
undergone changes that may contribute to airway remodelling and BHR. Several studies have 
identified an increase in airway smooth muscle cell number (hyperplasia) and an increase in 
cell size (hypertrophy) in the asthmatic airway (81-83). Increases in ASM cell size and cell 
number result in an overall increased ASM mass. ASM of asthmatic individuals produce 
increased amounts of extracellular matrix components like collagen I and perlecan, but 
decreased amounts of laminin-a l and collagen IV (84). In addition, increased amounts of 
ECM have been observed around ASM-bundles in the asthmatic airway (85). This increase in 
ECM, either coming from the ASM itself, or of other origin like epithelial cells and 
fibroblasts, can induce increased proliferation of airway smooth muscle cells (86). ASM cell 
proliferation can also be induced by several growth factors and inflammatory mediators from 
a range of cell types, like histamine of mast cells (86, 87). Furthermore it is hypothesized that 
ASM cells have an increased migratory phenotype, as in vitro an increase in migration is 
observed after stimulation with cyclic AMP mobilizing agents (88). In addition to the increase 
of airway smooth muscle mass in asthmatic subjects, the ASM also displays an enhanced 
sensitivity towards contraction (89). Significantly increased shortening of smooth muscle was 
detected in ASM of asthmatic subjects when compared to healthy subjects (90, 91 ). Overall, 
the increase in proliferation and migration of ASMs are thought to be a major contributor to 
the increase in ASM mass observed in asthmatic patients, and these may in combination with 
the increased ASM shortening, be very relevant to bronchoconstriction of the asthmatic 
airway. 
Contribution of inflammatory and structural components to BHR BHR is hypothesized to consist of a persistent and a variable component, based on 
results from studies with histamine, methacholine, and indirect measurements of BHR (13). 
The persistent component is generally thought to be caused by structural changes of the 
airways collectively referred to as airways remodelling (92), although some of these changes, 
like thickening of the reticular basement membrane, can be partially reversible (93). 
Additionally, the variable component of BHR is attributed to airways inflammation, and 
therefore considered to be reversible upon anti-inflammatory treatment (94). Controversy 




First the contribution of the inflammatory components to BHR is discussed. An 
allergic reaction to allergen exposure is characterized by an early and late phase response as 
described previously. When BHR was determined before and at 3h, 24h and 48h after the 
allergen exposure, it became evident that the development of the late asthmatic response was 
accompanied by an increase in BHR (four-fold decrease in PC20 to histamine) at 3 hours after 
allergen challenge (95, 96). The increase in BHR both preceded and highly correlated with the 
magnitude of the late-phase asthmatic response (95, 96). In addition, the BHR remained 
increased up to 48h after the allergen exposure, emphasizing the close correlation between 
BHR and the late asthmatic response (95). 
Second, when the inflammatory component in asthma is treated for longer periods (i.e. 
6-8 weeks, up to 2 years) by anti-inflammatory corticosteroid therapy, an improvement in 
bronchial hyperreactivity was detected in several studies (93, 97-101 ). In addition lower 
numbers of inflammatory cells like eosinophils and mast cells, and a decrease in RBM 
thickness were detected (93, 98). Mast cells can release several factors like biogenic amines 
(histamine, serotonin), cytokines, proteoglycans, and various proteases (chymase, tryptase, 
carboxypeptidase), thereby dilating vessels, and initiating innate immune functions and 
allergic reactions. ( 102). Eosinophils can secrete factors like major basic protein (MBP), 
eosinophilic cationic protein (ECP), eosinophil-derived neurotoxin (EDN) and eosinophil­
derived peroxidise (EPO) ( 103). These factors may contribute to the contractility and 
proliferation of ASM, and thereby to BHR (I  02, 104), or might damage the integrity of the 
airway epithelium. Therefore, their reduction after anti-inflammatory therapy is important for 
asthma treatment. Clinical studies specifically targeted at reducing eosinophil numbers (anti­
IL-5 therapy), decreased the number of exacerbations of asthma patients, but no improvement 
in BHR was observed ( 105, 106). The results from allergen challenges and anti-inflammatory 
therapies with corticosteroids suggest that the inflammatory component can make a large 
contribution to BHR, although further studies are needed into the exact role of the 
inflammatory cell types separately, like eosinophils, in asthma pathogenesis. 
Next the contribution of the structural components to BHR is being discussed. One 
important structural component is the airway smooth muscle, which may by its increase in 
mass and contractility in asthmatic subjects contribute to BHR. The exact mechanism by 
which the increase in ASM mass contributes to BHR is unclear. The contribution of smooth 
muscle to BHR has been estimated and these studies suggest that the increase in smooth 
muscle mass could be the most important factor for the increase in BHR in asthma (107), but 
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in vivo studies provide conflicting results. In a mouse model of asthma it was shown that the 
smooth muscle layer thickness explains a considerable part of methacholine 
hyperresponsiveness ( I  08). In contrast, Siddiqui and co-workers show that ASM mass does 
not correlate with BHR to methacholine, but that instead the numbers of ASM resident mast 
cells per mm2 ASM correlate with BHR (109). In addition, James et al show that 
degranulation of mast cells correlates with asthma severity ( I I 0). In human, Tsurikisawa and 
co-workers show a positive correlation of ASM thickness with BHR to histamine, but not 
with BHR to acetylcholine (111 ). As histamine and acetylcholine target different receptors on 
the ASMs to induce bronchoconstriction (respectively the H 1-Receptors and the muscarinic­
receptors ( I  I I)), different pathways leading to BHR may be the underlying cause for these 
differences. As mast cells can contribute to both cell proliferation, by histamine and tryptase 
release, and contraction of ASM (104), further studies are needed to identify the exact 
contribution of ASM and mast cells to BHR. 
Another structural component of the airway is the airway epithelium. As previously 
discussed, the airway epithelium has potential defects in its repair, differentiation and barrier 
function, but it can also contribute to BHR. In airway wall biopsy studies it is shown that 
eosinophilic infiltration in the airway epithelium correlates with an increase in opening of 
epithelial tight-junctions and intercellular spaces, suggesting that eosinophils contribute to 
epithelial damage (112), which in tum contributes to BHR (113). As the primary function of 
the airway epithelium is to act as a cellular barrier between the air and lower located cell 
types, such as smooth muscle cells, a damaged airway epithelium with a weaker barrier 
function may thereby increase the sensitivity of the airways to allergic sensitisation, and 
increase the accessibility of factors inducing BHR (114). Interestingly, anti-inflammatory 
corticosteroids not only reduce inflammation in the lung, but also may improve epithelial 
repair (115) and epithelial barrier function (1 I 6, 117), by upregulation of adhesion molecules. 
Thus by restoring the protective epithelial phenotype corticosteroids may also improve BHR. 
Overall, the changes to the smooth muscle cells and airway epithelium may in 
combination with subepithelial extracellular matrix deposition, basement membrane 
thickening, increased numbers of activated fibroblasts, and vascular changes, all contribute to 
BHR. Some of these structural changes to the airway may not only contribute to BHR and 
asthma, but are also thought be compensating measures of the airway towards the increasing 
bronchoconstriction or environmental insults. Evidence of airway remodelling as an increase 
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in reticular membrane thickness was already visible in children before asthma was clinica11y 
diagnosed (118). In addition, in patients who were in complete asthma remission airway 
remode11ing is retained, as evidenced by presence of a thickened reticular basement 
membrane (119). In an animal study, remodelling was even shown to be protective for airway 
hyperresponsiveness. Rats exposed to the model a11ergen ovalbumin initia11y developed 
remodelling, and an increase in airway hyperresponsiveness. After longer period of a1 ergen 
exposure more extrace11ular matrix was deposited, the number of goblet ce1 s and tissue 
eosinophils were sti11 increased, but the difference in hyperresponsiveness had disappeared 
(120). Furthermore in asthmatic patients the increase in reticular basement membrane 
thickness positively correlated with methacholine PD20 in asthma patients (121). Altogether, 
the stiffening of the airway wa11 by ECM deposition and increase in RBM thickness may 
thereby protect for the increase in ASM-contractility and hyperresponsiveness (122). 
Clearly, the recent research efforts have increased our understanding of the 
pathogenesis of asthma and BHR, and the possible functional consequences of airway 
inflammation and remodelling. Our increasing knowledge also gives insight into the extreme 
complexity of the disease. Therefore we carefu11y need to indentify the underlying 
mechanisms of inflammation, remodelling and the contribution and significance to BHR and 
asthma. In order to further understand the origins of asthma, first the genetic background of 
asthma and BHR has to be revealed. Genetic studies are able to identify novel asthma and 
BHR susceptibility genes and may provide new clues in dissecting the underlying 
mechanisms in asthma and BHR. Therefore, evidence for the genetic contribution to asthma, 
and the evidence for asthma genes will be reviewed below. 
Genetic background of asthma 
Twin studies have indicated that the susceptibility to develop asthma has a considerable 
heritable component (50-90%), but that environmental factors also contribute (123, 124). In 
order to identify the genomic regions which are co-inherited with asthma, several genome­
wide linkage studies were conducted. These studies typica11y used a set of polymorphic short 
tandem repeats or micro-satellite markers to cover the genome, and aimed to identify the 
genomic regions that may contain asthma susceptibility genes. Regions on chromosomes 
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2q22-33, 5q31.1-33, 6p2 l .3, 11 q 13, l 2q 14.3-24.1, I 3q 14, l 4q 11.2-13 and l 9q 13 were 
identified to contain susceptibility genes for asthma and related traits like BHR, total IgE­
levels and positive skin prick tests (125). To determine which genes are responsible for the 
linkage-signal identified at these chromosomes, classical candidate gene association studies 
were performed. Candidate genes were selected based on their known function and potential 
involvement in asthma pathogenesis (126). Chromosome 5 for example, a region identified by 
a Dutch linkage study (127), harbours several genes in immune pathways (IL-4, IL- 13; 5q31) 
and bronchodilator response (B2-adrenergic receptor (ADRB2), 5q33) (128) that are 
associated with asthma and reported by many studies (Figure 2). In addition, single nucleotide 
polymorphisms (SNPs) of genes in well known pathways, such as the TLR-pathway, were 
shown to associate with asthma ( 129), but are reported by fewer studies (Figure 2). 
Altogether, a large number of candidate genes for asthma are identified using these candidate 
gene association studies ( I 30) (see Figure 2). 
Figure 2: Asthma candidate genes 
Replicated asthma candidate genes are shown and sorted according to their number of 
publications. Adapted from Weiss, Raby and Rogers, Asthma genetics and genomics 2009, 













































The advantages of candidate gene studies are that they are powerful studies in which 
novel gene asthma associations can be quickly identified using relatively small populations, 
while the required prior knowledge on the genes and pathways to investigate may induce a 
study bias and are disadvantageous. Furthermore, identified associated SNPs are not always 
replicated (77). Therefore, unbiased approaches are needed in order to reveal new genes for 
asthma. These approaches are chromosome or genome-wide screens, such as positional 
cloning and genome-wide association studies (GW AS). These screens employ a dense set of 
SNPs to cover a genomic region previously linked to asthma (positional cloning) or the 
complete genome (GW AS). Although these studies can identify previously unknown disease 
associated genes, they have lower power due to the number of tests that need to be performed, 
and thus require large (replication) populations ( 131 ). Still, these studies identified several 
novel susceptibility genes as summarized in Table I. 











PLAUR / UPAR 
Expression / Proposed function 
Smooth muscle, embryonic mesenchymal cells, 
Epithelium 
Brain, Immune cells (peptidase of chemokines) 
Immune related tissues 
A isoform predominantly in smooth muscle, 
B isoform predominantly in epithelium 
Immune cells; epithelium 
Undifferentiated lymphocytes 
Regulates splicing of CD45 of T-cells 
PBMCs, Epithelium 
PCDH1 Brain, Epithelial cells in lung 
Genome Wide Association Studies 
Gene(s) 
ORMDL3/GSMDL 











Expression / Proposed function 
Endoplasmatic Reticulum of several cells 
GSDML: Epithelium 
Range of immune cells, epithelium 
IL-33 receptor 
T-cells (activation protein) 
/ Epithelium (cytokine) 
Stored in a.o smooth muscle and epithelium 
TF for hematopoietic stem and prog. cells 
Constitutively expressed (DNA repair - Interleukin) 
Lymphocytes and several tissues 
Lymphocytes and several tissues 
cAMP signaling - Regulates a.o.ASM contractility 
human vascular smooth muscle cells 
Brain, Immune cells, rat branch.epithelium 
Peptidase of chemokines 
Chromosome Study 
20p1 3 (1 32) 
2q1 4  (1 33) 
1 3q1 4 (1 34) 
7p1 4 (1 35) 
6p21 (1 36) 
5q33 (1 37) 
1 2q24 ( 138) 
1 9q1 3 (1 39) 
5g31 .3 (1 40) 
Chromosome Study 
1 7q21 ( 141 - 144) 
2q1 2  (1 42-145) 
5q22 (1 45, 1 46) 
9p24 (1 45) 
6q23 (1 45) 
5q31 . 1  (1 47) 
6p21 .3 ( 142, 1 44, 1 46, 1 47) 
6p33 ( 148) 
5q1 2 (1 49) 
5q33 (1 50) 
2q1 2.3-q14.2 ( 1 50) 
General Introduction 
PRNP Brain, Immune cells (T and B-cells, DCs) 20pter-p1 2 ( 1 50) 
SMAD3 TGFb signalling, several cell-types 1 5  (1 42) 
IL2RB T-cell differentiation (TH 1 , T H2, TH 1 7) 22 (1 42) 
Near GATA3 (1Mb) Regulator of T H2-cell differentiation 1 0p1 4 (1 46) 
Near IKZF4 or EOS (2kb) Differentiation of T-reg cells 1 2q 13  ( 1 46) 
USP38-GAB1 Immune cells (cytokine signalling) 4q31 (1 46) 
IL6R Hepatocytes and several leukocytes 1 q21 .3 (1 43) 
Near LRRC32 Activated T reg cells 1 1 q1 3.5 ( 1 43) 
PYHIN1 or /FIX Leukocytes, lung tissues 1 q23 ( 1 44) 
ATPAF1 Range of cell-types, purinergic (ATP)-signaling 1 p31 -36 (1 51 ) 
DENND1B Natural killer cells and dendritic cells 1 q31 .3 (1 52) 
PERLD1 GPl-anchors for T-cell stimulation 1 7q1 2 (1 53) 
TLE4 B-cell differentiation 9g21 (1 54) 
PBMCs = Primary Blood Mononuclear Cells; DC = Dendritic Cell; TF = Transcription factor; cAMP = cyclic 
Adenosine Mono Phosphate; ASM = airway smooth muscle; GP/ = glycosylphoplzatidylinositol. 
Classical candidate studies have identified association of many genes in immune 
pathways. Interestingly, many of the novel genes identified by positional cloning and GWAS 
are expressed at the interface of structural ce11s of the airway, such as the airway epithelium, 
and the innate or adaptive immune system. (PIAUR, NPSRJ, HIA-G, PCDHJ, TSLP, Ill RLJ, IL-33, SMAD3). These results suggest that, besides the immune system the airway 
epithelium plays an important role in asthma pathogenesis, and that dysfunction of the 
epithelial ce11s is in part due to intrinsic heritable genetic differences. Moreover, release of 
inflammatory mediators from the airway epithelium, such as TSLP and IL-33, may 
subsequently activate the immune system, amongst others through the IL-33-receptor 
ILIRL I, leading to differentiation and activation of DCs and TH2-ce11s, while IL-33 pathway 
activation in mast ce11s can result in degranulation of these ce11s, and thereby contribute to 
bronchial hyperresponsiveness (155). Also genes involved in non-a11ergic non-immune 
pathways may contribute to asthma pathogenesis. Recent functional studies on ADAM33 
indicate involvement of smooth muscle and vascular remodelling pathways in asthma. In 
addition, the 17q.21 locus (ORMDL3 I GSDML) is specifica11y associated with childhood­
onset asthma. ORMDL3 encodes for a protein that localizes to the endoplasmatic reticulum 
(ER), its dysfunction is thought to induce cellular stress (156), and may therefore be a novel 
genetic cause of asthma ( 126). 
Over time, more and more knowledge regarding the genetic background of asthma is 
being obtained. But a large number of discovered asthma genes have not been replicated and 
most genetic variants only explain a small proportion of the genetic heritability of asthma 
( 130). The lack of replication of some asthma genes may be the result of a difference in the 
asthma-phenotype used in the different populations. Furthermore, as asthma is characterized 
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by an interplay of genetic and environmental factors (157), gene-gene and gene-environment 
interactions will also have to be determined. These gene-gene and gene-environment 
interactions may account for part of the "missing" heritability (158). Interestingly, gene-gene 
interaction analysis of genes annotated to the TLR-pathway and regulatory T-cell function, 
resulted in significant associations of combinations of SNPs with asthma or atopy, while the 
identified SNPs did not always display a significant association with asthma or atopy in a 
single-SNP association analysis ( 129, 159). These results suggest that indeed genetic effects 
may be missed when these gene-gene interactions are not taken into account. 
Environmental factors may influence the risk for asthma development. Examples are: 
endotoxin exposure (160), either due to day-care attendance, or living in a farming 
environment (161 ); air-traffic related pollution, due to particulate matter (PM(2.5)), soot and 
nitrogen dioxide (N02)) (162); cigarette smoke exposure, either intrauterine or environmental 
(163); and exposure to allergens from house-dust mite, dogs, cats ( 163), and farm living 
( I 61 ). Interestingly, results from a recent study of day-care attendance suggest that subjects 
with one TLR2-genotype (T-allele) may be protected against atopic wheezing development at 
day-care, while carriers of the other TLR2-genotype (AA-alleles) may be protected for atopic 
wheezing development when not attending day-care. Thus different environments may cause 
opposing effects on atopic wheezing development with a difference in genotype (1 64), 
pointing towards the complexity of gene-environment interactions. Therefore it is important 
to not only characterize the disease phenotype, but also the environmental exposures in great 
detail, and test for gene-environment interactions in large populations in order to determine 
the effect of both genetic variation and the environment, as well as their interactions, on 
asthma development. 
As the gene-gene and gene-environment interactions are extremely complex in 
asthma, it is similarly complex to understand how these statistical associations can be 
translated into altered biology in structural components of the lung, such as the airway 
epithelium. Therefore, functional studies are required, in which the gene function and the 
influence of environmental exposures on gene function is investigated, as well as the 
functional role of asthma associated SNPs in the gene, in order to further understand the role 




The Protocadherin gene family 
This thesis will focus on one of the novel susceptibility genes for BHR identified by 
positional cloning: Protocadherin-1 (PCDHJ) ((140), Table I). Protocadherins are a subfamily 
of the cadherin superfamily of adhesion molecules, and were ini tially identified in brain tissue 
(I 65). The Protocadherin-subfamily currently consists of 65 members and thereby is the 
largest subfamily of the cadherin superfamily (I 66). The protocadherin family can be further 
subdivided in clustered (53 members, consisting of a, �' and y-pcdh) and non-clustered 
protocadherins (12 members, consisting of 81 and 82-protocadherins) (Figure 3) (166). Most 
protocadherins show expression in the central nervous system, but some non-clustered 
Protocadherins also show expression in other organs, such as kidney and lung ( I  67). PCDH I 
is a member of the 8 I -subfamily of non-clustered protocadherin genes, which further consists 
of PCDH7, PCDH9 and PCDHJ JX/Y (168). 81-protocadherin gene-variants are associated 
with several diseases: PCDH7 SNPs act as prognostic factors for the overall survival in early 
stage non-small-cell lung cancer (169) and a PCDHJJX polymorphism associate with 
susceptibility to late-onset Alzheimer's disease (170). Furthermore PCDH9 protein expression 
was decreased in human cerebral glial tumors, which suggests that PCDH9 is an independent 
biological marker for survival of patients with gliomas ( I  7 I). 
8 1-protocadherins are characterized by the presence of seven extracellular cadherin 
repeats (ECs), and three evolutionary conserved motifs in their intracellular tail (CMI-3) 
( I 66). The protein has been implicated in tissue formation by cell-sorting ( 172), and displays 
weak adhesion activity ( I 65). Classical cadherins like E-cadherin, typically mediate adhesion 
through homotypic engagement of the first EC-domains (EC I), which is dependent on 
calcium-ions and tryptophan residues (173). The adhesive properties of protocadherins are 
generally weaker than that of classical cadherins (165), as protocadherins do not contain the 
conserved tryptophan residues in their EC I -domains (17 4 ). Adhesion of protocadherins may 
form by other mechanisms such as binding of calcium-ions by polar amino acids at the N­
terminus of the EC I (175), or may even not be its main function. Most 81-protocadherins 
encode multiple isoforms, including one with and one without conserved CM l -3 motifs (168). 
The presence of these evolutionarily conserved signalling motifs in the intracellular domains 
may point towards a function for 81-protocadherins in intracellular signal transduction (168). 
Indeed, the adaptor molecule protein phosphatase I alpha (PP I a) was shown to bind to the 
CM3-domain, which indicates that at least one of the protocadherin isoforms participate in 
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intracellular signal transduction (176). Overall, protocadherins are involved in different 
diseases and may participate in cell-cell adhesion or intracellular signalling processes, but 
their functions remain to be elucidated. 
Figure 3: Phylogenetic tree of the Protocadherin subfamily of adhesion molecules and 
related molecules 
A phylogenetic tree is constructed based on the intracellular sequences of representative 
protocadherins and related molecules. The protocadherin sub/ amity can be categorized into 
clustered and non-clustered (<51 and b2-PCDHs, PCDH12, PCDH20) protocadherins, also 
referred to as cadherin-related 1 cluster (Cr-1 ). PCDH20 has high similarity with the 
extracellular cadherin domains (EC) of <51 -pcdhs, but has only a short intracellular tail and is 
therefore not considered a <51-PCDH, but named bO-PCDH (166). PCDH15, FAT, FAT-like, 
and Dachsous (DCHS) cadherin molecules are large molecules and contain 1 1  up to 34 EC­
domains, while CDHR5/Mu-PCDH only contains 4 EC-domains. CDHRJ/PCDH21, CDHR2 
IPCDH24, CDHR5/Mu-PCDH, and PCDH15 are very distant from protocadherins and are 
therefore named Cadherin-related (CDHR) (166), and clustered in the cadherin-related 2 
(Cr-2) or 3 (Cr-3) clusters, together with CDHR23/CDH23 (Cr-2), and CDHR3/CDH28, and 
FAT-like molecules (Cr-3). Adapted from Redies et al. ,  2005 (168); and Hulpiau and Van 
Roy, 2009 ( 166 ). 
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Aims of this thesis In this thesis we aim to investigate the role of Protocadherin- 1 in asthma pathogenesis. As protocadherins are involved in ce11-ce11 adhesion, and the epithelial barrier in asthma is compromised, we hypothesize that PCDHI dysfunction leads to increased susceptibility of the bronchial epithelium to environmental insults, like house-dust mite allergen and environmental tobacco smoke exposure, which leads to a decreased epithelial integrity and attenuated repair responses, which contribute to asthma and BHR development. Therefore, we investigate the genetics, expression, regulation and function of Protocadherin- I .  In chapter 2, we describe the identification of this gene as a novel gene for BHR and asthma. Previously the chromosomal region 5q3 1 -33 was linked to BHR ( 1 27). We aimed to identify which gene on 5q3 l -33 contributes to the observed linkage signal, and describe the genetic variation of this gene in the Dutch population and its association with BHR and asthma. We then replicate these findings in different populations from the Netherlands, the United Kingdom and the United States. We subsequently investigate PCDHI mRNA and protein expression in the airways. In chapter 3, we aim to identify whether PCDHJ polymorphisms that were previously found to be associated with BHR and asthma, also associate with eczema. As PCDH I is expressed in skin epithelium as well ( 1 77), we aimed to investigate whether asthma and eczema have a common genetic background that could in part be attributed to variation in PCDHJ . In chapter 4 we aim to describe PCDH I mRNA and protein isoforms and their expression levels in freshly isolated and cultured Primary Bronchial Epithelial Cells (PBECs) of asthma patients. Furthermore we aimed to investigate whether PCDHI expression was regulated by airway epithelial mucociliary differentiation ex vivo. In chapter 5, we aimed to test whether Pcdhl expression in vivo is regulated by relevant environmental exposures. To this end, we first established the expression levels of Pcdh I in mouse lung under basal conditions. Next, we assessed the regulation of Pcdh I expression by environmental challenges that induce airway hyperresponsiveness, such as house dust mite and cigarette smoke exposure. In chapter 6 we aimed to functionally characterize Pcdh I proteins, by investigating the subcellular localization of the different PCDH I protein isoforms in bronchial epithelial cells. Furthermore we tested whether interactions of the PCDHI protein isoforms with a candidate interacting protein SMAD3 ( 1 78), that was recently also identified as a novel asthma gene and is expressed in airway epithelial cells ( 1 42). 
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Finally, in chapter 7, the previous chapters are discussed and suggestions for future 
research are given. 
REFERENCES 
I .  Masoli M, Fabian D, Holt S, Beasley R ,  Global Initiative for Asthma (GINA) Program. The global burden 
of asthma: Executive summary of the GINA dissemination committee report. Allergy. 2004;59(5):469-78. 
2. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, et al . A longitudinal, population­
based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003;349(1 5) : 1 4 1 4-22. 
3. Lemanske RF,Jr, Busse WW. Asthma: Clinical expression and molecular mechanisms. J Allergy Clin 
lmmunol. 20 1 0; 1 25(2 Suppl 2):S95- 1 02. 
4. Spahn JD, Covar R. Clinical assessment of asthma progression in children and adults. J Allergy Clin 
lmmunol. 2008; 1 2 1 (3):548,57; quiz 558-9. 
5. Savenije OE, Granell R, Caudri D, Koppelman GH, Smit HA, Wijga A, et al. Comparison of childhood 
wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA. J Allergy Clin Immunol. 20 1 l ;  
1 27(6): 1 505, 12.e 1 4. 
6. Martinez FD. Development of wheezing disorders and asthma in preschool children. Pediatrics. 2002; 1 09(2 
Suppl):362-7. 
7. van den Berge M, Heijink HI, van Oosterhout AJ, Postma OS. The role of female sex hormones in the 
development and severity of allergic and non-allergic asthma. Clin Exp Allergy. 2009;39( 1 0): 14 77-8 1. 
8. Http://www.ginasthma.org/pdf/GINA_Report_20 I 0.pdf [Internet]. 
9 .  Jansen DF, Timens W, Kraan J ,  Rijcken B ,  Postma OS. (A)symptomatic bronchial hyper-responsiveness 
and asthma. Respir Med. 1 997;9 I (3): 1 2 1 -34. 
I O. Rage E, Siroux V, Le Moua) N, Pin I, Kauffmann F. Re: Are asymptomatic airway hyperresponsiveness and 
allergy risk factors for asthma? A longitudinal study. Eur Respir J .  2009;33( I ) :2 1 8-9. 
1 1 . Yan Den Berge M, Meijer RJ, Kerstjens HA, de Reus DM, Koeter GH, Kauffman HF, et al . PC(20) 
adenosine 5'-monophosphate is more closely associated with airway inflammation in asthma than PC(20) 
methacholine. Am J Respir Crit Care Med. 200 I ;  1 63(7): 1 546-50. 
1 2. van den Berge M, Kerstjens HA, Meijer RJ, de Reus OM, Koeter GH, Kauffman HF, et al . Corticosteroid­
induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in 
airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med. 2001 ; 
1 64(7): 1 1 27-32. 
1 3 . Busse WW. The relationship of airway hyperresponsiveness and airway inflammation: Airway 
hyperresponsiveness in asthma: Its measurement and clinical significance. Chest. 20 1 0; 1 38(2 Suppl):4S-
1 0S.  
14. Svensson M,  Kaye PM. Stromal-cell regulation of dendritic-cell differentiation and function. Trends 
lmmunol. 2006;27( 1 2):580-7. 
1 5 .  Hammad H, Lambrecht BN.  Dendritic cells and airway epithelial cells at the interface between innate and 
adaptive immune responses. Allergy. 20 1 1 ;66(5):579-87. 
1 6. Palomares 0, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of treg in immune regulation of 
allergic diseases. Eur J lmmunol . 20 I 0;40(5): 1 232-40. 
1 7 . Oliphant CJ, Barlow JL, McKenzie AN. Insights into the initiation of type 2 immune responses. 
Immunology. 20 1 1 ;  1 34(4) :378-85. 
1 8 . Li H, Rostami A. IL-9: Basic biology, signaling pathways in CD4+ T cells and implications for 
autoimmunity. J Neuroimmune Pharmacol. 201 0;5(2): 1 98-209. 
1 9. Minai-Fleminger Y, Levi-Schaffer F. Mast cells and eosinophils: The two key effector cells in allergic 
in flammation. lnflamm Res. 2009;58( 1 0) :63 1 -8. 
20. O'Byrne P. Asthma pathogenesis and allergen-induced l ate responses. J Allergy Clin Immunol. 1 998; 
1 02(5):S85-9. 
2 1 .  Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL- 1 7  family cytokines and the expanding diversity of 
effector T cell lineages. Annu Rev Immunol. 2007;25:82 1 -52. 
22. Robinson OS. The role of the T cell in asthma. J Allergy Clin lmmunol. 201 0; 1 26(6): 1 08 1 -9 1 .  
23. Enk AH. Dendritic cells i n  tolerance induction. Immunol Lett. 2005;99( l) :8- 1 1 .  
24. Venuprasad K, Kong YC, Farrar MA. Control of Th2-mediated inflammation by regulatory T cells. Am J 
Pathol. 20 I O; 1 77(2):525-3 1 . 
30 
General Introduction 
25. Lloyd CM, Hessel EM. Functions of T cells in asthma: More than just T(H)2 cells. Nat Rev lmmunol. 
20 I O; I 0( 1 2):838-48. 
26. Durrant OM, Metzger OW. Emerging roles of T helper subset<; in the pathogenesis of asthma. Immunol 
Invest. 20 1 0;39(4-5):526-49. 
27. Laitinen A, Laitinen LA. Airway morphology: Epithelium/basement membrane. Am J Respir Crit Care 
Med. 1 994; 1 50(5 Pt 2):S 1 4-7. 
28. Westergren-Thorsson G, Larsen K, Nihlberg K, Andersson-Sjoland A, Hallgren 0, Marko-Varga G, et al. 
Pathological airway remodelling in inflammation. Clin Respir J .  20 I 0;4 Suppl I :  1 -8. 
29. Bergeron C, Boulet LP. Structural changes in airway diseases: Characteristics, mechanisms, consequences, 
and pharmacologic modulation. Chest. 2006; 1 29(4): 1 068-87. 
30. Nawijn MC, Hackett TL, Postma OS, van Oosterhout AJ, Heijink IH. E-cadherin: Gatekeeper of airway 
mucosa and allergic sensitization. Trends lmmunol. 20 1 1 ;32(6):248-55. 
3 1 .  Wiszniewski L, Sanz J ,  Scerri I ,  Gasparotto E, Dudez T, Lacroix JS, et al. Functional expression of 
connexin30 and connexin3 I in the polarized human airway epithelium. Differentiation. 2007;75(5) :382-92. 
32. Crystal RG, Randell SH, Engelhardt JF, Voynow J, Sunday ME. Airway epithelial cel ls : Current concepts 
and challenges. Proc Am Thorac Soc. 2008;5(7):772-7. 
33. Montefort S, Baker J, Roche WR, Holgate ST. The distribution of adhesive mechanism:- in the normal 
bronchial epithelium. Eur Respir J. 1 993;6(9): 1 257-63. 
34. Giepmans BN, van ljzendoom SC. Epithelial cell-cell junctions and plasma membrane domains. Biochim 
Biophys Acta. 2009; 1 788(4):820-3 1 .  
35. Hackett NR, Shaykhiev R, Walters MS, Wang R ,  Zwick RK, Ferris B ,  et al . The human airway epithelial 
basal cell transcriptome. PLoS One. 20 I I ;6(5):e 1 8378. 
36. Knight DA, Holgate ST. The airway epithelium: Structural and functional properties in health and disease. 
Respirology. 2003 ;8(4):432-46. 
37. Jeffery PK, Li D. Airway mucosa: Secretory cells, mucus and mucin genes. Eur Respir J. 1 997; 1 0(7): 1 655-
62. 
38. Young LR, Brody AS, Inge TH, Acton JD, Bokulic RE, Langston C, et al . Neuroendocrine cell distribution 
and frequency distinguish neuroendocrine cell hyperplasia of infancy from other pulmonary disorders. 
Chest. 20 1 1 ; 1 39(5) : 1 060-7 1 .  
39. Linnoila RI.  Functional facets of the pulmonary neuroendocrine system. Lab Invest. 2006;86(5):425-44. 
40. Muir A, Soong G, Sokol S, Reddy B, Gomez MI,  Yan Heeckeren A, et al. Toll-like receptors in normal and 
cystic fibrosis airway epithelial cells. Am J Respir Cell Mot Biol. 2004;30(6):777-83. 
4 1 .  Yareille M, Kieninger E, Edwards MR, Regamey N.  The airway epithelium: Soldier in the fight against 
respiratory viruses. Clin Microbiol Rev. 20 1 1 ;24( 1 ):2 1 0-29. 
42. Chen K, Xiang Y, Yao X, Liu Y, Gong W, Yoshimura T, et al. The active contribution of toll-like receptors 
to allergic airway inflammation. Int Immunopharmacol. 20 1 1 ;  1 1  ( I  0) : 1 39 1 -8. 
43. Kato A, Favoreto S,Jr, Avila PC, Schleimer RP. TLR3- and Th2 cytokine-dependent production of thymic 
stromal lymphopoietin in human airway epithelial cells .  J lmmunol. 2007; 1 79(2): I 080-7. 
44. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, 
infection and cancer. Int lmmunopharmacol. 2007;7( 1 0): 1 27 1 -85. 
45. Bianchi ME. DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol. 2007; 
8 1 ( 1 ): 1 -5 .  
46. Ferhani N, Letuve S, Kozhich A, Thibaudeau 0, Grandsaigne M, Maret M, et al . Expression of high­
mobility group box I and of receptor for advanced glycation end products in chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med. 20 1 0; 1 8 1  (9):9 1 7-27. 
47. Moussion C, Ortega N, Girard JP. The IL- I -like cytokine IL-33 is constitutively expressed in the nucleus of 
endothelial cells and epithelial cells in vivo: A novel 'alarmin'? PLoS One. 2008;3( 1 0) :e333 1 .  
48. Kono H ,  Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8(4):279-
89. 
49. Holgate ST, Davies DE, Puddicombe S, Richter A, Lackie P, Lordan J, et al. Mechanisms of airway 
epithelial damage: Epithelial-mesenchymal interactions in the pathogenesis of asthma. Eur Respir J Suppl. 
2003; 44:24s-9s. 
50. Morishima Y, Nomura A, Uchida Y, Noguchi Y, Sakamoto T, Ishii Y, et al. Triggering the induction of 
myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir Cell Mo! Biol. 200 I ;24( I ) : 1 - 1 1 .  
5 1 .  Warburton D, Schwarz M, Tefft D, Flores-Delgado G ,  Anderson KO, Cardoso WY. The molecular basis of 
lung morphogenesis. Mech Dev. 2000;92( 1 ) :55-8 1 .  
52. Gerthoffer WT. Migration of airway smooth muscle cells. Proc Am Thorac Soc. 2008;5 ( 1 ) :97- 1 05.  




54. Mitzner W. Airway smooth muscle: The appendix of the lung. Am J Respir Crit Care Med. 2004; 
1 69(7):787-90. 
55. Volckaert T, Dill E, Campbell A, Tiozzo C, Majka S, Bellusci S, et al . Parabronchial smooth muscle 
constitutes an airway epithelial stem cell niche in the mouse lung after injury. J Clin Invest. 
20 1 1 ; 1 2 1 ( 1 1 ):4409- 1 9. 
56. Fahy JV.  Eosinophilic and neutrophilic inflammation in asthma: Insights from clinical studies. Proc Am 
Thorac Soc. 2009;6(3):256-9. 
57. AI-Muhsen S, Johnson JR, Hamid Q. Remodeling in asthma. J Allergy Clin Immunol. 201 1 ; 1 28(3):45 1 ,62; 
quiz 463-4. 
58. Bergeron C, AI-Ramli W, Hamid Q. Remodeling in asthma. Proc Am Thorac Soc. 2009;6(3):30 1 -5 .  
59 .  Proud D, Leigh R. Epithelial cells and airway diseases. Immunol Rev. 201 1 ;242( 1 ): 1 86-204. 
60. Tsartsali L, Hislop AA, McKay K, James AL, Elliot J, Zhu J, et al . Development of the bronchial epithelial 
reticular basement membrane: Relationship to epithelial height and age. Thorax. 20 1 1 ;66(4):280-5. 
6 1 . Zanini A, Chetta A, Imperatori AS, Spanevello A, Olivieri D. The role of the bronchial microvasculature in 
the airway remodelling in asthma and COPD. Respir Res. 2010;29 ; 1 1 : 1 32. 
62. Boulet LP, Laviolette M, Turcotte H ,  Cartier A, Dugas M, M alo JL, et al . Bronchial subepithelial fibrosis 
correlates with airway responsiveness to methacholine. Chest. 1 997; 1 1 2( 1 ):45-52. 
63. Yamada Y, Yoshihara S, Arisaka 0. Creola bodies in wheezing infants predict the development of asthma. 
Pediatr Allergy Immunol. 2004; 1 5(2): 1 59-62. 
64. Ordonez C, Ferrando R, Hyde OM, Wong HH, Fahy JV. Epithelial desquamation in asthma: Artifact or 
pathology? Am J Respir Crit Care Med. 2000; 1 62(6):2324-9. 
65 . Ordonez CL, Fahy JV. Epithelial desquamation in asthma. Am J Respir Crit Care Med. 200 1 ; 1 64( 1 0  Pt 
1 ): 1 997. 
66. de Boer WI, Sharma HS, Baelemans SM, Hoogsteden HC, Lambrecht BN, Braunstahl GJ. Altered 
expression of epithelial junctional proteins in atopic asthma: Possible role in inflammation. Can J Physiol 
Pharmacol. 2008;86(3): I 05- 1 2. 
67. Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, Puxeddu I, et al. Defective epithelial 
barrier function in asthma. J Allergy Clin lmmunol. 20 1 1 Jul 1 1 . 
68. Hackett TL, Singhera GK, Shaheen F, Hayden P, Jackson GR, Hegele RG, et al. Intrinsic phenotypic 
differences of asthmatic epithelium and its inflammatory responses to RSV and air pollution. Am J Respir 
Cell Mol Biol. 20 1 1  Jun 3. 
69. Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, Puxeddu I, et al. Defective epithelial 
barrier function in asthma. J Allergy Clin lmmunol. 201 1 ;  1 28(3):549,56.e 1 - 1 2. 
70. Thomas B, Rutman A, Hirst RA, Haldar P, Wardlaw AJ, Bankart J, et al . Ciliary dysfunction and 
ultrastructural abnormalities are features of severe asthma. J Allergy Clin Immunol. 
20 1 0; 1 26(4):722,729.e2. 
7 1 .  Ordonez CL, Khashayar R, Wong HH, Ferrando R, Wu R, Hyde OM, et al. Mild and moderate asthma is 
associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit 
Care Med. 200 I ;  1 63(2):5 1 7-23. 
72. DUNNILL MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin 
Pathol .  1 960; 1 3 :27-33. 
73. Kicic A, Sutanto EN, Stevens PT, Knight DA, Stick SM. Intrinsic biochemical and functional differences in 
bronchial epithelial cells of children with asthma. Am J Respir Crit Care Med. 2006; 1 74( 1 0) :  1 1 1 0-8. 
74. Uller L, Leino M, Bedke N,  Sammut D, Green B, Lau L, et al . Double-stranded RNA induces 
disproportionate expression of thymic stromal lymphopoietin versus interferon-beta in bronchial epithelial 
cells from donors with asthma. Thorax. 20 I 0;65(7):626-32. 
75. Vignola AM, Chanez P, Chiappara G, Merendino A, Pace E, Rizzo A, et al . Transforming growth factor­
beta expression in mucosa) biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med. 
1 997; 156(2 Pt 1 ) :59 1 -9. 
76. Puddicombe SM, Polosa R, Richter A, Krishna MT, Howarth PH, Holgate ST, et al . Involvement of the 
epidermal growth factor receptor in epithelial repair in asthma. FASEB J. 2000; 14( 10): 1 362-74. 
77. Howard TD, Meyers DA, Bleecker ER. Mapping susceptibility genes for asthma and allergy. J Allergy Clin 
Immunol. 2000; 1 05 (2 Pt 2):S477-8 1 .  
78. Boxall C, Holgate ST, Davies DE. The contribution of transforming growth factor-beta and epidermal 
growth factor signalling to airway remodelling in chronic asthma. Eur Respir J. 2006;27( 1 ) :208-29. 
79. Davies DE. The role of the epithelium in airway remodeling in asthma. Proc Am Thorne Soc. 
2009;6(8):678-82. 
80. Holgate ST. Epithelium dysfunction in asthma. J Allergy Clin Immunol. 2007; 1 20(6): 1 233,44; quiz 1 245-6. 
8 1 .  Ebina M, Takahashi T, Chiba T, Motomiya M. Cellular hypertrophy and hyperplasia of airway smooth 
muscles underlying bronchial asthma. A 3-D morphometric study. Am Rev Respir Dis. 1 993; 1 48(3):720-6. 
32 
General Introduction 
82. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively 
associated with �evere asthma. Am J Respir Crit Care Med. 2003; I 67( I 0): I 360-8. 
83. Woodruff PG, Dolganov GM, Ferrando RE, Donnelly S, Hays SR, Solberg OD, et al. Hyperplasia of 
smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir 
Crit Care Med. 2004; I 69(9): I 00 1 -6. 
84. Johnson PR, Burgess JK, Underwood PA, Au W, Poniris MH, Tamm M, et al . Extracellular matrix proteins 
modulate asthmatic airway smooth muscle cell proliferation via an autocrine mechanism. J Allergy Clin 
Immunol. 2004: I I 3(4):690-6. 
85. Araujo BB, Dolhnikoff M, Silva LF, Elliot J, Lindeman JH, Ferreira OS, et al . Extracellular matrix 
components and regulators in the airway smooth muscle in asthma. Eur Respir J. 2008;32( 1 ) :6 1 -9. 
86. Bara I, Ozier A, Tunon de Lara JM, Marthan R, Berger P. Pathophysiology of bronchial smooth muscle 
remodelling in asthma. Eur Respir J. 20 I 0;36(5): I I 74-84. 
87. Alkhouri H, Hollins F, Moir LM, Brightling CE, Armour CL, Hughes JM. Human lung mast cells modulate 
the functions of airway smooth muscle cells in asthma. Allergy. 20 1 1 ;66(9): 1 23 1 -4 1 .  
88. Goncharova EA, Billington CK, Irani C ,  Vorotnikov AV, Tkachuk VA, Penn RB, e t  al . Cyclic AMP­
mobilizing agents and glucocorticoids modulate human smooth muscle cell migration. Am J Respir Cell 
Mol Biol. 2003;29( 1  ): I 9-27. 
89. Sutcliffe A, Hollins F, Gomez E, Saunders R, Doe C, Cooke M, et al. Increased nicotinamide adenine 
dinucleotide phosphate oxidase 4 expression mediates intrinsic airway smooth muscle hypercontractility in 
asthma. Am J Respir Crit Care Med. 20 1 2 ; 1 85(3):267-74. 
90. Ma X, Cheng Z, Kong H, Wang Y, Unruh H, Stephens NL, et al. Changes in biophysical and biochemical 
properties of single bronchial smooth muscle cells from asthmatic subjects. Am J Physiol Lung Cell Mol 
Physiol. 2002;283(6):LI 1 8 1 -9. 
9 I .  Leguillette R, Lauzon AM. Molecular mechanics of smooth muscle contractile proteins in airway 
hyperresponsiveness and asthma. Proc Am Thorac Soc. 2008;5( ] ):40-6. 
92. Kariyawasam HH, Aizen M, Barkans J, Robinson OS, Kay AB. Remodeling and airway 
hyperresponsivcness but not cellular inflammation persist after allergen challenge in asthma. Am J Respir 
Crit Care Med. 2007; 1 75(9):896-904. 
93. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and 
histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long­
term treatment. the AMPUL study group. Am J Respir Crit Care Med. 1 999; 1 59(4 Pt I ): 1 043-5 1 .  
94. Cockcroft OW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol. 2006; 
I I 8(3):55 I ,9; quiz 560- I .  
95. Durham SR, Craddock CF, Cookson WO, Benson MK. Increases in airway responsiveness to histamine 
precede allergen-induced late asthmatic responses. J Allergy Clin Immunol. 1 988;82(5 Pt 1 ):764-70. 
96. Aalbers R, Kauffman HF, Koeter GH, Postma OS, De Vries K, De Monchy JG. Dissimilarity in 
methacholine and adenosine 5'-monophosphate responsiveness 3 and 24 h after allergen challenge. Am Rev 
Respir Dis. I 99 I ;  I 44(2):352-7. 
97. Boulet LP, Turcotte H, Laviolette M, Naud F, Bernier MC, Martel S, et al. Airway hyperrespon�iveness, 
inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. 
influence of inhaled corticosteroids. Am J Respir Crit Care Med. 2000; I 62(4 Pt I ) : I 308- 1 3 . 
98. Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, et al. Effect of short-term treatment 
with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: A 
placebo-controlled study. Am J Respir Crit Care Med. 1 997; 1 55(6): 1 864-7 1 .  
99. van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled 
steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with 
asthma. Thorax. I 999;54(5):403-8. 
1 00.Kerstjens HA, Brand PL, Hughes MD, Robinson NJ, Postma OS, Sluiter HJ, et al . A comparison of 
bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. dutch 
chronic non-specific lung disease study group. N Engl J Med. I 992;327(20): 1 4 1 3-9. 
1 0 1 . Kraan J, Koeter GH, vd Mark TW, Sluiter HJ, de Vries K. Changes in bronchial hyperreactivity induced by 
4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: A comparison between 
budesonide and terbutaline. J Allergy Clin Immunol. 1 985;76(4):628-36. 
1 02.Sawaguchi M, Tanaka S, Nakatani Y, Harada Y, Mukai K, Matsunaga Y, et al . Role of mast cells and 
basophils in IgE responses and in allergic airway hyperresponsiveness. J Immunol. 20 1 2; 1 88(4): 1 809- 1 8. 
1 03 .Kariyawasam HH, Robinson OS. The role of eosinophils in airway tissue remodelling in asthma. Curr Opin 
Immunol. 2007; 1 9(6):68 1 -6. 
1 04.Bradding P. The role of the mast cell in asthma: A reassessment. Curr Opin Allergy Clin Immunol. 2003; 
3( I ):45-50. 33 
CHAPTER 1 
1 05 .Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate 
safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care 
Med. 2007; 1 76( 1 1 ) : 1 062-7 1 .  
1 06.Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al . Mepolizumab for 
prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360( 1 0) :985-93. 
1 07.Lambert RK, Wiggs BR, Kuwano K, Hogg JC, Pare PD. Functional significance of increased airway smooth 
muscle in asthma and COPD. J Appl Physiol. 1 993;74(6):277 1-8 1 .  
108. Blacquiere MJ, Timens W ,  Melgert BN,  Geerlings M ,  Postma OS, Hylkema MN. Maternal smoking during 
pregnancy induces airway remodelling in mice offspring. Eur Respir J. 2009;33(5): 1 1 33-40. 
1 09.Siddiqui S, Mistry V, Doe C, Roach K, Morgan A, Wardlaw A, et al . Airway hyperresponsiveness is 
dissociated from airway wall structural remodeling. J Allergy Clin lmmunol. 2008; 1 22(2):335,4 1 ,  34 1 .e 1 -3 .  
I J O.Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal and 
asthmatic subjects. Eur Respir J. 2002; 1 9(5):879-85. 
1 1 1 .Tsurikisawa N, Oshikata C, Tsuburai T, Saito H, Sekiya K, Tanimoto H, et al . Bronchial 
hyperresponsiveness to histamine correlates with airway remodelling in adults with asthma. Respir Med. 
201 0; 1 04(9): 1 27 1 -7. 
1 1 2.Amin K, Ekberg-Jansson A, Lofdahl CG, Venge P. Relationship between inflammatory cells and structural 
changes in the lungs of asymptomatic and never smokers: A biopsy study. Thorax. 2003 ;58(2): 1 35-42. 
I 1 3 .Ohashi Y, Motojima S,  Fukuda T, Makino S. Airway hyperresponsiveness, increased intracellular spaces of 
bronchial epithelium, and increased infiltration of eosinophils and lymphocytes in bronchial mucosa in 
asthma. Am Rev Respir Dis. 1 992; 1 45(6): 1 469-76. 
1 1 4.Sparrow MP, Omari Tl, Mitchell HW. The epithelial barrier and airway responsiveness. Can J Physiol 
Pharmacol .  1 995;73(2) : 1 80-90. 
1 1 5 .  Wadsworth SJ, Nijmeh HS, Hal l  IP. Glucocorticoids increase repair potential in a novel in vitro human 
airway epithelial wounding model. J Clio Immunol. 2006;26(4):376-87. 
1 16.Sekiyama A, Gon Y, Terakado M, Takeshita I, Kozu Y, Maruoka S, et al . Glucocorticoids enhance airway 
epithelial barrier integrity. Int lmmunopharmacol. 20 1 1 Dec 27. 
1 1 7.Laitinen LA, Laitinen A. Modulation of bronchial inflammation: Corticosteroids and other therapeutic 
agents. Am J Respir Crit Care Med. 1 994; 1 50(5 Pt 2):S87-90. 
1 1 8.Pohunek P, Warner JO, Turzikova J, Kudrmann J, Roche WR. Markers of eosinophilic inflammation and 
tissue re-modelling in children before clinical ly diagnosed bronchial asthma. Pediatr Allergy lmmunol. 
2005; 1 6( I ):43-5 1 . 
1 1 9.Broekema M, Timens W, Vonk JM, Volbeda F, Lodewijk ME, Hylkema MN, et al. Persisting remodeling 
and less airway wall eosinophil activation in complete remission of asthma. Am J Respir Crit Care Med. 
20 1 1 ;  1 83(3):3 1 0-6. 
1 20.Palmans E, Kips JC, Pauwels RA. Prolonged allergen exposure induces structural airway changes in 
sensitized rats. Am J Respir Crit Care Med. 2000; 1 6 1  (2 Pt 1 ):627-35 .  
1 2 1 .Milanese M, Crimi E ,  Scordamaglia A, Riccio A,  Pellegrino R,  Canonica GW, et  al . On the functional 
consequences of bronchial basement membrane thickening. J Appl Physiol. 2001 ;9 1 (3): I 035-40. 
1 22.McParland BE, Macklem PT, Pare PD. Airway wall remodeling: Friend or foe? J Appl Physiol. 
2003;95( I ):426-34. 
1 23. van Beijsterveldt CE, Boomsma DI. Genetics of parentally reported asthma, eczema and rhinitis in 5-yr-old 
twins. Eur Respir J. 2007;29(3):5 1 6-2 1 .  
1 24. Thomsen SF, van der Sluis S ,  Kyvik KO, Skytthe A ,  Backer V .  Estimates of asthma heritability in a large 
twin sample. Clin Exp Allergy. 201 0;40(7): 1 054-6 1 .  
1 25.Denham S ,  Koppelman GH, Blakey J ,  Wjst M ,  Ferreira MA, Hall IP, et al . Meta-analysis of genome-wide 
linkage studies of asthma and related traits. Respir Res. 2008;9:38. 
1 26.Ober C, Yao TC. The genetics of asthma and allergic disease: A 2 1 st century perspective. lmmunol Rev. 
201 1 ;242(1 ): 1 0-30. 
1 27 .Postma OS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J ,  Panhuysen CI, et al . Genetic susceptibility to 
asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med. 
I 995;333( 14) :894-900. 
1 28.Cookson WO. Asthma genetics. Chest. 2002; 1 2 1  (3 Suppl):7S- 1 3S. 
1 29.Reijmerink NE, Bottema RW, Kerkhof M, Gerritsen J, Stelma FF, Thijs C, et al. TLR-related pathway 
analysis: Novel gene-gene interactions in the development of asthma and atopy. Allergy. 201 0;65(2) : 1 99-
207. 
1 30.Weiss ST, Raby BA, Rogers A. Asthma genetics and genomics 2009. Curr Opin Genet Dev. 2009; 
1 9(3) :279-82. 
1 3 1 .  Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev lmmunol. 2008;8(3): 1 69-82. 
34 
General Introduction 
1 32.Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, et al. Association of the 
ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002;4 1 8(6896):426-30. 
1 33 .Allen M, Heinzmann A, Noguchi E, Abecasis G, Broxholme J, Ponting CP, et al . Positional cloning of a 
novel gene influencing asthma from chromosome 2q 14. Nat Genet. 2003;35(3):258-63. 
1 34.Zhang Y, Leaves NI, Anderson GG, Ponting CP, Broxholme J, Holt R, et al. Positional cloning of a 
quantitative trait locus on chromosome I 3q 14 that influences immunoglobulin E levels and asthma. Nat 
Genet. 2003;34(2): 1 8 1 -6. 
I 35.Laitinen T, Pol vi A, Rydman P, Vendelin J, Pulkkinen V, Salmikangas P, et al. Characterization of a 
common susceptibility locus for asthma-related traits. Science. 2004;304(5668):300-4. 
1 36.Nicolae D, Cox NJ, Le�ter LA, Schneider D, Tan Z, Billstrand C, et al. Fine mapping and positional 
candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p2 I .  Am J Hum Genet. 
2005;76(2):349-57. 
1 37 .Noguchi E, Yokouchi Y, Zhang J, Shibuya K, Shibuya A, Bannai M, et al. Positional identification of an 
asthma susceptibility gene on human chromosome 5q33. Am J Respir Crit Care Med. 2005; 1 72(2): 1 83-8. 
I 38 .Brasch-Andersen C, Tan Q, Borglum AD, Haagerup A, Larsen TR, Vestbo J, et al. Significant linkage to 
chromosome I 2q24.32-q24.33 and identification of SFRS8 as a possible asthma susceptibility gene. Thorax. 
2006;6 I ( I  0):874-9. 
1 39 .Barton SJ, Koppelman GH, Vonk JM, Browning CA, Nolte IM, Stewart CE, et al. PLAUR polymorphisms 
are associated with asthma, PLAUR levels, and lung function decline. J Allergy Clin l mmunol. 
2009; 1 23(6): 1 39 1  ,400.e l 7. 
140.Koppelman GH, Meyers DA, Howard TD, Zheng SL, Hawkins GA, Ampleford EJ, et al. Identification of 
PCDH I as a novel susceptibility gene for bronchial hyperresponsiveness. Am J Respir Crit Care Med. 
2009; 1 80( I 0):929-35 .  
1 4 1 .Moffatt MF, Kabesch M, Liang L,  Dixon AL, Strachan D, Heath S, et  a l .  Genetic variants regulating 
ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007;448(7 1 52):470-3. 
1 42.Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. A large-scale, consortium-based 
genomewide association study of asthma. N Engl J Med. 20 10;363( 1 3) :  1 2 1 1 -2 1 .  
143 .Ferreira MA, Matheson MC, Duffy DL, Marks GB, Hui J ,  Le Souef P, et al. Identification of IL6R and 
chromosome 1 1  q 1 3 .5 as risk loci for asthma. Lancet. 20 1 1 ;378(9795) :  I 006- 14. 
144.Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, Graves PE, et al. Meta-analysis of 
genome-wide association studies of asthma in ethnically diverse north american populations. Nat Genet. 
20 1 1 ;43(9):887-92. 
1 45 .Gudbjartsson DF, Bjomsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM, et al . Sequence 
variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet. 2009; 
4 1 (3):342-7. 
146.Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Doi S, et al . Genome-wide association study 
identifies three new susceptibility loci for adult asthma in the japanese population. Nat Genet. 
20 1 I ;43(9):893-6. 
1 47.Li X, Howard TD, Zheng SL, Haselkom T, Peters SP, Meyers DA, et al. Genome-wide association study of 
asthma identifies RAD50-ILI 3 and HLA-DR/DQ regions. J Allergy Clin Immunol. 
20 1 O; 1 25(2) :328,335.e 1 1 .  
1 48.Noguchi E, Sakamoto H, Hirota T, Ochiai K, Imoto Y, Sakashita M, et al. Genome-wide association study 
identifies HLA-DP as a susceptibility gene for pediatric asthma in asian populations. PLoS Genet. 20 1 1 ;  
7(7):e 1 002 1 70. 
1 49.Himes BE, Hunninghake GM, Baurley JW, Rafaels NM, Sleiman P, Strachan DP, et al. Genome-wide 
association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet. 2009;84(5):5 8 1 -
93. 
1 50. Mathias RA, Grant AV, Rafaels N, Hand T, Gao L, Vergara C, et al . A genome-wide association study on 
african-ancestry populations for asthma. J Allergy Clin Immunol. 20 1 0; I 25(2) :336,346.e4. 
1 5 1 .Schauberger EM, Ewart SL, Arshad SH, Huebner M, Karmaus W, Holloway JW, et al. Identification of 
ATPAFl as a novel candidate gene for asthma in children. J Allergy Clin Immunol. 
20 1 1 ; 1 28(4) :753,760.e l I .  
1 52.Sleiman PM, Flory J, Imielinski M, Bradfield JP, Annaiah K, Willis-Owen SA, et al. Variants of 
DENNO I B associated with asthma in children. N Engl J Med. 20 I 0;362( I ) :36-44. 
1 53 .Anantharaman R, Andiappan AK, Nilkanth PP, Suri BK, Wang de Y, Chew FT. Genome-wide association 
study identifies PERLDI as asthma candidate gene. BMC Med Genet. 20 1 1 ;  1 2: 1 70. 
1 54.Hancock DB, Romieu I, Shi M, Sienra-Monge JJ, Wu H, Chiu GY, et al. Genome-wide association study 
implicates chromosome 9q2 I .3 I as a susceptibility locus for asthma in mexican children. PLoS Genet. 
2009;5(8):e I 000623.  
35 
CHAPTER I 
1 55 .Liew FY, Pitman NI, Mcinnes IB . Disease-associated functions of IL-33: The new kid in the IL- I family. 
Nat Rev Immunol. 20 1 0; 1 0(2): 1 03-1 0. 
1 56.Cantero-Recasens G, Fandos C, Rubio-Moscardo F, Valverde MA, Vicente R. The asthma-associated 
ORMDL3 gene product regulates endoplasmic reticulum-mediated calcium signaling and cellular stress. 
Hum Mol Genet. 20 1 0; 1 9( 1 ): 1 1 1 -2 1 .  
1 57 .  Koppelman GH. Gene by environment interaction in asthma. Curr Allergy Asthma Rep. 2006;6(2): 1 03- 1 1 .  
1 58 .Vercel l i  D .  Gene-environment interactions in asthma and allergy: The end of the beginning? Curr Opin 
Allergy Clin Immunol. 201 0; 1 0(2): 1 45-8. 
1 59. Bottema RW, Kerkhof M, Reijmerink NE, Thijs C, Smit HA, van Schayck CP, et al . Gene-gene interaction 
in regulatory T-cell function in atopy and asthma development in childhood. J Allergy Clin Immunol. 
20 1 0; 1 26(2):338,46, 346.e 1 - 1 0. 
1 60.Smit LA, Heederik D, Doekes G, Koppelman GH, Bottema RW, Postma OS, et al . Endotoxin exposure, 
CD 1 4  and wheeze among farmers: A gene--environment interaction. Occup Environ Med. 201 1 ;68(1 1 ):826-
3 1 .  
1 6 1 .Ege MJ, Strachan DP, Cookson WO, Moffatt MF, Gut I, Lathrop M ,  et al . Gene-environment interaction for 
childhood asthma and exposure to farming in central europe. J Allergy Clin Immunol. 20 1 1 ;  1 27 ( 1  ) :  1 38,44, 
1 44.el -4. 
1 62. Kerkhof M, Postma OS, Brunekreef B, Reijmerink NE, Wijga AH, de Jongste JC, et al. Toll-like receptor 2 
and 4 genes influence susceptibility to adverse effects of traffic-related air pollution on childhood asthma. 
Thorax. 20 10;65(8):690-7. 
1 63 .Reijmerink NE, Kerkhof M, Bottema RW, Gerritsen J, Stelma FF, Thijs C, et al . Toll-like receptors and 
microbial exposure: Gene-gene and gene-environment interaction in the development of atopy. Eur Respir J .  
20 1 1 ;38(4):833-40. 
1 64.Custovic A, Rothers J, Stern D, Simpson A, Woodcock A, Wright AL, et al . Effect of day care attendance 
on sensitization and atopic wheezing differs by toll-like receptor 2 genotype in 2 population-based birth 
cohort studies. J Allergy Clin Immunol. 201 1 ; 1 27(2):390,397.e l -9. 
165 .Sano K, Tanihara H, Heimark RL, Obata S, Davidson M, St John T, et al. Protocadherins: A l arge family of 
cadherin-related molecules in central nervous system. EMBO J. 1 993; 1 2(6):2249-56. 
1 66.Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol. 
2009;41 (2):349-69. 
1 67. Kim SY, Yasuda S, Tanaka H, Yamagata K, Kim H.  Non-clustered protocadherin. Cell Adh Migr. 201 1 ;  
5(2):97- 1 05 .  
1 68. Redies C, Vanhalst K,  Roy F .  Delta-protocadherins: Unique structures and functions. Cell Mol  Life Sci. 
2005;62(23):2840-52. 
1 69.Huang YT, Heist RS, Chirieac LR, Lin X, Skaug V, Zienolddiny S, et al. Genome-wide analysis of survival 
in early-stage non-small-cell lung cancer. J Clin Oncol. 2009;27( 1 6):2660-7. 
1 70.Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, et al . Genetic variation in PCDHl I X  
is associated with susceptibility to late-onset alzheimer's disease. Nat Genet. 2009;4 1  (2): 1 92-8. 
1 7 1 .Wang C, Yu G, Liu J, Wang J, Zhang Y, Zhang X, et al . Downregulation of PCDH9 predicts prognosis for 
patients with glioma. J Clin Neurosci. 20 1 2; 1 9(4):541 -5 .  
1 72.Kuroda H, lnui M, Sugimoto K, Hayata T,  Asashima M. Axial protocadherin is a mediator of prenotochord 
cell sorting in xenopus. Dev Biol. 2002;244(2):267-77. 
1 73.Patel SD, Chen CP, Bahna F, Honig B,  Shapiro L. Cadherin-mediated cell-cell adhesion: Sticking together 
as a family. Curr Opin Struct Biol. 2003 ; 1 3(6):690-8. 
1 74.Morishita H,  Umitsu M, Murata Y, Shibata N,  Udaka K, Higuchi Y, et al . Structure of the cadherin-related 
neuronal receptor/protocadherin-alpha first extracellular cadherin domain reveals diversity across cadherin 
families. J Biol Chem. 2006;28 1 (44):33650-63. 
1 75 .Elledge HM, Kazmierczak P, Clark P, Joseph JS, Kolatkar A, Kuhn P, et al. Structure of the N terminus of 
cadherin 23 reveals a new adhesion mechanism for a subset of cadherin superfamily members. Proc Natl 
Acad Sci U S  A. 20 10 ; 107(23): 1 0708- 1 2. 
1 76. Vanhalst K, Kools P, Staes K, van Roy F, Redies C. Delta-protocadherins: A gene family expressed 
differentially in the mouse brain. Cell Mol Life Sci. 2005;62( 1 1 ): 1 247-59. 
1 77 .Fitsialos G, Chassot AA, Turchi L, Dayem MA, LeBrigand K, Moreilhon C, et al . Transcriptional signature 
of epidermal keratinocytes subjected to in vitro scratch wounding reveals selective roles for ERK 1 /2, p38, 
and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem. 2007;282(20): 1 5090- 102. 
1 78.Colland F, Jacq X, Trouplin V, Mougin C, Groizeleau C, Hamburger A, et al. Functional proteomics 
mapping of a human signaling pathway. Genome Res. 2004; 1 4(7): 1 324-32. 36 
Chapter 2 
Identification of PCDHJ as a novel susceptibility gene 
for bronchial hyperresponsiveness 
Gerard H. Koppelman 
Deborah A. Meyers 
Timothy D. Howard 
S. Lilly Zheng 
Greg A. Hawkins 




Ilja M. Nolte 
Cleo C. van Diemen 
H. Marike Boezen 
Wim Timens 
Paul A. Whittaker 
0. Colin Stine 
Sheila J. Barton 
John W. Holloway 
Stephen T. Holgate 
Penelope E. Graves 
Fernando D. Martinez 
Antoon J.M. van Oosterhout 
Eugene R. Bleecker 
Dirkje S. Postma 
Am J Respir Crit Care Med. 2009. Vol 180(10): p929-935 
CHAPTER 2 
ABSTRACT 
Rationale. Asthma is a chronic inflammatory airway disease that affects over 300 million individuals worldwide. Asthma is caused by interaction of genetic and environmental factors. Bronchial hyperresponsiveness (BHR) is a hallmark of asthma and results from increased sensitivity of the airways to physical or chemical stimulants. BHR and asthma are linked to chromosome 5q31-q33. 
Objective . To identify a gene for BHR on chromosome 5q31-33 
Methods. In 200 Dutch asthma families, linkage analysis and fine mapping was performed, and the Protocadherin 1 gene (PCDHJ) was identified. PCDHJ was resequenced in 96 subjects from ethnically diverse populations to identify novel sequence variants. Subsequent replication studies were undertaken in seven populations from the Netherlands, UK and USA, including two general population samples, two family and three case-control samples. PCDHl mRNA and protein expression was investigated using PCR, Western blotting and immunohistochemistry. 
Main results. In seven out of eight populations (n = 6,168) from the Netherlands, UK, and USA, PCHDJ gene variants were significantly associated with BHR (p values: 0.005 - 0.05) This association was present in both asthma families and general populations. PCDHl mRNA and protein was expressed in airway epithelial cells, and in macrophages. 
Conclusion. PCDHJ is a novel gene for BHR in adults and children. The identification of 
PCDHJ as a BHR susceptibility gene may suggest that a structural defect in the integrity of the airway epithelium, the first line of defence against inhaled substances, contributes to the development of BHR. 38 
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INTRODUCTION 
Asthma is a chronic inflammatory airway disease that affects over 300 million 
individuals worldwide (I). It is characterized by respiratory symptoms, variable airway 
obstruction, and bronchial hyperresponsiveness (BHR) and caused by multiple genetic and 
environmental factors that may interact (2). BHR is a hallmark of asthma and is due to 
increased sensitivity of the airways to physical or chemical stimulants (cold air and cigarette 
smoke) and to pharmacological agents such as methacholine and histamine. BRR has a 
considerable genetic component (3) and constitutes a risk factor for asthma development, 
even in subjects without respiratory symptoms (4). Furthermore, BHR is increased in children 
who are exposed to environmental tobacco smoke (ETS) in utero and in the first years of life 
(5). 
Our initial report of linkage of bronchial hyperresponsiveness (BHR) to chromosome 
5q3 l -q33 in Dutch asthma families (6) has been confirmed in six other populations for asthma 
associated phenotypes (7-12). This finding has been extended by showing that chromosome 
5q3 l -q33 interacts with ETS exposure in utero and/or early childhood in the development of 
BHR and asthma (13, 14). This region of chromosome 5q31-q33 contains a large number of 
candidate genes for allergy and asthma, such as Interleukin-] 3, Interleukin-9, Interleukin-4, 
CDJ4, IRF-1, GM-CSF, TIM-] and the beta-2- adrenoceptor (15). These genes have been 
reported to be associated with asthma associated phenotypes, which strongly suggests that 
chromosome 5q3 l -q33 contains multiple asthma susceptibility genes that each contribute to 
the observed asthma linkage. 
In this article, we report the identification of protocadherin-I (PCDH 1) as a novel 
gene for BHR on chromosome 5q31-33. We used positional cloning to identify this gene in 
the Dutch population, subsequently identified novel sequence variants, performed genetic 
replication studies in seven independent populations in the Netherlands, the USA and the 
United Kingdom and show that PCDHI mRNA and protein expression is present in airway 
epithelium, the first line of defence against inhaled allergens and toxic substances known to 
contribute to asthma development. 
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MATERIAL AND METHODS 
Study populations Recruitment and clinical characterization of all study samples are described in detail in the Supplementary Data. The primary population consists of two hundred families (1259 individuals) ascertained through probands with asthma who were initially studied between 1962 and 1975 at Beatrixoord Hospital, Haren, The Netherlands (Supplementary Table El )  (16). The Dutch replication samples include an asthma trio population of 407 trios (17), and the longitudinal Vlagtwedde/Vlaardingen cohort study, that includes subjects from the general population that have been tested for bronchial hyperresponsiveness at one or more time points during follow up (n=4 18) (Supplementary Table E2) (18). Replication samples from the United States include the prospective Children' s  Respiratory Study (Tucson, AZ, USA), in which children were tested for  BHR to methacholine at age 11 and 16 (n=329) (table E2) (19). Furthermore, three US case control populations were recruited from three ethnically diverse US populations (African American (n=522), Hispanic (n=246), and Caucasian (n=665)) as part of the Collaborative Study on the Genetics of Asthma (20, 21 ). BHR measurements to methacholine or reversibility to albuterol were performed in the cases (Supplementary Table E2) (21 ). The replication sample from the United Kingdom is an asthma family study from Southampton, UK, which includes 341 affected sib pair families with asthma (n=1508) (22). Bronchial responsiveness was measured in subjects with a baseline FEV 1 of >70% predicted using inhaled methacholine (Supplementary Table E2) (22). Local medical ethics committees approved these studies, and all participants provided written informed (parental) consent. 
Genotyping and sequence analysis Genotyping methods and marker selection are described in the Supplementary Data. Briefly, 22 microsatellite markers were identified on chromosome 5q31-33 and genotyped in the Dutch family study ( 14). Subsequently, 103 SNPs were selected for fine mapping and genotyped in the Dutch family study (Supplementary Table E3). The PCDHJ gene (2 kb of the putative promoter region, all exons, and the complete 3' untranslated region (UTR) region) was resequenced in 96 subjects as described previously (23). 
Statistical analysis 
Linkage analysis of the microsatellite fine screen markers on chromosome 5q31-33 was performed using GENEHUNTER-PLUS, using the same model as described previously (14). 40 
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Association analysis. Dutch families, trios and UK families were analyzed with FBAT using 
an additive model, using the -e option in case of linkage (24). Case-control analysis was 
performed using Chisquare tests and ANOV A, if appropriate. In the Vlagtwedde/ Vlaardingen 
cohort study, the association between PCDH 1 SNPs and the occurrence of becoming BHR 
positive over time was investigated longitudinally using a Cox regression model (SPSS 14.0), 
with adjustment for smoking, age at investigation and FEV 1 at baseline. All statistical tests 
were performed two sided. 
PCDHl expression 
PCDHJ mRNA expression was investigated using PCR in mRNA obtained from an 
epithelial cell line 16HBE, and human cells including a.o. blood cells, brain, lung fibroblasts 
as well as cultured airway epithelial cells of asthma patients. PCDH1 protein expression was 
investigated using two different antibodies (a polyclonal and a monoclonal antibody) using 
Western Blotting and immunohistochemisty as described in the Supplementary Data. 
RESULTS 
Linkage analysis using a dense map of 29 microsatellite markers in the linked region 
on chromosome 5q31-q33 in 200 Dutch families (n= l ,259) revealed significant LOD scores 
in two regions, i.e. HLOD was 3.88 at marker 5q31-33_36 and 3.84 in a region flanked by 
markers D5S2117 and /L9. In 95 ETS-exposed families, a peak HLOD score of 4.36 was 
flanked by markers 5q31-33_56 and FGF a (Supplementary Figure El). 
Using the approach previously used to identify DPPJO and PHFJJ, two positionally cloned 
genes for asthma (25, 26), allelic association of microsatellite markers and BHR was tested. 
One allele of marker 5q31-33_ 40 was significantly associated with BHR using probands and 
spouses in a case-control design (p= 0.0029). This marker is located next to the peak LOO 
score in the ETS-exposed families at 142.13 centiMorgan ( cM); its physical position is at 
136,413,897-136,414,296 on the reference sequence. The 250 kb region surrounding this 
marker was investigated, based on the extent of linkage disequilibrium between markers on 
5q in the Dutch population. 103 Haplotype tagging and functional single nucleotide 
polymorphisms (SNPs) were genotyped and family based association tests identified 
significant associations of SNPs in protocadherin-1 (PCDHJ) with BHR, and specifically 
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with rs3797054, which encodes a synonymous SNP (Ala750Ala) in PCDHJ (p=0.005) 
(Figure 1). 
Figure 1: Linkage disequilibrium (D') and association of SNPs at chromosome 5q31-q33 
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Resequencing of PCDHJ in 96 subjects of ethnically diverse populations revealed 22 
SNPs and two insertion deletion polymorphisms (Supplementary Table E4). 
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Potential functional SNPs significantly associated with BHR were genotyped in seven 
replication populations from the Netherlands (adults), the United States (adults and children) 
and the United Kingdom (children), displaying significant associations in two Dutch, one UK 
and three US populations (Table 1 ). 
Table 1: Association of PCDHl gene variants with bronchial hype"esponsiveness in 8 
populations (n=6,168) SNP Rs nurnher Risk allele Allele Netherlands Netherland� Netherland� Netherland� ruc�on. Al Southampton. US-White ( W): (All frequenc� 200 Asthma 200 Asthma 407 asthma General General population UK 34 1  families I lispanic (I I )  and population,) in Dutch families parcnb tno� pupula110n. Children Aged \\ith asthma Afro-American families (case- adult, 1 1  and 1 6 )  children (A). control) Case-control 
N 1 259 401 1 22 1 "  4 1 8  3 1 8* 329* 1 508 W: 338 ca�e�. 327controls II 1 1 6 CJ!>CS. 1 30 control� A: 222 C:t�es. 300 controls Anal)�I� l'RAT Chi-square l'RAT Co, ANOVA ANOVA l'RAT Chi square. regression ANOVA - 1 1 9 1  RS l 3355929 A 0.03 0.45 0.3 1 0.09 Ns Ala5 1 4  lnr RS3822357 G 0.92 0.47 0. 1 1  0.72 0.58 0.07 o.oos · 0.009 Ns Ala750Ala RS3797054 r 0.67 0.005 0.02 0.49 0.05 0.04 • 0.28 0. 1 9  Ns IVS3+ 1 64 RS l4359 C 0.45 0.93 0.09 0.37 1 .0 0. 1 8  Ns IVS3- l 1 6  Del I l C  0.08 0.04 0.25 0.05 0.95 § § 0.58 0.OZ (C, BIIR) 
Definition of abbreviations: ANOVA = analysis of variance; BHR = bronchial hyperresponsiveness; Del = 
Deletion; FBAT = Family Based Association Tests; Rs = Ref SNP accession ID; SNP = single nucleotide 
polymorphism. 
Significant cases appear in bold. US case control populations:BHR was analyzed in cases only, as BHR was not 
measured in the controls. Due to low numbers of Hispanic cases, power was low for BHR analysis and 
therefore asthma was analyzed (p = 0.02 for IVS3_1 16}. In all polulations, the same risk allele was tested for 
association. 
# dominant model (p value for ANO VA 2 d.f = 0. 13) 
I\ Number represents total number of subjects of these trios, including 407 asthma probands. 
* Only children with BHR measurements were included in these analyses. 
§ Data not shown due to differences in allele frequency of Hispanic and Caucasian populations. 
First, the association found between rs3797054 (T-allele) and BHR was consistently observed 
in the parents of the Dutch families (using the probands with asthma as cases and unaffected 
spouses in a case-control design) and in the children of the Dutch families (using FBAT). The 
association of rs3797054 with BHR was replicated in participants of the population-based 
Children's Respiratory Study in Tucson, Arizona, USA, who were investigated for BHR at 
age 11 and age 16 (19). Moreover, rs3797054 was associated with the development of BHR 
in adults from a longitudinal adult population-based study in the Netherlands (Figure 2) (18). 
Second, a three base pair insertion/deletion polymorphism (IVS3 -116) in the intronic region 
of exon 3 was associated with BHR in two Dutch populations and with asthma and BHR in 
two US case-control populations. Third, the major allele of rs3822357, which encodes 
Ala5 I 4Thr localised in the 5th cadherin repeat, was associated with BHR in the US Children 
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Respiratory Study (19), and with BHR in a UK population of 341 families ascertained 
through affected siblings with asthma (22). Interestingly, PCDHJ Ala514Thr was associated 
with BHR when ETS exposure in utero and the first years of life was taken into account in the 
latter population (Table 1 ). However, there was not strong evidence for gene by smoking 
interaction in the Dutch or the US Tucson populations. 
In addition to BHR, we investigated PCDHJ SNPs in asthma defined by an algorithm 
(14) and observed significant association of rs3797054 and asthma (p = 0.003) in the 200 
Dutch families. Haplotype analysis did not further improve these results. 
Figure 2: Longitudinal analysis of PCDHl Ala750Ala in the general Dutch population. 
Hazard function of developing BHR in the general Dutch population of Vlagtwedde­
Vlaardingen over time. PCDHJ CT or TT carriers are at increased risk of becoming 
hyperresponsive over time compared to PCDHJ Ala750Ala CC homozygotes (p=0.05) 
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By PCR, we identified high PCDHJ mRNA expression in  human brain, airway 
epithelial cell lines ( l 6HBE) and in primary epithelial cell cultures of asthma patients. Weak 
mRNA expression was observed in airway fibroblasts, peripheral blood mononuclear cells 
and granulocytes (Figure 3). 
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PCDHJ is a new bronchial hyperresponsiveness gene Figure 3: mRNA expression of PCDHI in various tissues and cells. PCDHI exon 2-3 PCDHl exon 3-5 GAPDH 2 3 4 5 6 ....... _, ... ...... . ..  _ ....., ,...... __ _ _ 7 1. = 16HBE 2. = Primary epithelial cells (asthma) 3. = Lung fibroblast 4. = Granulocytes 5. = PBMCs 6. = Brain (Hippocampus) 7. = Control (water) Western blot analysis showed consistent and specific PCDHl protein expression in bronchial epithelial cell line 16HBE and primary epithelial cell cultures of asthma patients using different polyclonal and monoclonal antibodies. Proteins of 150-160 kD were identified with a protein weight consistent with previous observations (Figure 4) (27). 
Figure 4: Western Blot of epithelial cell line 16 HBE, and primary epithelial cell culture of 





















with peptide blocking Immunohistochemistry using the PCDHl polyclonal antibody showed a specific expression pattern of PCDHl protein in the apical part of differentiated airway epithelial cells lining the airway lumen and in the membrane of macrophages in lung resection specimens of a patient with bronchitis as well as airway wall biopsies in asthma patients (Figure 5). PCDHl expression was also observed between epithelial cells at the apical side of the epithelium. 45 
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Figure 5: Protein expression of PCDHJ in airway epithelial cells and macrophages. 
Protein expression of PCDHJ in airway epithelial cells and macrophages on lung (panel a and 
b) and airway wall biopsy of asthma patient; panel c). Expression is observed at the apical 
part of airway epithelial cells (panel a and c) and in macrophages (panel b ). 
DISCUSSION 
This study identified PCDHJ as a novel gene for BHR in children and adults. 
Interestingly, we have provided evidence that PCDHJ, particularly rs3797054, is important in 
the development of BHR in an asthma family sample. In addition, PCDHJ is associated with 
BHR in two population based samples from the Netherlands and the US, irrespective of the 
presence of asthma. Moreover, we present strict replication of a second gene variant in 
PCDHJ, a three base pair insertion-deletion, in three additional study samples ascertained for 
asthma. Finally, loose replication (28) was observed in the Tucson cohort and a UK family 
study for a coding SNP not associated with BHR in the primary Dutch population. Of 
importance for the relevance of the PCDHJ gene for BHR and asthma, PCDHJ mRNA and 
protein expression was shown in macrophages and airway epithelial cells in asthma and 
controls. 
In order to interpret these findings, several strengths and limitations need to be 
considered. First, to our knowledge this is the first gene that is identified by positional cloning 
for an intermediate phenotype of asthma, bronchial hyperresponsiveness. PCDHJ gene 
variants are associated with BHR in asthma families as well as two general populations, not 
ascertained for asthma. Previous epidemiological data has shown that BHR is a risk factor for 
asthma, even in subjects without respiratory symptoms (4). Based on these data, we 
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hypothesize that mechanisms related to the function of PCDHJ contribute to susceptibility to 
BHR and subsequent asthma development. This may implicate that PCDHl dysfunction plays 
an early role in asthma pathogenesis. 
Second, in all study populations, a direct agonist of BHR was used (either histamine or 
methacholine). Our findings suggest that PCDH I function is not specific for BHR induced by 
either methacholine or histamine. Previous work has indicated that BHR to histamine and 
methacholine is highly correlated (29). We suggest that further work should be performed on 
the role of PCDH 1 in indirect measures of BHR, such as exercise or adenosine-mono­
phosphate. 
Third, we used the positional cloning approach that has been previously used to 
identify DPPIO and PHD I I  (25, 26). This approach is based on identification of a genetic 
association with a microsatellite marker used for linkage analyses, to subsequently fine map 
the region that is in possible LD with this marker and the gene of interest. Our fine mapping 
results indicate that we have adequately screened the region for SNPs in other genes that may 
be in LD with PCDHJ, given the extent of LD of about I 00 kB in this region in the Dutch 
population (Figure I). 
Fourth, we identified PCDHJ in a primary family population, in which linkage to 
BHR was reported (6, 14). We did not correct for multiple testing, but rather performed 
extensive replication studies of significant and/or functional SNPs in 7 independent 
populations. We interpret the consistent signal in parents and offspring in the Dutch families 
as internal validation of this genetic association in the Dutch families. Moreover, the strict 
replication of two PCDH I gene variants with the same risk allele being associated with BHR 
in the same direction in 4 independent populations provides strong support for a role of 
PCDHJ in BHR (28). Specifically, we found strict replication with regard to phenotype and 
genotype for Ala750Ala and IVS3_1 16. Loose replication with regard to genotype was 
observed for Ala5 I 4Thr. The reasons for this allelic heterogeneity are yet to be determined, 
but include the presence of multiple functional SNPs, other SNPs that are in linkage 
disequilibrium with the associated SNPs or gene by environment interaction. Since gene 
variants on 5q3 l -33 have been shown to interact with ETS exposure in utero/early life, we 
investigated the association of PCDHI with BHR in ETS exposed and non-exposed children 
in four populations. These gene-environmental interaction analyses (Supplementary Table ES) 
in the study cohorts revealed evidence of gene environment interaction for PCDH I in the UK 
family cohort only, but not in the other populations. However, the power to detect such an 
interaction was low. 
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We suggest characterizing the functional role of these gene variants in PCDHJ . 
Ala750Ala and IVS3_116 are localised in the 3'UTR and intronic region of exon 3 and may 
affect mRNA stability or splicing; whereas Ala514Thr is localised in the 5th cadherin repeat of 
the extracellular domain and may affect cell-cell adhesion. 
The Protocadherin-1 gene (PCDHJ , PC42) has 5 exons and encodes multiple mRNA 
isoforms through alternative splicing (Supplementary Table E4). There are two annotated 
isoforms: a 3 and 5 exon isoform. The three exon isoform lacks the major part of the 
cytoplasmic domain, which encodes conserved signalling sequences CMI, CM2 and CM3 
(22). Protocadherins are thought to play an important role in homotypic cell adhesion and 
organ development, in particular within the neural system (30). Overexpression of PCDHI 
induces calcium dependent cell-cell adhesion and membrane expression of PCDHI in a 
mouse fibroblast L-cell assay (27). Protocadherin-1 belongs to the 81-protocadherin family of 
transmembrane proteins, together with a.o. PCDH7. 81-protocadherins are characterized by 7 
cadherin repeats in the extracellular region, and three conserved regions designated CMI, -2 
and -3 in the intracellular domain (31 ). The conserved region CM3 interacts with protein 
phosphatase 1 a (PPI a) in PCDH7 (31 ). Interestingly, PPI a plays an important role in lung 
development, as inhibition of PPI a in a mouse model led to impaired lung development and 
branching morphogenesis (32). Finally, in a skin keratinocyte wounding model, PCDHJ 
mRNA was significantly upregulated 24 hours after wounding, compatible with a role of 
PCDHI in epithelial repair (33). 
The expression pattern of PCDHI is consistent with expression in the apical adhesion 
complex of airway epithelial cells. We therefore hypothesize that PCDHl plays a role in 
epithelial integrity of the airways and that loss of function of PCDHI is associated with 
increased BHR which may lead to symptomatic asthma (34). It is tempting to speculate that 
PCDHl dysfunction may provide a functional explanation for the observed epithelial 
vulnerability and increased epithelial shedding in asthma (35). Further investigations will 
address the functional relevance of genetic variations in PCDH 1 in epithelial cell adhesion 
and its interaction with environmental tobacco smoke exposure. Moreover, these finding may 
be relevant for other diseases in which the integrity of the epithelium is a potential 
pathogenetic mechanism, such as atopic dermatitis (36) and celiac disease (37). We therefore 
suggest performing genetic studies of PCDH 1 in these diseases. 
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In conclusion, this is the first report of a gene specifically identified for BHR, an 
important hallmark of asthma. Further investigations in PCDHI function may provide novel 
insight into its role in the integrity of the airway epithelium in BHR and asthma development. 
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Dutch asthma families and asthma trios. Two hundred families (1259 individuals) were 
ascertained through probands with asthma who were initially studied between 1962 and 1975 
at Beatrixoord Hospital, Haren, The Netherlands (El ). Patients with symptomatic asthma who 
were not experiencing a current asthma exacerbation were referred to this hospital and 
admitted for a standardized, comprehensive evaluation for asthma and atopy. At the time of 
initial testing, all probands had asthma symptoms, were hyperresponsive to histamine (PC20 
histamine :'.S 32 mg/ml), and were younger than 45 years of age. The families of two hundred 
of these original probands with their spouses, children, children's spouses, and grandchildren 
older than 6 years of age were recruited and evaluated between 1991 and 1999. Participants 
had been asked to stop their asthma and allergy medication if possible. They stopped inhaled 
corticosteroids for 14 days before testing, inhaled long acting beta-agonists and oral 
antihistamines 48 hours before testing, and inhaled short acting beta-agonists and 
anticholinergics 8 hours before testing. Therapy with oral corticosteroids was continued. 
Asthma diagnosis was based on an algorithm (E 1 ). Standardized pulmonary function testing, 
bronchial responsiveness to histamine, and total serum lgE and skin tests were performed as 
described previously (Table El). BHR was defined as a PC20:'.S 32 mg/ml histamine using a 
30-second inhalation protocol. 
A second, independent asthma population of 407 patients with asthma has been 
ascertained through local hospitals and media appeals between 1998 and 2003 (E2). Available 
parents, sibs, spouses and children donated DNA to form trios (e.g. a proband and both 
parents) for genetic analyses. All probands have been characterized using the standardized 
study protocol used in the families (Table E2). PCDHI SNPs were genotyped using the 
Massarray SNP genotyping platform (Sequenom, Inc). Family based association tests in the 
families and the trios were performed using FBAT (httpl//www.biostat.harvard.edu) (E3). 
FBAT uses phenotype information of the children, but not of the parents. Therefore, a case­
control analysis of PCDHJ SNPs was done in the probands and their age-matched unaffected 
spouses using a Chi square test as an additional, independent test for association. The Medical 
Ethics Committee of the University Hospital Groningen, the University of Maryland and 
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VlagtweddeNlaardingen cohort study. The VlagtweddeNlaardingen cohort is a general population-based cohort of Caucasian subjects in the Netherlands, which started in 1 965 with a follow-up of over 25 years. In the last survey in I 989- I 990, 2,467 subjects participated. Surveys were performed every three years, in which information was collected on respiratory symptoms, smoking status, FEV 1 , and allergy skin tests (Table E2) (E4). At every visit, hyperresponsiveness to histamine was assessed in a random sample of this population, resulting in 4 1 8  subjects with one or more BHR measurement(s) over time and sufficient DNA. Bronchial hyperresponsiveness (BHR) was defined as a 1 0  % fall of forced expired volume in I second (FEV 1 ) at 1 6  mg / ml histamine, using a 30 seconds inhalation protocol. The association between PCDHJ SNPs and the occurrence of becoming BHR positive over time was investigated. Data were analysed longitudinally using a Cox regression model (SPSS 1 4.0), with adjustment for smoking, age at investigation and FEV I at baseline. PCDH 1 SNPs were genotyped using primers and probes that were obtained from Applied Biosystems TaqMan® SNP Genotyping Assays using the Assay-by-Design service for which we provided sequences. The study protocol was approved by the local university hospital medical ethics committee and all participants gave their written informed consent 
US children 's respiratory study (Tucson, AZ, USA). A total of 1 ,246 healthy newborns and their nuclear families were enrolled between 1 980 and 1984. More than three-fourths of these subjects (n=943) have been followed for the first 1 4  to 1 6  yr of life. Of this cohort, 5 1 3  unrelated enrollees who were still living in Tucson gave consent for genetic studies of asthma and allergies. Of these 5 1 3  subjects, 3 1 4  were non-Hispanic whites, 89 were Hispanics, 99 were mixed non-Hispanic whites/other (90% non-Hispanic white/Hispanic), and 1 1  were of other ethnicities. BHR was measured using nebulised cumulative dosages from 0.004 to 2.048 mg methacholine, until a fall of 20 % in FEV 1 • Children were tested for BHR at age 1 1  and 1 6, and were excluded if experiencing an upper respiratory infection or using asthma medication in the previous three months (Table E2) (E5). Data was expressed as a methacholine dose response slope and differences between genotype groups were assessed using ANOVA. PCDHJ SNPs were genotyped using standard methods. The Human Subjects Committee of the University of Arizona (Tucson, AZ) approved this study. Informed consent was obtained from parents of all subjects involved. 53 
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UK asthma families (Southampton). Three hundred forty one affected sib pair families from 
the UK were investigated, that have been investigated previously in identification of the 
ADAM33 gene (E6). Asthma was defined as a physician's diagnosis of asthma and the report 
of current medication use. For the purpose of this analysis, a least squares slope measure of 
bronchial hyperresponsiveness was investigated using age and smoking status as covariates. 
Lung function and BHR testing were performed as described previously. Bronchial 
responsiveness was measured in subjects with a baseline FEV1 of >70% predicted using 
inhaled methacholine. Passive smoking was assessed using a questionnaire response to 
questions on passive exposure to cigarette smoke in utero or in the first years of life (Table 
E2). PCDHJ SNPs were genotyped using primers and probes that were obtained from 
Applied Biosystems TaqMan® SNP Genotyping Assays using the Assay-by-Design service 
for which we provided sequences. Family based association analyses were performed with 
FBAT (http///www.biostat.harvard.edu) (E3). Ethical approval for this work was granted by 
the Local Research Ethics Committees for each collection site and parental or individual 
informed consent obtained from all subjects. 
US case control populations were recruited as described previously (E7). In brief, asthma 
cases and unaffected controls were recruited from three ethnically diverse US populations 
(African American, Hispanic, and Caucasian) as part of the Collaborative Study on the 
Genetics of Asthma (E8). Patients with asthma were defined by having a physician's 
diagnosis of asthma with BHR or bronchodilator reversibility; and reporting respiratory 
symptoms. Controls did not report symptoms of asthma, and were not tested for BHR or 
reversibility and did not have any first degree relatives with a diagnosis of asthma. Lung 
function testing, allergy skin tests, BHR measurements to methacholine or reversibility to 
albuterol were performed in the cases as described previously (Table E2) (E8). BHR was 
defined as a fall in baseline FEV 1 >20% after inhalation of <25 mg/ml methacholine. SNPs 
were genotyped using the Massarray SNP genotyping platform (Sequenom, Inc). Asthma 
susceptibility was tested in cases and controls using Chi square analysis, whereas BHR was 
tested using ANOV A in the cases only. This study was approved by the Institutional Review 
Board of Wake Forest University School of Medicine. Written informed consent for all 
adults, as well as written parental assent for children were obtained from all participants. 
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Microsatellite marker screen 
PCDH 1 is a new bronchial hyperresponsiveness gene 22 microsatellite markers were identified by resequencing the region of interest on NT_029289. Primers designed around repeat regions were used to screen for polymorphic markers and subsequently genotyped in the Dutch families, together with known markers (E9). Multiplex PCR was performed with fluorescently labeled primers. PCR products were separated on denaturing polyacrylamide gels, and the fragments were detected with ABI 377 sequencers (Perkin Elmer Applied Biosystems, Foster City, Calif). The fragments were scanned and scored with ABI software. A modified version of the program Linkage Designer was used to bin the alleles and check inheritance (EI 0). Genotyping errors, double recombinants, and inheritance inconsistencies were detected with the LINKAGE and CRIMAP software. Linkage analysis of the microsatellite fine screen markers on chromosome 5q3 1 -33 was performed using GENEHUNTER-PLUS, as described previously (E9). Fine mapping markers were selected based on linkage disequilibrium through the computer package Merlin (r2>0. I )  to select on LD block. Microsatellite marker is available through NCBI databases and further information is available through the author upon request. 
SNP screen SNPs were selected in the region of interest from Hapmap using the tagger function of Haploview (r2 =0.8, minor allele frequency of 5 % ). Outside this region, additional SNPs were selected at I O  kb intervals to further characterize the region. SNPs were genotyped using the Massarray SNP genotyping platform (Sequenom, Inc). PCR and extension primers were designed by using Spectrodesigner software (Sequenom, Inc), and reactions were performed according to the manufacturers instructions. The genotyped SNPs are listed in Table E3. Genotyping was performed blinded from the clinical data. Quality control of the SNP screen included measures of Hardy Weinberg equilibrium, with all markers that were out of HWE (p value < 0.01) being removed. Moreover, the family design enabled us to observe any Mendelian errors that may have been due to low genotyping quality. 
Resequencing of the PCDH I gene The PCDHI gene was resequenced in 96 subjects that have been described previously (E l 1 ): 1 6  cases and 8 controls from four different populations: Dutch, US African Americans, US Hispanics and US Caucasians. Overlapping PCR fragments ~ 400-600 bp were generated to sequence approximately 2 kb of the putative promoter region, all exons, and the complete 3' 55 
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untranslated region (UTR) regions. Each 30 µ1 PCR contained 30 ng of genomic DNA, Ix 
PCR buffer (Life Technologies, Gaithersburg, MD, USA), 1.5 mM dNTPs, 1.5 mM MgC12, 
200 mM dNTPs, 15 pmoles of each forward and reverse primer, and 0.5 U of Taq 
polymerase. Depending on prior reaction optimization, general cycling conditions were: 94 
�C 4 min, followed by 25-30 cycles at 94 °C for 1 min, Tanneal for 1 min, and at 72 °C for I 
min; and finishing with a single extension cycle at 72 °C for 5 min. PCR products were 
purified using the Quick step 96 well PCR purification kit (Edge Biosystems, Gaithersburg, 
MD, USA) and stored in water at - 20 ° C. DNA sequencing was performed using ABI Big 
Dye Terminator sequencing kit (Applied Biosystems, Inc., Foster City, CA, USA). Each 
sequencing reaction contained 10 - 50 ng of purified PCR product, 1.5 pmoles of sequencing 
primer, 1 mmol of BigDye Terminator mix, 1.5 µ1 of 5X sequencing dilution buffer ( 400 mM 
Tris pH 9.0, 10 mM MgC12) and water to volume. Cycling conditions were 94 °C for 1 min; 
25 cycles at 94 °C for 30 sec, 50 °C for 30 sec, and 60 °C for 4 min; and finishing with a 
single 72 °C extension step for 5 min. Sequencing products were ethanol precipitated, air 
dried, resuspended in IO -25 1 of ddH2O, and analyzed on an ABI 3700 DNA analyzer. Data 
was aligned and polymorphisms were detected using Sequencher DNA analysis software 
(Gene Codes Corporation, Ann Arbor, MI, USA). 
PCDHI mRNA expression. The human bronchial epithelial cell line 16HBE 140- (16HBE) 
was provided by Dr. D. C. Gruenert (University of California, San Francisco, CA) and 
cultured as described previously (El2). Epithelial cells were obtained through fiberoptic 
bronchoscopy by epithelial brushings from asthma patients, and were cultured for three 
passages as described previously (E13). After three passages mRNA and protein were 
isolated. Other cells were obtained from healthy donors or from autopsy material. Total RNA 
was isolated from 5 to 10 million cells by using the RN easy® mini kit (Qiagen) as described 
by the manufacturor. Next 2 µg of RNA was reverse transcribed into cDNA via Omni script® 
RT reaction (Qiagen), resulting in equal amount of cDNA. Generally 25 ng to 50 ng of cDNA 
was used as template for PCR. Two PCR reactions were performed for detecting PCDHI on 
RNA level. The first PCR detects both predicted isoforms, the second only the 5 exon 
isoforms. First PCR of exon 2 towards exon 3 was performed with forward primer: 5' -
TTCGCCTCACCAGTCATCACT-3' ,  and reverse primer: 5'­
TTGCTGTCACTGCCTGTCTCA-3' .  The second PCR from exon 3 towards exon 5 was 
performed with forward primer: 5'-ACCTGCCACCTGCAAACACAT-3' ,  and reverse primer 
TGGTAAGGCACGAAGGTGGAGA-3'. As housekeeping/control gene GAPDH was used 
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(forward primer: 5'-CGGAGTCAACGGATTTGGTCGTAT-3' ,  reverse primer: 
AGCCTTCTCCATGGTGGTGAAGAC-3'). PCRs were performed by using Expand High 
Fidelity PCR System (Roche). 
PCDHJ protein expression. For western blotting, confluent layers of I 6HBE or primary 
epithelial cells ( ~5 * I 06 cells) were lysed and mixed with protein sample buffer. Protein 
samples were separated on 7.5% or 10% acrylamide SOS-page gels (Bio-Rad Laboratories). 
Separated protein samples were transferred to PVDF-membranes (0.2µm pore-size, Bio-Rad 
Laboratories) by means of wet blotting procedure (Mini Trans-Blot cell, Bio-Rad 
Laboratories). Detection of PCDHI on PVDF membranes was performed by applying two 
primary antibodies, one polyclonal, generated from immunized rabbit against 12 amino-acid 
peptide (DIAGDPEYERSK, Eurogentec, Liege, Belgium), and one monoclonal (H00005097-
M0I, 100 mg, Abnova, Taiwan). As secondary antibodies goat anti rabbit conjugated to 
peroxidase (GARPO) and Peroxidase-conjugated rabbit-anti-mouse secondary antibody 
(RAMPO) were used, as tertiary antibodies rabbit anti goat conjugated to peroxidase 
(RAGPO) and GARPO were applied (Dako Cytomation, Denmark). Finally PCDHl signal 
was detected by applying Luminol reagent (Fluka Biochemika) on membranes, and exposing 
membranes to Medical X-Ray films (Fuji Photo Film Gmbh, Germany). 
Lung tissue samples and airway wall biopsies were embedded in paraffin. 
Immunohistochemistry was performed using the affinity purified polyclonal antibody 
(Eurogentec, Liege, Belgium). As secondary step, GARPO (Daco, Heverlee, Belgium), and as 
tertiary step RAGPO (Dako, Heverelee, Belgium) was used. Subsequently, AEC (3 amino - 9 
- ethylcarbazole (Merck, Darmstadt, Germany) was applied as a chromogen and 
counterstained with haematoxylin (Merck, Darmstadt, Germany). Similar concentrations of 
rabbit IgG isotype antibodies were used as control. PCDHI expression could be completely 
blocked by peptide preincubation (data not shown). Medical ethics committee approval and 
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Supplementary Figures and Tables 
Figure El. Multipoint point linkage analysis of microsatellitefine map on chromosome 5q31-
33 in 200 Dutch families (all); 95 families ascertained through a proband with asthma and a 
significant cigarette smoking history of > 5 pack years ( 'smoke exposed ') ; and 105 families 
not exposed to cigarette smoke. HLOD scores were generated using Genehunter using the 
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Table El: Clinical characteristics of 200 Dutch families of probands with asthma. 
* Mean values with range. Total IgE: geometric mean. # One proband married twice, both 
spouses participated in the study. Prebr= prebronchodilator. All probands were 
hyperresponsive at initial testing. Asthma was defined according to an algorithm ( class I and 
II) (El). 
Probands Spouses Children Grandchildren 
Number 200 201 540 1 86 
Age*, years 52. 1 (8.4) 5 1 .0 (9.2) 24.3 (9.2) 1 2. 1  (5.6) 
Male, % 62.0 37.8 45.0 49.3 
Total IgE*, kU/1 92.9 26.2 64. 1  62.4 
( 1 .0 - 2880) (0.5 - 1 940) (0 - 3360) (0.5 - 37 1 0) 
Positive skin test 8 1 .9 3 1 .0 54. 1 38.0 
FEY 1 %predicted prebr 69.6 98.4 93.7 90.5 
FEV 1 %VC prebr, % 59.7 76.7 8 1 .0 82.6 
BHR, % 88.2 25 .6 46.2 59.6 
Asthma, % 1 00 1 0.6 3 1 .5 39.2 
� 5 pack years smoking,% 47.5 58.2 24.6 7.3 
Table E2: Clinical characteristics of the replication cohorts 
Legend. Means and percentages are presented. Dutch asthma trios. All patients had a 
doctor's diagnosis of asthma, 86.9 % was classified as class I or II according to an 
algorithm. Dutch general population: Data was presented for last visit (1989/1990), apart 
from BHR data, that was taken from any visit where BHR measurements were peiformed. 
BHR was defined as PCJO � 16 mg /ml. * In UK families, BHR was reported as FEY] 
response to methacholine (transformed to 1/(least squares slope+30) X 1,000; BHR = 
Bronchial Hyperresponsiveness, Quest = Questionnaire. # In US case control populations, 
757 controls (Caucasian, n = 327; Hispanic, n = 130 and Afro American n = 300) were 
defined as having no symptoms of asthma and a negative family history. These controls did 
not undergo clinical testing. 
Dutch Dutch us UK us us US Afro-
asthma trio general Tucson Southampton Caucasian Hispanic Am. 
probands population (Age 1 1) families Cases # Cases # Cases # 
(children) 
N 407 4 1 8  3 1 8  822 338 1 16 222 
Age, years 33 . 8  5 1 .7 10 .7 1 1 .4 27. 1 1 7.4 24.4 
Male, % 36.9 54 .8 48 .2 53 .6 37.9 46.5 40.5 
Asthma, % 86.9 N.  I A. 9.7 87.2 100 100 100 
BHR, % 9 1 .0 5 1 .4 25 .6  1 4.6 * 89.7 9 1 .4 69.8 
FEV1 (% pred.) 87.4 96.3 100.4 95 .7 8 1 .4 95 .2 75.4 
Pos. skin  test, % 82.9 1 3 .6 65 . 1  6 1 .3 90.6 85 . 1  90.4 
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PCDH 1 is a new bronchial hyperresponsiveness gene Table E3: SNPs (name and chromosomal location on chromosome 5 built 36.3, NT _029289.10) genotyped on chromosome Sq in 200 Dutch asthma families 
rs2530223 1 40994677 rs2974703 1 4 1 205502 rs37477 1 7  1 4 1 30 1 822 
rs456998 1 4 1 005345 rs l 720855 1 1 4 1 207 1 54 rs l 64083 1 4 1 30582 1 
rs6580 1 94 1 4 1 0 1 4306 rs ! 70978 1 2 1 4 1 209072 rs2434322 1 4 1 3 1 5 1 05 
rs49 1 26 1 0  1 4 1 034423 rs77 1 939 1 1 4 1 209824 rs l 64073 1 4 1 3 1 5425 
rs349 1 32 1 4 1 0448 1 0  rs3935792 1 4 1 2 1 2 1 77 rs l 64075 1 4 1 3 1 6448 
rs658020 1 1 4 1 052668 rs77 l l 783 1 4 1 2 1 5263 rs 1 64077 1 4 1 3 1 7409 
rs349 1 28 1 4 1 06 1 080 rsl 1 745262 1 4 1 2 1 6080 rs252 1 08 1 4 1 3 1 8955 
rs2486 1 6  1 4 1 07 1 494 ivs3- l 16  1 4 1 2 1 7333 rs376 1 762 14 1 3 1 90 1 1 
rs755772 1 4 1 08 1 269 rs l 2523337 1 4 1 2 1 7532 rs252 1 09 1 4 1 3 1 9072 
rs9686896 1 4 1 09 1 090 rs l 1 1 6776 1 1 4 1 2 1 8526 rs l64078 1 4 1 3 1 9 164 
rs32926 1 4 1 099223 rs l 2653948 1 4 1 222067 rs l64079 1 4 1 3 1 9947 
rs32946 1 4 1 1 09387 rs l4359 1 4 1 2228 17  rs6580209 1 4 1 324307 
rsl 1 7388 1 8  1 4 1 1 1 8664 rs3797054 1 4 1 223830 rs252 1 37 1 4 1 3270 1 4  
rs740666 1 4 1 1 28665 rs3822357 1 4 1 224540 rs740662 1 4 1 336 1 32 
rs l 52355 1 4 1 1 36482 rs l 0063472 1 4 1 226830 rs252 1 0 1  1 4 1 344936 
rs248492 1 4 1 1 46058 rs l 0054 1 86 1 4 1 226998 rs364287 1 4 1 34799 1 
rs457639 1 4 1 1 5 1 926 rs l 25 1 5587 1 4 1 229 1 46 rs433623 1 4 1 348082 
rs l 76 1 0222 1 4 1 1 535 1 1 rs4563655 1 4 1 23 1 724 rs409037 1 4 1 354387 
rs l 52267 1 4 1 1 57045 rs l 25 1 7246 1 4 1 232232 rs252 1 1 4 1 4 1 362768 
rs l 428726 1 4 1 1 62888 rs6888 1 35 1 4 1 234246 rs l 08593 1 4 1 366822 
rs2974706 1 4 1 1 67646 rs6580203 1 4 1 237242 rs l64080 1 4 1 37 1 7 1 6  
rsl 7097654 1 4 1 168499 rs 1 0057 1 57 1 4 1 238949 rs39 10558 1 4 1 3775 10  
rs l 87454 1 4 1 1 7 1 907 rs l 3355929 1 4 1 2392 1 7  rs492620 1 4 1 394644 
rs l 764889 1 1 4 1 1 765 1 6  rs49 1 2782 1 4 1 2426 1 0  rs7722 1 6 1  1 4 1 406068 
rs l 7648933 1 4 1 1 8 1 22 1  rs l 7097839 1 4 1 258742 rs65802 1 6  1 4 1 4 1 3259 
rs1 76 1 0605 1 4 1 1 8 1 524 rs9324859 1 4 1 259534 rs l 438699 1 4 14223 1 7  
rs1 76 1 06 1 9  1 4 1 1 82387 rs6862407 1 4 1 266527 rs2522 1 5  1 4 1 43 1 02 1 
rsl 7525960 1 4 1 1 84044 rs4 1 4 1 206 1 4 1 276686 rs49 1 2800 1 4 1 437879 
rs2485 14  1 4 1 1 85 1 29 rs l 003563 I 1 4 1 2770 1 3  rs2338874 1 4 1 447 1 1 0  
rs l 7705472 1 4 1 1 86045 rs49 1 2787 1 4 1 277307 rs89 1 990 1 41 455645 
rs 1 3 1 62099 1 4 1 1 865 1 5  rs3855086 1 4 1 279 1 6 1 rs735683 1 4 1 465352 
rs248504 1 4 1 1 8965 1 rs386 1 854 1 4 1 280553 rs l 7287 1 76 1 4 1 483936 
rs l 66040 1 4 1 1 90936 rs4453 1 0  1 4 1 28 1 090 rs2043280 1 4 1 493875 
rs400540 1 4 1 1 97958 rs9 1 753 I 1 4 1 285467 rs1 062 1 58 1 41 503 1 84 
rs38 1 5355 1 4 1 200 1 89 rs35 1 260 1 4 1 290008 rs449454 1 4 1 5 1 3246 
rsl 709780 1 4 1 202437 rs2286523 1 4 1 294434 rs l 77059 1 3  1 4 1 52 1 095 
rs6890366 1 4 1 53 1 043 6 1  
CHAPTER 2 
Table E4: Protocadherin-1: Gene, mRNA expression and SNP position. 
NT_ AC094107.3: position on reference contig NT_ AC094107.3. Cauc. US Caucasian; Afr 
Am US African American, Hisp. US Hispanic. Np not polymorphic. SNPs in bold were 
selected for genotyping in complete study populations. 
mRNA NM_002587.3 
mRNA NM_032420.2 
exon 1 2 3 4 5 
DNA 
SNP 1 3 1 2  
1 1  1 3 
Frequency (allele 2) in 
SNP region name AC0941 07.3 rs number Allelel 1 Allele 2 seguencing eanel 
Afr 
Cauc. Am Hise. Dutch 
promoter -1 440 92385 A C np 0.02 np np 
2 promoter - 1 362 92307 A Ins A Del np 0.02 np np 
3 promoter -1206 921 51 rs1 3355929 G A 0.05 0.41 np 0.02 
4 promoter -938 91883 rs10057157 G A 0.45 0.13 0.60 0.39 
5 promoter -924 91 869 C T np 0.02 np np 
6 promoter -909 91 854 TT Ins TT Del np 0.02 np np 
7 intron 1 IVS1 -26 821 40 C T 0.04 np np 0.05 
8 exon 2 Leu 1 5Phe 821 1 2  rs1 251 7385 C T np np 0.02 0.02 
9 exon 2 His25Pro 82081 rs12515587 A C 0.1 1 0.80 0.10 0.1 7 
1 0  exon 2 Ala287Ala 81 294 C T 0 .02 0.04 np np 
1 1  exon 3 Ala514Thr 77474 rs3822357 G A 0.04 0.02 0.08 np 
1 2  exon 3 Asn601 Lys 7721 1 T G np 0.04 np np 
1 3  exon 3 Ala71 2Thr 76880 rs34636888 G A np np np 0.03 
1 4  exon 3 Ala750Ala 76764 rs3797054 T C 0.35 0.37 0.34 0.25 
1 5  exon 3 Gly903Ser 76307 G A np 0.02 np np 
1 6  exon 3 Gly 10 1 3Gly 75975 C G 0.04 np np 0.02 
1 7  exon 3 IVS3 +1 64 75751 rs14359 G C 0.1 9 0.09 0.1 3 0.25 
1 8  intron 3 IVS3 -1 16  70270 TTC lns ITC Del 0.09 0.02 0.1 0 0.08 
1 9  intron 4 IVS4 +50 69885 G A 0.03 np np np 
20 intron 4 IVS4 +1 52 69783 T C 0.03 np np np 
21 intron 4 IVS4 +233 69702 C T np 0.02 np np 
22 exon 5 Ala1 1 49Ala 66992 C T 0.02 np np np 
23 3' UTR 3'UTR +43 66682 C T np np 0.04 np 
24 3' UTR 3'UTR+238 66487 rs1 021 3790 G T ne 0.06 ne ne 
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Table ES: Interaction of PCDHJ gene variants and environmental tobacco smoke exposure 
in utero I first years of life 
* Data not shown due to differences in allele frequency of Hispanic and Caucasian 
populations 
SNP Risk Dutch Dutch Asthma trios Tucson, US UK 
allele Asthma families General population, children asthma families 
At age I I at age 1 6  
ETS No ETS ETS I No ETS ETS / No ETS ETS / No ETS ETS / No ETS 
N 635 624 944 277 58/2 1 5  50/233 1 508 1 508 
Analysis FBAT FBAT FBAT FBAT ANOVA ANOVA FBAT FBAT 
Ala5 1 4Thr G 0.35 0.09 0.89 0.53 0.4 I 0.06 0.33 / 0. 1  0.009 0.09 
Ala750Ala T 0. 1 8  0.0 1 0.88 0.24 0.D78 / 0. 1 25 0.9 / 0.035 0. 1 9  0.68 
IVS3+ 1 64 C 0.58 0. 1 9  0.79 / 0.70 0.75 I 0.88 0 . 1 8  0.4 1 
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CHAPTER 3 
ABSTRACT 
Background: Eczema and asthma share a common genetic background and show linkage to 
chromosome 5q31-33. Protocadherin-1 (PCDHJ) is located in this region and was identified 
as a susceptibility gene for bronchial hyperresponsiveness (BHR), a hallmark of asthma. 
PCDHJ encodes an adhesion molecule, expressed in airway and skin epithelium. 
We determined whether PCDHJ polymorphisms, previously associated with asthma or BHR, 
also associated with questionnaire and UK Working Party (UKWP) defined eczema. 
Methods: Four PCDHJ polymorphisms were genotyped in two Dutch birth cohorts, PIAMA 
(n=967) and KOALA Birth Cohort Study (n= 1560). Association with eczema was determined 
by Chi-square tests, and Generalized-Estimating-Equations (GEE). 
Results: Insertion deletion IVS3-l l 6 was associated with development of UKWP-eczema in 
PIAMA (age 4, OR=l .90 (1.14-3.18)), and borderline with questionnaire-reported eczema in 
PIAMA (GEE, OR=l .33 (0.98-1.81)). Furthermore IVS3-l 16 was associated with 
questionnaire-reported eczema in KOALA (age I, OR=l.44 (1.00-2.07)). Pooled analysis of 
questionnaire-reported eczema of both cohorts resulted in a significant association of IVS3-
l 16 with eczema (OR= 1.26 ( 1.01-1.58)). Rs3822357 (A-allele) associated with protection for 
eczema in PIAMA only (questionnaires, OR=0.19 (0.06-0.63)). 
Conclusions: PCDHJ gene variant IVS3- l 16 associates with eczema in two independent birth 
cohorts. Combined with previous observations this indicates a shared genetic susceptibility to 
BHR, asthma and eczema. 
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INTRODUCTION 
Atopic diseases such as eczema and asthma are increasingly prevalent in the western 
world (I). These complex diseases are caused by an interplay of genetic and environmental 
factors (2). Several prospective studies have shown that eczema pre-dates or co-exists with 
asthma (3, 4). Twin studies indicate that these atopic diseases share a common genetic 
background, but that also disease specific genetic factors exist (5). 
The chromosomal region 5q31-33 is strongly linked to eczema (6, 7), asthma and 
bronchial hyperresponsiveness (BHR) (8-10). In this region, multiple atopy susceptibility 
genes have been identified, such as SPINKS (eczema), IL-13 (asthma, atopy) and CD14 
(atopy). One gene in this region, Protocadherin-1 (PCDHJ), has recently been discovered as 
a BHR susceptibility gene ( 11 ). 
PCDHI is thought to play a role in cell-cell adhesion (12, 13). PCDHI mRNA and 
protein expression was identified in airway epithelium (11 ), whereas PCDHI mRNA is 
expressed in skin keratinocytes (14, 15). A defect in epithelial barrier function may represent 
an underlying common mechanism in asthma, BHR, and eczema (16). 
We hypothesized that PCDHJ gene variants may represent a common genetic 
background of eczema and asthma, due to its proposed barrier function in epithelial cells. We 
therefore determined whether SNPs, that were shown previously to associate with asthma and 
BHR, are associated with eczema. To this aim we investigated the association of PCDH 1 
SNPs with eczema in two Dutch prospective birth cohorts. 
MATERIAL AND METHODS 
Study populations 
Two Dutch populations were investigated: I) The Prevention and Incidence of Asthma 
and Mite Allergy (PIAMA) birth cohort, 2) KOALA (Dutch acronym for: Child, Parent, 
health, Focus on Lifestyle and Predisposition) birth cohort. The local medical ethics 





Recruitment of subjects for PIAMA birth cohort - Study design of the PIAMA birth 
cohort has been described previously (17). In summary, recruitment took place during the first 
trimester of pregnancy with a validated screening questionnaire (18) and was conducted by 52 
midwife practices in 3 different regions in the Netherlands: north (Groningen and 
surroundings), central (Bilthoven and Wageningen and surroundings), and southwest 
(Rotterdam and surroundings). Women reporting any of the following symptoms were 
defined as allergic (i.e. a history of asthma, current hay fever, current allergy to house dust 
mite, or pets) and their children were defined as 'high-risk' .  A total of 10,232 pregnant 
women completed the questionnaire and 2,949 (29%) of them were 'allergic'. The 
participating children were born between May 1996 and December 1997, and were followed 
yearly, up to 8 years of age. 
At baseline, the PIAMA study population consisted of 4,146 children, 183 (5%) were 
lost to follow-up. The study therefore started with 3963 newborns: 1,327 children from 
allergic mothers and a random sample of 663 children from non-allergic mothers were 
sc1ccted for medical examinations, from which 1,808 children were eligible for a medical 
examination at age 4, and of whom 1,288 children participated. DNA was collected at age 4 
from 1037 children during medical examinations for atopic eczema. Children of non-Dutch 
mothers were excluded from the analysis. At the age of 1 year medical examination for 
eczema was performed only for the intervention group (n=414). Intervention consisted of 
mite-impermeable mattress covers. Study population characteristics are described in Table 1 .  
Recruitment of subjects for the KOALA cohort - The design of the study has been 
described previously ( 1 9). Briefly, participants with diverse lifestyles ( conventional and 
alternative) were recruited at 34 weeks of gestation. Pregnant women with a conventional 
lifestyle (n=2343) were recruited from an ongoing prospective cohort study on Pregnancy­
related Pelvic Girdle pain in the Netherlands. Additionally, pregnant women with an 
alternative lifestyle (n=491) were recruited through organic food shops, anthrophosophic 
doctors and midwifes, Steiner Schools, and magazines. During the first two years postpartum, 
and at the age of 6 years information on atopic outcomes and their determinants were 
collected for all members of the cohort by repeated questionnaires at ages 3, 7, 12, 24 months 
and 6 years. The study was approved by the medical ethics committee of the Maastricht 
University. Written informed parental consent was obtained from all participants. All 
participants were asked for providing DNA via buccal swaps (n= 1,560). Dutch children were 
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Clinical evaluation Diagnosis of eczema. For the PIAMA cohort at the age of I to 8 years, and for the KOALA cohort at 7, I 2, 24 months, and 6 years, infants were defined as having developed eczema if their parents reported eczema based on ISAAC (the International Study of Asthma and Allergies in Childhood) questions. The ISAAC questionnaire defines eczema as 'the presence of a history of itchy rash which was coming and going in the last I 2 months, localized on flexural sites on folds of the elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, ears or eyes. Cases of only diaper rash, rash around the eyes and/or scalp scaling were excluded. At home visits at the age of I and 4 years for PIAMA and at 2 years for KOALA, trained health nurses examined infants for atopic dermatitis according to the UK Working Party (UKWP) criteria (20-22) in a subset of the population. In PIAMA, home visits were performed at 1 year for children of the intervention study, and at 4 years for a random sample of the cohort. In PIAMA, a mandatory modification was made to the UKWP - criteria at I year only, since the UKWP criteria "early onset" and "presence of other atopic diseases" are less relevant for children at 1 2  months of age (23). In KOALA, home visits were performed in children whose parents gave permission to draw blood samples. Infants with a UKWP probability score (20) of atopic dermatitis (AD) > 90% were regarded as infants with 'probable presence of atopic dermatitis' as was determined previously (24). Diagnosis of asthma: In the PIAMA cohort we analysed 'doctor-diagnosed asthma' ,  defined as asthma ever diagnosed by a doctor and asthma present i n  the last 1 2  months. Second, we used a definition of asthma based on symptoms, defined as at least one attack of wheeze or dyspnoea and/or the prescription of inhaled corticosteroids in the last 1 2  months (25). In PIAMA bronchial hyperresponsiveness at 8 years was defined as a fall of 2:20% in FEV I after inhalation of a maximum of 0.62 mg methacholine bromide (26). In the KOALA cohort asthma at the age of six years was defined by asthma symptoms: at least one attack of wheezing or dyspnoea, or regular use of inhaled asthma medications in the last year. 69 
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Table 1: Participant characteristics for PIAMA and KOALA study populations and total 
birth cohorts 
Characteristics PIAMA PIAMA KOALA KOALA 
Study Total Cohort Study Total 
PO}!Ulation PO}!Ulation Cohort 
Number 967 3,963 1 ,560 2,834 
Ethnicity (% Dutch origin) 1 00 94.2 1 00 95.8 
Boys (%)  5 1 .9 5 1 .8 50.3 5 1 .3 
Education level mother ( % ) 
Low 1 8.3 23.5 8.3 1 0.7 
Intermediate 42.7 4 1 .5 37.3 39.4 
High 39.0 35.0 54.4 49.9 
Family history ( % ) 
Atopy mother 65.9 3 1 .3 32.9 34. 1 
Asthma mother 1 6.3 7.9 8.9 9.3 
Atopy father 3 1 .7 30.8 36.6 35.0 
Asthma father 7.3 7.7 J O. I  1 0.0 
Children at risk (%)1 75.6 5 1 .5 55.8 56.5 
Intervention (type) Mattress covers Mattress Covers No No 
No (%) 57. 1 80.7 1 00 1 00 
Placebo (%) 24.3 1 0.0 0 0 
Active (%) 1 8 .6 9.3 0 0 
Environmental exposures 
Breast feeding (%) 
Never 14.6 1 7.9 1 4.6 1 9.8 
< 3 months 35.0 38.4 20.7 2 1 . 1  
� 3 months 50.4 43.7 64.7 59. 1 
ETS at home first year (%) 22.9 27.8 1 1 .5 15 .4 
Pet (dog and/or cat) first year (%) 39.6 43.2 39.8 4 1 .9 
Dog first year (%) 14.3 1 6. 1  1 9.8  22.2 
Cat first year (%) 29. 1 32.8 24.3 23.8 
Presence older siblings at birth (%) 48.8 50.5 58.3 55.7 
Eczema manifestations 
ISAAC questionnaire 
1 year (%) 1 8.5; n= 1 74 1 5 .2; n=559 1 8.0; n=263 1 9.4; n=484 
2 years (%) 20. 1 ;  n=1 89 1 6.6; n=6 1 6  1 5 .4; n=234 1 5 .3; n=389 
3 years (%) 22.3; n=209 1 7.3; n=632 N.a. N.a. 
4 years (%) 2 1 .5 ;  n=200 1 7.9; n=63 1 N .a. N.a. 
5 years (%) 1 7.9; n= 1 64 1 5 .3; n=5 1 5  N.a. N .a. 
6 years (%) 1 8.0; n= 1 65 1 5 .4; n=527 1 3 .6; n=1 77 1 3 .9; n=275 
7 years (%) 1 6.9; n=l 50 1 4.3; n=479 N.a. N.a. 
8 years (%) 1 8.3; n=1 59 1 6.0; n=5 1 5  N.a. N.a. 
UKWP criteria 
1 year (%) 1 3 .7; n=56 1 4.3; n=479 N.a. N.a. 
2 years (%) N.a. N.a. 1 3 .8 ;  n=93 1 3 .4; n= l 1 6  
4 years (%) 1 2.0 ; n=l 15 1 2.2; n= l 55 N.a. N.a. 
Total serum IgE 
1 year (IU/ml)2 7. 1 (2.0-1 7.0) 6.6 (2.0- 1 7  .0) 6.0 (2.6- 1 2.4) 6.4 (2.7- 1 3 .3) 
n=346 n=565 n=644 n=9 1 2  
2 years (IU/ml)2 N.a. N.a. 1 2.0 (3.6-38.0) 1 2.2 (3.8-38.5) 
n=658 n=829 
4 years (IU/ml)2 35.0 ( I  2.0-95.0) 37.3 ( 1 3 .0- 1 07.3) N .a. N.a. 
n=664 n=746 
8 years (IU/ml)2 65.0 (23.0-230) 62.8 (20.0-227.5) N.a. N.a. 
n=703 n=l ,7 1 3  
Asthma manifestations 
Asthma symptoms 
3 years (%) 25.3; n=245 22.9; n=844 N.a. N.a. 
4 years (%) 24.0; n=230 1 8.8; n=670 N.a. N.a. 
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5 years (%) 
6 years (%) 
7 years (%) 
8 years (%) 
Doctor-diagnosed asthma 
I year (%) 
2 years (%) 
3 years (%) 
4 years (%) 
5 years (%) 
6 years (%) 
7 years (%) 
8 years (%) 
Bronchial hyperresponsiveness 
8 years (%) 
22. 1 ;  n=2 1 1 
1 8.3 ;  n= 1 74 
1 6.6; n= 1 5 1  
1 7.2; n= 1 58 
7.2; n=69 
5.6; n=54 
5 . 1 ;  n=49 
5.2; n=50 
5 . 1 ;  n=48 
5 .8 ;  n=55 
4.2; n=38 
5 . 1 ;  n=45 
44.9; n=293 
1 7.6; n=6 1 5  
1 4.6; n=507 
1 2.3;  n=4 1 6  
1 3 .0; n=429 
6. 1 ;  n=224 
4.8; n= l 77 
4. 1 ;  n= l 52 
4. 1 ;  n= 145 
4.0; n= 1 38 
3.9; n= l 34 
2.8; n=98 
3.6; n= l 1 6  
42.9; 402 
N.a. N.a. 






N.a. N .a. 
N.a. N.a. 
N.a. N.a. 
N.a. N .a. 
N.a. N.a. 
N.a. N.a. 
Abbreviations: n = number of samples available; N.a. = not available. Definitions of characteristics were 
described previously (27). 
1 Defined as: children who have at least one parent with asthma or atopy. 2 Geometric mean (interquartile range). 
Genotyping 
Subjects from the PIAMA and KOALA cohorts were genotyped for three PCDHJ 
single nucleotide polymorphisms (SNPs) (rs3797054, rs3822357, and rs l4359) and one 
insertion deletion (NS3-I 16, Figure IA), in amplified DNA by Competitive Allele-Specific 
PCR using KASPar™ genotyping chemistry, performed under contract by K-Biosciences, as 
described previously (27). These polymorphisms were selected based on previous associations 
of PCDHJ with BHR and asthma (11). 
Linkage Disequilibrium (LD) was calculated using Haploview v4.1, by determining 
D' and r2 values (http://www.broad.mit.edu/mpg/haploview). Genotyping was performed 
blinded of the clinical status and considered successful when less than 5% of the genotypes 
were missing. Furthermore, all SNPs were tested for deviations from Hardy Weinberg 
equilibrium, using x,2-tests (p>0.05). 
Statistical analysis 
Eczema was investigated for association with PCDHJ gene variants using chi-squared 
tests, comparing genotype frequencies between affected and non-affected individuals. Odds 
Ratios (OR) and 95% confidence intervals (95% Cl) were calculated from logistic regression 
analysis. To detect a possible influence of asthma on the associations of PCDHJ with eczema, 
analyses were repeated adjusted for asthma. 
Generalized Estimating Equations (GEE) were used to assess associations between PCDHJ gene variants and the presence of eczema in the first 8 years of life. GEE is a 
longitudinal statistical technique that takes correlations between repeated measurements in the 
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same individual into account. Since 8 observations on atopic dermatitis were made on the 
same subject, we performed a GEE analyses to analyse the relationships of PCDHJ SNPs 
with eczema simultaneously. A 7-dependent working correlation structure fitted the data best. 
This assumes that the correlations t measurements apart are equal, the correlations t+ I 
measurements apart are equal and so on for t= l to t=7. We present the overa11 estimates based 
on yearly measurements. We repeated GEE analysis adjusted for parental atopy, sex, 
breastfeeding, intervention and study population, and inspected whether these covariates alter 
the regression coefficient 2: 10%. In addition analyses were repeated adjusted for asthma. We 
previously investigated and reported the validity of pooling data from these two highly 
comparable birth cohorts (27). For a11 statistical analysis we report associations obtained by 
the best-fitting genetic model. 
RESULTS 
Genotyping 
All tested SNPs were located in or nearby exon 3 of PCDHJ. All SNPs were in Hardy 
Weinberg equilibrium (p>0.05). The allele frequencies were similar in the PIAMA and 
KOALA cohorts (Figure 1 A). Measures of LD were comparable between study populations. 
Strong LD was observed for rs3822357, rs3797054, rs 14359 and IVS3-l 16, as D' approaches 
the value of 1. LD expressed as r2 was remarkably lower (0.0-0.17), due to differences in 
a11ele frequencies between SNPs (Figure 1 B). 
Association with eczema in PIAMA and KOALA cohorts 
In the PIAMA cohort (see Table I for characteristics), the del IVS3-l 16 variant was 
significantly associated with UKWP defined eczema at the age of 4 years, using the best­
fitting dominant model (OR=l .90 (95% CI: 1.14-3. 18)), and a tendency in a similar direction 
was observed at 1 year of age (OR=l .74 (0.81-3.72)) for this eczema definition. Furthermore 
IVS3-1 16 was border-line associated with increased risk of eczema, defined by questionnaire, 
in the PIAMA cohort (GEE analysis of 0-8 years; dominant model: (OR=l.33 (0.98-1.81)) 
(Table 2). 
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Figure 1: Protocadherin-1: Gene, mRNA expression, SNP position and LD-pattern. 
PCDHJ SNPs are numbered 1 to 4 and corresponding minor allele frequencies are calculated 
per population (A). Linkage disequilibrium, plots are displayed for D '  and R-square values 
both for PIAMA and KOALA. D '  is represented by black colour, meaning D '  is >0.9. r2=0 is 
white and r2=1 is represented in black (B). 
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PIAMA KOALA 
exon 3 Aia5 14Thr 77474 rs3822357 G A 0.08 O.Q7 
2 exon 3 Ala750Ala 76764 rs3797054 T C 0.36 0.36 
3 exon 3 IVS3 + 164 7575 1 rs 14359 G C 0.23 0.23 
4 intron 3 IVS3 - 1 16 70270 (submitted) TTC Ins TTC Del 0.06 0.07 
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Rs3822357 (A-allele) was significantly associated with decreased risk of eczema, 
defined by questionnaire (GEE of 0-8 years, co-dominant model OR=0. I 9 (0.06-0.63)) in the 
PIAMA study. Numbers were too low to accurately determine association with UKWP 
criteria. 
In the KOALA birth cohort (see Table I for characteristics) we also observed an 
association of IVS3-116 with increased risk of eczema. IVS3-116 del was significantly 
associated with ISAAC questionnaire defined eczema at I year (OR=l .44 (1.00-2.07), 
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dominant model), but not at later age and not with UKWP criteria (Table 2). The protective 
effect of rs3822357 (A-allele) was not identified in KOALA (Table 2). Other PCDHJ SNPs 
were not significantly associated, neither with ISAAC questionnaire nor UKWP defined 
eczema, both in PIAMA and KOALA cohorts (data not shown). 
Importantly, GEE analysis on pooled ISAAC questionnaire data of PIAMA and 
KOALA cohorts resulted in a significant association of IVS3-116 with eczema (OR= 1.26 
(1.01 -1.58), dominant model) (Table 2 and Figure 2), but not of rs3822357 (OR=0.68 (0.23-
2.03)). For IVS3-116 associations with eczema were specifically identified at age 1 and 3 
years (OR=l .38 (1.03-1.84) and OR=l .59 (1.04-2.43)), and border-line at age 7 year 
(OR=l .60 (0.98-2.60), Figure 2). Adjustment for potential confounders (paternal atopy, sex, 
breastfeeding, intervention or study population) did not change any of the above mentioned 
associations. 
Figure 2: Association of IVS3-116 with eczema in pooled PIAMA and KOALA cohorts. 
Results of Generalized Estimating Equations are shown for IVSJ-116. Odds ratios and 95% 
confidence intervals are calculated per year for pooled PIAMA and KOALA cohorts, using a 
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When we constructed haplotypes using the selected SNPs, the significant associated 
deletion variant IVS3-116 was only in a haplotype with wild type rs 14359, rs3797054, and 
rs3822357 alleles, with similar allele frequencies as IVS3-116 alone (PIAMA 0.063; KOALA 
0.070). Therefore the haplotype analysis did not result in different associations. 
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PCDH I polymorphisms associate with eczema As PCDHI was previously associated with BHR and asthma, we investigated whether asthma status, at the same age as when the association of PCDHJ with eczema was determined, had influence on the association of PCDHJ with eczema. For the association of UKWP eczema at 4 year, we observed no confounding relationship of asthma phenotypes on the association of PCDHJ with eczema. In addition, correction for doctor-diagnosed asthma had no influence on the association analyzed by GEE between PCDHJ NS3- 1 1 6  and questionnaire defined eczema (OR= l .33 (0.98- 1 .8 1  ), p=0.07). Correction for asthma symptoms even showed a small increase in odds ratio (OR = 1 .38 (0.99- 1 .92), p=0.058). Finally, in children with eczema, there was no significant association of PCDHJ with BHR or asthma at later age (data not shown). 
Table 2: Associations of PCDHJ SNPs with eczema in PIAMA and KOALA cohorts 
Cohort Eczema Age SNP # Total Risk Allele Outcome (OR (95%CI)) P-value 
definition (�rs) Subjects 
PIAMA Question- 0-8 IVS3- l 1 6  96 1 TTC Del (3) 1 .33 (0. 98- 1 .8 1  ) 0.070 
naire (GEE 
Analysis) 
Question- 0-8 rs3822357 96 1 A ( I )  1 . 1 6  (0.84- 1 .6 1 )  0.36 
naire (GEE (2) 0. 1 9  (0.06-0.63) 0.0068 
Analysis) 
UKWP I IVS3- l 1 6  392 TTC Del (3) 1 .74 (0.8 1 -3.72) NS 
4 IVS3- l 1 6  929 TTC Del (3) 1 .90 ( 1 . 14-3 . 1 8) 0.0 1 3  
KOALA Question- I IVS3- l  1 6  1 427 TTC Del (3) 1 .44 ( 1 .00-2.07) 0.032 
naire 2 IVS3- l  1 6  1483 TTC Del (3) 0.9 1 (0.60- 1 .39) NS 
6 IVS3- I 1 6  1 283 TTC Del (3) 1 . 1 0  (0.70- 1 .72) NS 
Question- rs3822357 1438 A ( I )  0.75 (0.49- 1 . 1 5) NS 
naire (2) 0.48 (0.06-3.84) NS 
2 rs3822357 1 496 A ( I )  0.90 (0.59- 1 .39) NS 
(2) 2.32 (0.60-9.05) NS 
6 rs3822357 1 290 A ( I )  0.63 (0.37- 1 .09) NS 
(2) 1 .72 (0.35-8.33) NS 
UKWP 2 IVS3- l  1 6  (3) 1 .00 (0.52- 1 .92) NS 
rs3822357 ( I )  0. 72 (0.33- 1 .55) NS 
(2) 6.2 1 (0.86-44.73) NS 
Pooled Question- 1 -8 IVS3- l 1 6  2486 TTC Del (3) 1 .26 ( 1 .0 1 - 1 .58) 0.042 
naire (GEE 1 -8 rs3822357 2486 A ( I )  1 .03 (0.8 I - 1 .3 1 )  NS 
Anal�sis) (2) 0.68 (0.23-2.03) 
Definition of models: (I) = Heterozygous minor allele compared to homozygous wild type, (2) = Homozygous minor allele 
compared to homozygous wild type, ( 3) = Dominant model (heterozygous and homozygous minor alleles compared to 
homozygous wild type). NS = not signijicalll. 75 
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DISCUSSION This study showed significant association between the PCDHJ insertion deletion polymorphism IVS3- l l 6 and increased risk of eczema, defined by objective measurements for eczema, the UK Working Party criteria. Moreover, in a pooled analysis of 2486 children of these birth cohorts, IVS3-116 was significantly associated with questionnaire defined eczema at age O to 8. We observed association between the PCDHJ polymorphism IVS3-1 16 and eczema in two independent Dutch birth cohorts. Importantly, the annual ISAAC core questions provided similar prevalence rates of eczema in these cohorts. We excluded children from non-Dutch origin and investigated a homogeneous Dutch population. Our studies were hypothesis driven, and we therefore did not correct for multiple testing but rather determined association of 
PCDHJ polymorphisms in a second cohort. Furthermore, the same allele (del IVS3-116) was previously found to be associated with asthma and BHR (11), providing evidence that these diseases share a genetic background. We detected several differences in the pattern of the association of PCDHJ with eczema that related to an age specific effect, and the association of PCDHJ with eczema defined through UKWP criteria. For KOALA, data on eczema is available in the first 2 years, and IVS3-116 associated with questionnaire eczema at age 1, but not at 2 or 6 years, in children not selected for maternal allergy. This may suggest that PCDHJ is associated with an early onset of eczema. However, when analyzing PIAMA questionnaire data longitudinally with GEE, no change in risk was observed in time. In addition, when pooling the questionnaire data of both cohorts, a significant association was identified during the whole period in this larger sample size (Figure 2). Additionally, the association of IVS3-116 with eczema was not modified by paternal allergy. The association of UKWP eczema with IVS3-116 was identified at the age of 4 years in a subset of the PIAMA cohort, while no association existed in KOALA at age 2 using this definition. One explanation for the difference in association of IVS3-116 with UKWP eczema can relate to the slightly different usage of UKWP-criteria. As in KOALA at the age of 2 years no data is available on asthma in children, the UKWP-criteria "History of asthma or hay fever" was not applied, while in PIAMA for the eczema assessment at the age of 4 years this criterion was included. This could have led to an enrichment of children in de PIAMA cohort with asthma or hay fever, and thereby influence the association. However, we detected no confounding relationship of asthma on the association of PCDHJ with eczema. The detected 
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differences in the associations may relate to the onset or severity of eczema, or cohort specific 
gene-gene or gene-environmental interactions. 
Although not strongly replicated, we do observe significant association in two 
independent cohorts. The significant associations were identified using 115 and 263 eczema 
subjects respectively. In order to investigate replication, we suggest analysing IVS3-I I 6 in a 
larger sample size. 
We did identify an association of the coding SNP rs3822357 (Ala5 I 4Thr) with eczema 
in PIAMA. Again, the same risk allele was observed for BHR in a family study from the UK 
and a birth cohort from the US (11 ). This finding was not significantly replicated in KOALA. 
This difference in association could not be explained by the difference in study design, as 
correction for potential confounders (paternal atopy, sex or breastfeeding) did not alter the 
association of rs3822357 with eczema in PIAMA. Given the low allele frequency of the risk 
allele, power was low to investigate replication and we therefore suggest that larger studies 
have to analyse this SNP in order to increase power to detect association. 
Three PCDHJ polymorphisms (rs3797054, IVS3-l 16, and rs3822357) have been 
previously reported to associate with BHR and asthma in Dutch, UK and US populations (11) 
and we now report that one of these polymorphisms (IVS3- l l 6) to be associated with eczema. 
The functional effects of these gene variants are not known. Together with the published 
evidence on the adhesion function of PCDHI (13) and its expression in skin keratinocytes 
(14), this points towards a role of this gene affecting epithelial integrity in BHR and asthma, a 
mechanism that also has been proposed for eczema ( I 6, 28). 
It is of interest to compare our results with data on filaggrin (FLG), a replicated gene 
for eczema, resulting in loss of epithelial integrity in the skin. Previously, we genotyped the 
PIAMA cohort for three FLG SNPs, and confirmed the relative high prevalence of the FLG 
null mutations in the north of Europe (29), which clearly differs for Mediterranean 
populations, were the frequency of these SNPs was low or not detected (30). These results 
point towards genetic heterogeneity of this disease. For FLG, we and others have observed an 
association with early age at onset of eczema (31-34). In addition, it has been reported that 
persons with eczema carrying FLG mutations are at increased risk to develop asthma. Albeit 
not that strong as for FLG, we do observe significant associations of relative rare PCDHJ 
gene variants with eczema. We were not able to determine FLG and PCDHJ gene-gene 
interactions due to low numbers of children carriers of both FLG and PCDHJ deletions. 
Interestingly, for PCDHJ we did not observe a progression towards asthma at age 6 to 8. 
Since the initial genetic association of PCDHJ gene variants with asthma was identified in an 
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CHAPTER 3 older age group, longer fo11ow up may be needed to assess progression from eczema to asthma. In conclusion, our study provides evidence for the association of PCDHJ polymorphism IVS3-l l 6 with eczema. Previously, IVS3-l 1 6  was shown to be associated with BHR. Our data show that PCDHJ may have a pleiotropic effect on BHR and eczema in different populations. 
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CHAPTER 4 
ABSTRACT 
Protocadherin-1 (PCDHJ) is a novel susceptibility gene for asthma that is expressed 
in airway epithelium. We aimed to characterize PCDHJ mRNA transcripts and protein 
expression in primary bronchial epithelial cells, and to determine regulation of PCDHJ during 
mucociliary differentiation. Total RNA and protein was isolated from human primary 
bronchial epithelial cells. PCDHJ transcripts were characterized by Rapid Amplification of 
cDNA Ends in bronchial epithelial cells of four subjects. PCDHl expression was quantified 
by qRT-PCR and western blotting in bronchial epithelial cells directly ex vivo and after air 
liquid interface (ALI) or submerged culture. We identified 5 novel exons on the 5'end and 1 
exon on the 3'end of PCDHJ. Novel transcripts showed major variation in expression of 
intracellular conserved motifs. Expression levels of PCDHJ transcripts encoding exon 1-2 
were 4-fold higher, and transcripts encoding exon 3-4 were 15-fold higher in freshly isolated 
bronchial epithelial cells than in submerged cultures. PCDHl mRNA (3-8 fold) and protein 
levels (2-3 fold) were strongly upregulated during mucociliary differentiation of primary 
bronchial epithelial cells in ALI cultures. In conclusion, PCDHJ transcripts display 
remarkable variability in expression of conserved intracellular signaling domains. Enhanced 
PCDHl expression levels strongly correlate with differentiation of bronchial epithelial cells. 
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INTRODUCTION 
Protocadherins are the largest subfamily of the cadherin superfamily of adhesion 
molecules (I). Protocadherins can be subdivided into clustered protocadherins (a-, f3- and y­
protocadherins), flamingo (CELSR) cadherins, the large (Fat- and Dachsous-related) 
protocadherins, and non-clustered protocadherins (8-protocadherins, PCDHI 2, PCDH20) 
(2;3). The 8-protocadherin family consists of 81-protocadherins (PCDHI, PCDH7, PCDH9, 
PCDHI DUY), and 82-protocadherins (PCDH8, PCDHIO, PCDHl7, PCDHl8, PCDHl 9) (4). 
8-protocadherins are characterized by the presence of 7 (81) or 6 (82) extracellular cadherin 
repeats, and variable intracellular signaling domains with no similarity to classical cadherins 
(5). They are generally highly conserved, with a remarkable conservation of two intracellular 
signaling domains across evolution (6). The expression of clustered protocadherins is mainly 
restricted to the nervous system, but interestingly the non-clustered 81-protocadherins are 
additionally expressed in a wide range of different tissues (7;8). 81-protocadherins are 
implicated in several diseases, such as non small-cell lung cancer (PCDH7) (9), autism 
spectrum disorder (PCDH9) (I 0), and Alzheimer's  disease (PCDHI I) ( 11 ). 
Recently, we identified Protocadherin-1 (PCDHJ) as a novel susceptibility gene for 
asthma (12). PCDHI, as well as other members of the 61-protocadherin sub-family, is 
characterized by the presence of three conserved motifs (CMI, -2 and 3) in the intracellular 
cytoplasmic tail (3 ). The CM I - and CM2 motifs are present in both 8 I - and 82-
protocadherins, while the CM3-motif is characteristic for 61-protocadherins only. CM3 has 
been shown to bind to the catalytic subunit of protein phosphatase I alpha ( 13), a protein 
implicated in lung morphogenesis (14). PCDHI also contains a PDZ-domain Binding Site 
(PDZ-BS) at the C-terminal end of the cytoplasmic tail (15). The extracellular cadherin 
repeats of PCDHI have been shown to display homotypic adhesion activity, but weaker than 
classical cadherins (16; 17). Clearly, the function of PCDH I is largely unknown, and hence i ts 
putative role in the pathogenesis of asthma. 
PCDHJ mRNA is expressed in brain (6), skin (18), nose (19) and lung (12), as well as 
in a range of endothelial and epithelial cell lineages throughout mouse embryonic 
development (19). PCDHJ mRNA expression is upregulated in a skin keratinocyte wounding 
model, suggesting a possible role of PCDHJ in epithelial repair (18). We have shown 
expression of PCDH 1 in human peripheral blood mononuclear cells, fibroblasts, and primary 
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bronchial epithelial ce11s, and confirmed the presence of two PCDHJ mRNA isoforms in the 
airway epithelium based on published annotated short 3 exon, and long 5 exon isoforms (12). 
The expression of 81-protocadherins in the nervous system is we11 characterized, but 
apart from their homotypic adhesion function, the exact function, expression and regulation of 
these genes is unknown. As 81-protocadherins are highly conserved across evolution, analysis 
of the expression of PCDHI in epithelial ce11s wi11 contribute to the understanding of the 
function of the 8 1-protocadherin family in general. Therefore, we aimed to characterize 
PCDHJ mRNA and protein expression levels in freshly isolated and cultured primary 
bronchial epithelial cells. Moreover, we investigated if mucociliary differentiation of 
bronchial epithelial ce11s has an effect on PCDHJ mRNA and protein expression levels. 
MATERIAL AND METHODS 
Cell culture 
Primary bronchial epithelial cells (PBECs) were obtained by bronchial brushings of 19 
asthma patients, using endoscopic cytology brushes ( 1.9mm, Ce11ebrity ™, Boston-Scientific­
International, France). All asthma patients had a doctor's  diagnosis of asthma, showed 
reversibility and were hyperresponsive to histamine and/or adenosine 5' -monophosphate 
(AMP). Lung function measurements, histamine and AMP provocation tests, and atopy 
measurements have been described previously (20). All subjects gave written informed 
consent. Two bronchial brushings were co11ected from each subject. One brush was directly 
stored in RLT buffer (QIAGEN Benelux BV, Venlo, the Netherlands) for RNA extraction, 
while the second brush was collected in HBSS on ice for ce11 culture. Primary bronchial 
epithelial cells were cultured as described previously (21) for three passages before RNA and 
protein was extracted. The human bronchial epithelial ce11-line 16HBE14o- ( 16HBE) was 
kindly provided by D.C. Gruenert (Department of Medicine, University of Vermont, and 
University of California, San Fransisco, USA) and cultured as described previously (22). 
To investigate the potential role of PCDHI in airway epithelial cell differentiation, a 
time-course series of air liquid interface cultured cells (ALis) and submerged cultured cells 
was purchased (MucilAir™, Epithelix Sarl, Geneva, Switzerland). These cells originated 
from bronchial airways of a healthy female donor (60 years). Bronchial epithelial cells were 
cultured under ALI and submerged conditions at Epithelix according to the fo11owing 
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Characterization of PCDH I in bronchial epithelium protocol: bronchial airways were digested enzymatically for 2 days, and epithelial cells were isolated. 250,000 cells were seeded in each 24-wells Transwell insert, and cultured submerged for two days. Next, cells were cultured at air liquid interface or under submerged culture conditions for another 45 days (7 weeks). At time-points I ,  7, 2 1  and 45 days after start of ALI culture, cells were harvested both for RNA and protein in duplicate. Differentiation status was confirmed by FoxJ I and ZO- 1 protein expression levels, both markers of epithelial differentiation (23-25). 
RNA and protein isolation RNA was extracted using RNeasy Mini or Micro Elute kits according to the manufacturer's protocol (QIAGEN Benelux BV, Venlo, the Netherlands). Extensive in solution DNaseI treatment (QIAGEN Benelux BV, Venlo, the Netherlands) was performed to remove gDNA traces. For isolation of total protein, T25 culture dishes and Transwell inserts were treated with Triton-X lysis buffer ( 1  % Triton-X 1 00, 1 50mM NaCl, 5mM MgCh, I OmM HEPES), and 2x Leammli buffer (4% SDS, 20% glycerol, 1 0% 2-mercaptoethanol, 0.004% bromphenol blue, 0. 1 25 M Tris HCI, pH 6.8), immediately boiled for 5 min and stored until further usage. 
Rapid Amplification of cDNA Ends (RACE) RACE-ready cDNA was generated using RNA isolated from four submerged cultured PBECs and 1 6HBE using RNA-ligase mediated RACE (GeneRacer-RLM-RACE Kit, Invitrogen, Carlsbad, USA), according to the manufacturer's protocol. Five- and 3' (nested) RACE reactions were performed using specific primer sets (Table I ), using PCR cycling conditions as described by manufacturer's  protocol. The resulting PCR products were cloned into TOPO pCR2. I plasmids using TOPO TA Cloning Kit for Sequencing (Invitrogen, Carlsbad, USA). Twenty-five colonies (detection of transcripts with >4% abundance) were picked for each RACE reaction (5' and 3') for four patients and 1 6HBE. Plasmids were isolated using QIAGEN Miniprep kit (QIAGEN Benelux BV, Venlo, the Netherlands), and cloned PCR products were identified by nucleotide sequencing (M1 3-reverse or T7-forward primers, Baseclear, Leiden, The Netherlands). For confirmation of the 5' PCDHI RACE results, long range PCR reactions were performed from the newly discovered 5' exons towards either exon 2 UTR (primer 3656-Rev; corresponding to isoform I ), or towards exon 3 (primer 3327-Rev; corresponding to isoform 2), using Expand High Fidelity PCR System (Roche Diagnostics, Almere, the Netherlands) 85 
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(Table 1 for primer sequences). The 3' PCDHI RACE results were confirmed by a PCR 
reaction spanning exon 3-5 (Table I for primer sequences). The DNA sequence of the PCR 
products was confirmed by nucleotide sequencing (Baseclear, Leiden, the Netherlands). 
Determination of transcript quantities by quantitative Reverse Transcriptase (qRT)PCR 
To determine the relative expression levels of individual PCDHI transcripts, qRT­
PCR assays were designed across exon-exon boundaries. qRT-PCR was performed using 
inventoried or in-house designed Taqman Assays (Applied Biosystems Europe BV, 
Nieuwekerk AID Ussel, the Netherlands). qRT-PCRs were performed on the ABI7900HT 
cycler in 384-well format. For PCDHJ two inventoried assays (assay exon 1-2, 
Hs00170174_ml ;  assay exon 3-4, Hs00260937_ml ), and two On-Demand assays were 
purchased (assay exon IB-1 and assay I C-1; Applied Biosystems Europe BV, Nieuwekerk 
AID Ussel, the Netherlands). In addition, pre-designed assays for four house-keeping genes 
were used: GAP DH (Hs99999905_m I), /3-actin (Hs99999903_m I), RPLPO 
(Hs99999902_ml), and /3-2-microglobulin (Hs99999907_ml ). Assay exon IF-I was designed 
in house; FAM-labelled probe was ordered at Eurogentcc, Liege, Belgium (Table 1 for primer 
sequences). 
cDNA was produced using Omniscript™ Reverse Transcriptase (QIAGEN Benelux 
BV, Venlo, the Netherlands). A total of 1.75 µg of RNA was reverse transcribed into cDNA 
using Oligo-dT(l 2-18) primers in a 35 µ1 reaction volume, including RNase inhibitor, at 37°C 
for 1 hour. Each qRT-PCR reaction contained 50ng of cDNA, 250nM of probe, 900nM of 
forward and reverse primers, 5 µ1 TaqMan Universal PCR Master Mix (Applied Biosystems 
Europe BV, Nieuwekerk AID Ussel, The Netherlands), in a final volume of 10 µ1. All samples 
were measured in triplicate using recommended cycling conditions. Data was analyzed using 
SDS2.3 software by applying the ��Ct-method (Applied Biosystems User Bulletin 2). As 
four house-keeping genes were used, the best combination of house-keeping genes for 
normalization was determined by using the Norm-finder applet (26). Efficiencies of all assays 
were determined by a 2-fold or 10-fold dilution series of pooled brush or cultured cells cDNA 
(Supplementary Table E l ). 
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Table 1: GeneRacer and PCDHl primers and combinations for S'and 3' RACE reactions 
Nr Primer name 
RACE reaction primers 
I .  GeneRacer 5 '  primer 
2. GeneRacer 5' nested primer 
3 .  GeneRacer 3 '  primer 
4. GeneRacer 3' nested primer 
5. 5 'RACE 684 
6. 5 'RACE nested 437 
7. 3 ' RACE 2973 
8. 3 'RACE nested 32 1 3  
9. 3 'RACE Ex3 
1 0. 3 'RACE nested Ex3 
PCR exon 3-5 primers 




Long range PCR reaction primers 
1 3 . Ex 1 8-FW 1 
1 4. Ex 1 C-FW 1 
1 5 . Ex 1 F-FW3A 
1 6. Ex 1 D-FW 1 
1 7 . Ex 1 E-FW 1 
1 8 . 3327-Rev 
1 9. 3656-Rev 
qRT-PCR assay primers and probes 
20. Ex l 8-FW 
2 1 . Ex 1 8-Rev 
22. Ex l 8-Probe 
23. Ex 1 C-FW 
24. Ex 1 C-Rev 
25. Ex 1 C-Probe 
26. Ex 1 F-FW 
27. Ex I F-Rev 
28. Ex 1 F-Probe 
RACE PCR reactions 





























1 A GeneRacer 5' primer + 5 'RACE 684 
1 8  GeneRacer 5 '  nested primer + 5 'RACE nested 437 
2A GeneRacer 3 '  primer + 3 'RACE 2973 
28 GeneRacer 3 '  nested primer + 3' RACE nested 32 1 3  
3 A  GeneRacer 3 '  primer + 3 'RACE Ex4 
38  GeneRacer 3 '  nested primer + 3'RACE nested Ex3 
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Detection of CpG-islands in silico 
CpG-islands were detected using the Emboss CpGPlot program 
(http://www.ebi.ac.uk/Too1s/emboss/cpgplot/), by submitting a sequence of 10kb upstream of 
exon 1, derived from gen bank template AC094 l 07. 
Statistics 
To test the differences between brushed PBEC and submerged cultured PBEC qRT­
PCR results, a non-parametric paired Wilcoxon test was performed using SPSS 16.0 (IBM 
Netherlands BV, Nieuwegein, the Netherlands) .  
Detection of PCDHl isoform 1, isoform 2, FoxJl and Z0-1 by Western-blotting 
Both for cultured PBECs and ALI cultures, protein samples were separated on 8% 
acrylamide SDS-page gels (Bio-Rad Laboratories BV, Veenendaal, the Netherlands), or pre­
cast NuView 4-20% gradient gels (Generon, Maidenhead, Berkshire, UK). Blotting 
procedures were performed as described previously (12), using affinity purified PCDHI 
isoform specific polyclonal antibodies, FoxJ I antibody (AF36 1 9, R&D systems Europe, 
Abingdon, Oxon, United Kingdom), Zona Occludens (ZO)-1 antibody (33-9100, Zymed 
Laboratories, Invitrogen, Carlsbad, USA), and B-actin antibody (sc-47778, Santa-Cruz 
Biotechnology, Heidelberg, Germany). Polyclonal PCDHI antibodies were generated from 
immunized rabbits against I 5 amino acid peptide (QPFQLSTPQPLPHPYH, ep78) for 
isoform I and 15 amino acid peptide (SPSPPEDRNTKTAPV, ep76) for isoform 2 (Figure 
I A). Antibodies were affinity column purified against immunizing peptides (Eurogentec, 
Liege, Belgium). Validation of antibodies is described in the Supplementary Data. Protein 
levels were quantified by densitometric analysis using Quantity One Software v4.6.2 (Bio­
Rad Laboratories BV, Veenendaal, the Netherlands), relative to the B-actin loading control. 
RESULTS 
Identification of novel PCDHl transcripts in primary bronchial epithelial cells 
The PCDHJ gene encodes two main isoforms through alternative splicing in brain (6): 
a short three exon isoform (Genbank ID: NM_002587) and a long five exon isoform 
(Genbank ID: NM_032420). The short isoform contains a specific sequence at exon 2, which 
is spliced out in the long isoform (Figure 1 A). Rapid Amplification of cDNA Ends (RACE) 
was performed to identify the presence of annotated and possible novel PCDHJ transcripts in 
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primary bronchial epithelial ce11s (PBECs) that had been cultured under submerged conditions 
for 3 passages. We revealed expression of five novel exons located 5' to annotated exon 1 of PCDHJ (NM_002587) and one novel exon located 3' to annotated exon 4 of PCDHJ 
(NM_032420) in cultured PBECs. In contrast, we did not detect expression of the annotated 
exon I A previously observed in brain (6) (Figure I B; Supplementary Figure E2). Expression 
of newly identified exons I B - IF was confirmed by sequence determination of transcript 
fragments PCR-amplified from cDNA samples of PBECs (Table I for primer sequences; 
Figure 1B for transcripts). We detected expression of novel 5' exons ID, IE and IF in 
transcripts encoding both long and short PCDH 1 isoforms, whereas exons I B and IC were 
only detected in transcripts encoding the short isoform. A11 novel 5'exons were found in 
separate transcripts spliced directly to exon I, with the exception of exon 1 E, for which we 
also detected a transcript in which it was spliced to exon IF and then to exon I (Figure IB). In 
addition to novel 5' and 3' exons, we observed the presence of a gap within exon 4 or even 
fu11 skipping of exon 4 in PCDHJ transcripts of the long isoform (Figure IC). Since exon 4 
contains the highly conserved CM2 and PDZ-BS domains, these variants will affect the 
expression of these intrace11ular signaling domains (Figure I A, C). 
Culture of PBECs influences PCDHl expression levels and detected isoforms 
We designed quantitative RT-PCR assays spanning all novel exon - exon boundaries, 
and successfu11y validated these for transcripts containing the exon boundaries I B-1, IC-I 
and I F-1. As expression levels were found to be low for these transcripts, only presence or 
absence of these transcripts in cultured vs freshly isolated brush PBECs was determined. For 
submerged cultured PBECs, expression of transcripts encoding both exon I C-1 ( l  7 /19 of 
subjects) and exon I F-1 (18/19 of subjects) was detected, while transcripts encoding exon IB-
1 were not detected. In a preliminary study of 3 healthy subjects we also detected expression 
of transcripts encoding exon IC-I and IF-I in PBECs , but no expression of transcripts 
encoding exon I B-1 (results not shown). In freshly isolated PBEC samples, expression of 
only the transcript encoding exon 1 F-1 was detected in a subset of subjects (6/19). 
These results suggest that submerged culturing of ce11s induces alternative 5'exon usage in PCDHJ transcripts. Epigenetic mechanisms can be an explanation for the low expression 
levels of these novel exons. Therefore we investigated by in silico analysis whether the exons 
were contained within a CpG-island. We detected a CpG-island of 565bp containing exon IA, 
which was not detected by our RACE experiments, but no CpG-islands were detected around 
the other exons (Figure ID). 
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Figure 1: Protocadherin-1 gene, RNA and protein structure. 
(A) RNA and protein structure of PCDHJ isoform I and 2. Please note that exon numbering 
follows the annotation of mouse Pcdhl by Van Roy and co-workers (6). Ep76 and Ep78 
indicate the presence of the polypeptide sequence that was used to generate isoform specific 
antibodies. (B) Variation on 5 'end of PCDHJ in primary bronchial epithelium of asthma 
patients. Novel exons were connected to isoform I or isoform 2 or both. Exons IE and IF 
exist both separately and connected to each other, both with isoform I and 2. (C) Variation 
on 3 'end of PCDHJ, which can result in alternative usage of conserved domains (CM2 and 
PDZ-BS). (D) A CpG-Island was detected surrounding exon IA. Genbank accession numbers 
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In addition to exons I B-1, I C-1 and I F-1, we quantified expression of transcripts 
containing exon 1-2 and exons 3-4 boundaries in PBECs. According to the annotated gene 
structure of PCDHI, qRT-PCR assay for exon 1-2 can detect both short and long PCDHJ 
isoforms, while the exon 3-4 assay is specific for the long isoform. PCDH I expression levels 
in submerged cultured PBECs and freshly isolated brush samples were quantified relative to 
the average of three house-keeping genes (JJ-actin, GAPDH, RPLP0) using pre-validated 
qRT-PCR assays. We detected similar expression levels of PCDHI transcripts with the exon 
1-2 and exon 3-4 assays in cultured PBECs, indicating that almost all of PCDHI transcripts 
encode PCDHI isoform 2 (Figure 2A). Surprisingly, and in strong contrast to cultured 
PBECs, higher expression levels of PCDHl transcripts were detected with the exon 3-4 assay 
compared to the exon 1-2 assay in freshly isolated PBECs of all 19 subjects (Figure 2B). 
PCDHl expression levels in PBECs from 3 healthy controls displayed a very similar level 
and regulation between culture conditions as those in PBECs of asthma patients (results not 
shown). The expression difference between exon 1-2 and 3-4 indicates that a PCDHI mRNA 
transcript exists in freshly isolated PBECs, that contains exon 3 and 4, but not exon I and/or 
2, encoding the extracellular and transmembrane domains. This novel PCDHl transcript has 
not been reported before, and was not identified by our RACE approach since we used 
primers located in exon to characterize the 5' sequences of the PCDHl transcripts, and 
performed our analysis in submerged cultured PBECs that may not contain this novel 
transcript. 
Figure 2: Expression of exon 1-2 and 3-4 in submerged cultured cells and freshly brushed 
cells. 
(A, B) Quantification of transcripts encoding PCDHI exon 1-2 and exon 3-4 in submerged 
cultured and freshly brushed cells. (C, D) Comparision of exon 1-2 and exon 3-4 expression 
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CHAPTER 4 Therefore, we performed additional 5' RACE experiments from exon 3 in differentiated air liquid interface cultured PBECs to identify a putative novel transcript encoding exons 3-4 but lacking exons 1 and/or 2. Indeed we identified a PCDHJ transcript that does not encode exon 1, and presumably starts translation from within exon 2, where an in-frame start codon is present in the context of a strong KOZAK sequence 
(TCAGTGATGGAG, ATG3, Figure I A), allowing the expression of a PCDHI protein encoding the extracellular EC6 and EC7 domains, the transmembrane and intracellular domains, but missing the first five extracellular cadherin repeats. In addition to this novel 
PCDHJ transcript, we also observed significantly lower PCDHJ mRNA expression levels in submerged cultured cells compared to freshly isolated PBECs (p<0.0001), both with the exon 1 -2 assay (Figure 2C) and the exon 3-4 assay (Figure 2D). Specifically, exon 1-2 expression levels were 4-fold higher in freshly isolated PBECs, while exon 3-4 expression levels were 1 5-fold higher in freshly isolated than in cultured PBECs. These data show that higher 
PCDHJ mRNA expression levels are observed in freshly ex vivo isolated brush cells compared to submerged cultured PBECs. We found evidence for three PCDH I transcripts: (i) the short annotated isoform encoding exon 1 and exon 2 and displaying alternative upstream exon usage, (ii) the long annotated isoform encoding exons 1 ,  2, 3 and 4 and using alternative upstream exons and (iii) a novel 
PCDHJ transcript encoding exon 3-4 but not exon 1 and only part of the coding sequences of exon 2, identified by RACE in differentiated PBECs. We next aimed to identify the protein products encoded by these different transcripts. To this end, we first determined which PCDHI protein products were expressed in submerged cultured PBECs and 16HBE using novel antibodies that were raised to peptides specific to the cytoplasmic tail of the two annotated PCDHl isoforms (Figure I A, Supplementary Figure El for validation). The antibody specific to the exon-2 encoded intracellular sequences (annotated isoform 1 )  detected the full-length protein only, whereas the antibody specific to the exon-4 encoded intracellular sequences (annotated isoform 2) detected both the full-length protein and a shorter protein isoform of around 50 kD (Figure E IA). The size of the latter 50 kD protein is consistent with a PCDHI protein product encoded by the newly identified transcript. In cultured PBECs, we detected hardly any expression of the annotated PCDHI protein isoform 1 ,  in agreement with our qRT-PCR data (Supplementary Figure E2A and B). The antibody specific to annotated isoform 2 detected two PCDH 1 protein products: one corresponding to the full-length protein ( 1 70 kD), that was detected in cultured PBECs and 1 6HBE, and the 92 
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short protein product of approximately 50 kD in l 6HBE, but not in cultured PBECs, which is 
consistent with our qRT-PCR data (Figure E2B). 
PCDHl expression levels increase during air liquid interface culture conditions 
We observed a strong reduction of PCDHl mRNA expression levels during the 3 
passages of submerged culture used to expand the PBECs, compared to freshly brushed cells 
of the same subject (Figure 2). This expression difference between cultured and freshly 
brushed PBECs was not restricted to PBECs of asthma patients, as we observed the same 
expression pattern after preliminary analysis of PCDHl expression levels in PBECs of 
healthy subjects (results not shown). 
Figure 3: PCDHJ mRNA expression in air liquid interface cultures of epithelial cells o ver 
time. 
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We hypothesized that the loss of mucociliary differentiation of PBECs due to 
submerged culture conditions (27) reduced PCDHJ expression levels in PBECs. We therefore 
compared PCDHl mRNA expression levels between PBECs of healthy subjects grown under 
submerged and those grown under air liquid interface (ALI) culture conditions, as ALI 93 
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cultures have been described to induce mucociliary differentiation in primary bronchial 
epithelial cells (35) (Figure 3). 
We confirmed the kinetics of this differentiation in our ALI cultures using the ciliated­
cell specific protein FoxJ l (23) and the ratio of the isoforms of Z0-1 associated with 
differentiation (24, 25) (Figure 4A). We observed a strong increase (3-8 fold) in PCDHJ 
mRNA expression levels with both exon 1-2 and exon 3-4 assays after one week of air liquid 
interface culture, compared to the first day of ALI culture. PCDHJ mRNA expression levels 
gradually increased to reach similar levels at week 7 in ALI and submerged cultures when 
detected with the exon 1-2 assay, but remained much higher in ALI than submerged cultures 
at all times when detected with exon 3-4 assay (Figure 3A). 
As seen before (Figure 2), equal expression levels of transcripts encoding exon 1-2 
and transcripts encoding exon 3-4 were observed at day 1, when cells were transferred to ALI 
culture conditions from submerged cultures. In contrast, at day 45 of ALI culture, a 2.8-fold 
higher expression of PCDHJ transcripts was detected with the exon 3-4 assay compared to 
the exon 1-2 assay. For submerged cultures this difference was less pronounced (Figure 3B). 
To determine whether the upregulation of PCDHJ mRNA levels in differentiated ALI 
cultures is also observed at the protein level, we analyzed protein levels of PCDHl isoforms 
in the 7-week PBEC cultures, maintained either under ALI or submerged culture conditions. 
Both PCDHl full-length protein isoforms (corresponding to the extracellular domains, the 
transmembrane domain and the intracellular domains for both annotated isoforms) were 
strongly (2-3 fold) increased after 7 weeks of ALI culture compared to submerged culture 
conditions (Figure 4B). In addition, we detected a 50kD protein product, previously detected 
in 16HBE (Figure E2B), at the latest time points (day 21 and day 45) of air liquid interface 
culture, with higher expression in ALI cultured PBECs compared to submerged cultured 
PBECs (Figure 4B). These data indicate that PCDHl protein expression levels during PBEC 
culture by and large follow the kinetics of the qRT-PCR data, with elevated PCDHl 
expression under ALI culture conditions, both for the long PCDHl isoforms and the 50 kD 
protein product. 
Figure 4: PCDHl isoform 1 and isoform 2 protein expression in air liquid interface 
cultures of epithelial cells o ver time. 
(A) Mucociliary differentiation is indicated by FOXJJ and Z0-1 Alpha + expression, which 
are both markedly upregulated in ALI culures, but not in submerged cultures. (B) An increase 
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of PCDH 1 isofonn 1 and 2 expression is observed, with the highest expression at D45 ( day 
45). Submerged cultures show no clear increase in PCDHJ expression. Graphs show 
densitometric quantification of PCDHJ bands on western blots, relative to P-actin. A 
representative example of 3 independent experiments with comparable results is shown. Error 
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We recently identified protocadherin-I (PCDHJ) as a novel gene for asthma that is 
expressed in airway epithelial cells. PCDH I is a member of the 8 I-protocadherins, which 
encode transmembrane proteins with 7 extracellular cadherin repeats and in some isoforms 
intracellular conserved protein-protein interaction domains that are involved in signal 
transduction. 8 I -protocadherins have been shown to engage in homotypic interactions, but 
otherwise the functional role of these proteins is unknown. To explore a possible functional 
role for PCDHl in bronchial epithelial cells, we first characterized the PCDHJ transcripts 
present in PBECs and the regulation of PCDHJ isoform expression during PBEC mucociliary 
differentiation in the ALI culture model. Identification of novel PCDH 1 mRNA isoforms 
The starting points of our analysis were the annotated PCDHJ mRNA isoforms, 
originally identified in brain tissue: a 3 exon (isoforrn 1 ,  Genbank ID NM_002587) and a 5 
cxon isoforrn (isoform 2, Gen bank ID NM_032420), Figure 1 A). Both isoforrns share an 
extracellular and a transmembranc domain, but differ in their intracellular domains: isoform 1 
carries a short unique cytoplasmic region encoded by exon 2, whereas isoforrn 2 has a long 
cytoplasmic region encoding the conserved signaling domains encoded by exons 3 and 4 (6). 
In our RACE experiments on cultured PBECs, we identified five novel PCDHJ 5'exons that 
are mainly expressed in undifferentiated cells during submerged cell culture (Figure 2). By 
Jong-range PCR exons I B and 1 C were shown to be present only in transcripts encoding the 
short PCDHI isoforrn, while exons I D, IE and IF were present in transcripts encoding both 
PCDHI isoforrns. The alternative usage of 5' exons between the transcripts terminating at the 
exon 2 UTR (the annotated short isoforrn) and those terminating at the exon 4 UTR (the 
annotated long isoforrn), indicates that promoter usage might be different between these two 
main isoforms. Remarkably, we did not detect the annotated exon IA. PCR amplification of 
exon 1 A may, however have been hampered by the very high GC content (81.5 % ) of this 
exon, precluding identification by RACE as well as by RT-PCR. In fact, exon IA is located 
within a CpG island, indicating that epigenetic mechanisms may contribute to regulation of PCDHJ gene expression (Figure ID). The annotated PCDHJ isoforrns contain two in-frame 
start codons, one in exon IA (ATGI), and one in exon 1 (ATG2). In addition, we identified a 
putative additional in-frame start codon in exon 2 (ATG3) in the context of a strong KOZAK 
sequence. Of the five novel 5' exons, only exon 1 F contains an in-frame ATG sequence, but 
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Characterization of PCDH I in bronchial epithelium no conserved Kozak sequence, hence it is a less likely translation initiation site. The lack of conserved translational start sites and relatively low expression of the novel 5' exons suggest that these 5 'exons may contribute to mRNA translation regulation as part of the 5 'UTR sequences. Vanhalst and co-workers suggested that translation initiation of PCDH I employs the first start-codon of exon I (ATG2), since the corresponding Kozak sequence of ATG2 was best conserved between species (6). We investigated the expression levels of PCDHJ in 3 healthy controls. PCDHJ exon 1 -2 and 3-4 expression levels were by and large similar between healthy controls and asthmatic subjects, but a thorough comparison between healthy and asthma will be the focus of a future study. Furthermore we investigated whether PCDHI exon 1 -2 and 3-4 expression levels were influenced by three PCDHJ gene-variants (IVS3- l 1 6, rs 1 4359, and rs3797054), previously associated with bronchial hyperresponsiveness and asthma ( 1 2). With expression levels of 1 9  subjects we unfortunately were underpowered for this analysis. One of our most remarkable findings was the detection of higher PCDHJ mRNA expression levels with an exon 3-4 specific assay than an exon 1 -2 specific assay, both in freshly brushed epithelial cells and at later time-points in the ALI cultured PBECs, but not in submerged cultured PBECs. These data were in contrast to our expectations based on the published annotated isoforms of PCDHJ. We expected PCDHI expression detected by the exon 1 -2 specific assay to reflect expression of both isoforms, thereby constituting the total PCDHJ mRNA pool, whereas PCDHI expression detected by the exon 3-4 specific assay was expected to reflect the level of the long 5-exon isoform only. Based on our results we here hypothesize the presence of a novel putative PCDHJ transcript lacking exon I and/or 2. Importantly, the expression difference between exon 1 -2 and exon 3-4 was not due to lower efficiency of the exon 1 -2 qRT-PCR assay (Supplementary Table E I ). For this putative variant, translation may start from within exon 2, where an in frame start-codon is present within a Kozak­sequence (ATG3). In RACE experiments, we confirmed the presence of a transcript variant carrying ATG3, but not ATG2 or ATG I (Figure I A). Translational initiation from the putative ATG3 start codon located in exon 2 would result in a truncated protein product, lacking 5 of the extracellular domains, but retaining the conserved intracellular signaling domains. As adhesion typically forms by engagement of the EC I domain, this isoform would not be able to participate in cell-cell adhesion, but could still participate in signal transduction. A truncated variant was previously described for PCDH1 5, where PCDHl 5  isoform B has a deletion of I O  out of I I cadherin domains, but still retains the transmembrane domain and 97 
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intracellular domains (28). Interestingly, we did identify a PCDHI protein product of 50 kD 
using the antibody directed against the intracellular part of isoform 2. This 50kD product 
could be the protein product of the putative novel isoform, although we can not exclude the 
possibility that this product is the result of a full-length isoform modified by posttranslational 
cleavage or shedding. Such a shedding process was previously identified for the clustered 
gamma-protocadherins and the non-clustered Protocadherin- 1 2  (29; 30), but is yet unknown 
for 81 -protocadherins. Future studies such as proteomic analysis will be performed for the 
characterization of this novel PCDHI protein. 
81 -protocadherins are characterized by 3 conserved motifs in their intracellular tail (CM 1-
CM3), of which the function of CMI and CM2 is unknown. At the 3'end of PCDHJ mRNA 
we observed substantial variability in the transcription of cxon 4: we identified transcripts 
with an intra-exon gap (in-frame deletion of 96 basepairs) as well as transcripts with exon 
skipping of exon 4. This gap in exon 4 has also been described to be present in mouse Pcdhl 
(Gen bank ID: A Y861418), but has no consequence for the expression of conserved domains 
(6). In contrast, deletion of the entire exon 4 would result in the translation of a PCDHl 
protein lacking CM2, and a putative PDZ-domain binding site. The CM2 motif is strongly 
conserved during metazoan evolution, and therefore considered as an important motif for 
downstream functions of many protocadherins (31 ). However, function and putative binding 
partners for CM2 have not been identified to date. PDZ-containing proteins can provide 
linkage to the cytoskeleton, or initiate signaling functions either directly or indirectly by 
acting as scaffolds for large protein complexes. Deletion of the PDZ-BS might therefore 
potentially influence coupling of PCDHl to the cytoskeleton or downstream signaling 
functions (15;32). Besides PCDHl ,  the 81-protocadherin PCDHl l  has also been shown to be 
subject to complex splicing patterns, resulting in several transcripts with alternative 
expression of conserved motifs (33). Thus, 81-protocadherins seem to have multiple protein 
isoforms with different use of the three intracellular CM-domains, allowing the specific 
protein isoforms to selectively address certain, as of yet unknown, signalling pathways 
depending on the presence or absence of the different CM domains. Future research will be 
needed to identify the relevant signalling pathways regulated by the 81-protocadherins, as 
well as the regulation of splicing events leading to inclusion or exclusion of specific CM 
domains. We here thus describe evidence for an intriguing diversity of PCDHJ transcripts 
with strongly variable 5'and 3'exon usage, likely affecting protein function, and additionally 
for a novel transcript isoform encoding the intracellular and transmembrane domains, but only 
containing two of the extracellular cadherin repeats. Given the strong conservation between 
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<> I -protocadherin family members, these data are likely to be of relevance to the other family 
members as well. 
Interestingly, we observed higher PCDH 1 mRNA expression levels in freshly isolated 
cells than in PBECs of the same subject cultured for 3 passages under submerged conditions, 
both with the exon 1-2 and exon 3-4 specific assays. The cells obtained by bronchial brushing 
are about 85-90% epithelial cells (34;35), and we consider these brushed PBECs to be 
terminally differentiated. In contrast, submerged tissue culture conditions are likely to render 
undifferentiated cells, especially after multiple passages (27;36). We therefore hypothesized 
that PCDH 1 expression levels are regulated by the differentiation status of bronchial 
epithelial cells. In agreement with this, we observed increased PCDHJ mRNA and protein 
expression levels in PBECs cultured under ALI conditions, compared to submerged cultured 
cells. Since ALI cultures have been shown to induce terminal mucociliary differentiation of 
PBECs (35;36) and we also observed the same differences in PCDHI expression levels 
between freshly isolated (terminally differentiated) PBECs from bronchial brushes and 
cultured (relatively undifferentiated) cells, we conclude that high PCDH I expression levels 
are associated with terminal differentiation of bronchial epithelial cells. 
We are the first to show an increase of Protocadherin-1 expression at the mRNA and 
protein level over time in differentiated ALI cultures. Together with a proposed role of 
PCDH I in cell-cell adhesion, and its identification as an asthma susceptibility gene, this 
suggests that there may be a role for PCDHI in epithelial differentiation. Previously 
Protocadherin of the Liver, Kidney and Colon (PCDH-LKC/CDHR2) was shown to be 
regulated during Madin-Darby Canine Kidney (MDCK) epithelial cell differentiation (38). 
Furthermore, RNA expression of Protocadherin-7, a closely related <> 1-protocadherin 
gene, was shown to be upregulated during bronchial epithelial cell differentiation in a 
microarray experiment (39). Therefore, the increase of protocadherin expression levels during 
epithelial differentiation might be a common regulatory mechanism for the non-clustered <> 1-
protocadherins. Epithelial differentiation encompasses several processes, including 
upregulation of adhesion molecules, establishment of apical/basolateral cell polarity and 
planar cell polarity, and development of cilia (40). Asthma is characterized by a decreased 
epithelial barrier function ( 41) and abnormal repair of epithelial cells ( 42-44 ). One aspect of 
epithelial repair is the re-growth of columnar epithelial cells or differentiation and 
proliferation of basal epithelial cells (45). We propose that dysregulation of PCDH I 
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expression results in slower or incomplete differentiation of the epithelial layer, thereby 
contributing to an altered response to injury and a weaker epithelial barrier function. 
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SUPPLEMENTARY DAT A 
Supplementary methods: Validation of PCDHJ isoform specific antibodies: PCDH J 
isofonn specific antibodies were tested both on cell-lysates of L-cells overexpressing PCDH J 
protein products and by blocking experiments. Overexpression: Mouse L-cell fibroblasts 
(kindly provided by Dr C. van Kooten, Leiden University Hospital, the Netherlands) were 
transfected with PCDH I isofonn I and isofonn 2 contructs (TC 109553 and TC 109554, 
Origene, Rockville, USA) using Fugene 6 transfection reagent (Roche Diagnostics, Almere, 
the Netherlands). PCDH I protein was detected in cell-lysates by western blotting using 
isofonn specific antibodies (Figure EI A). Blocking experiments: Specificity of isofonn 
specific antibodies was tested by blocking experiments with pre-incubation of ten-fold molar 
excess of immunizing peptide. Intensity of PCDH I band at ~ 1 70 kDa was diminished in L­
cells overexpressing full length PCDH I isoform I or 2 or 16HBE after peptide pre­
incubation, thereby proving the specificity of the antibodies (Figure E IB). 
Table El: Efficiencies of qRT-PCR assays as determined by cDNA dilution series 
Brushed cells: Cultured cells: 
Assay Slope Efficiency (%) Assay Slope Efficiency (%) 
Exon 1 -2 -4,873 60,4 Exon 1 -2 -4,0403 76,8 
Exon 3-4 -5, 1 582 56,3 Exon 3-4 -4,5696 65,5 
P-actin -3,5666 90,7 Bact -3,949 79,2 
RPLPO -3,70 1 5  86,3 Rplpo -3,849 8 1 ,9 
P2M -3,7005 86,3 b2m -3,949 79,2 
GAPDH -3,6027 89,5 Gapdh -3,6963 86,4 
Table E2: Genbank accession numbers 
Exons Genbank accession nrs Prevalence (%) 
Exon I E - Exon I HO6635 1 I 2 
Exon I F  - Exon I HO6635 1 2  84 
Exon I B - Exon I HO6635 1 3  4 
Exon I C  - Exon I HO6635 14  2 
Exon I D - Exon I HO6635 1 5  8 
Exon 3 - Exon 4 NM_032420 2 1  
Exon 3 - Exon 4 with gap - Exon 5 HO663509 1 2  
Exon 3 - Exon 4 - Exon 5 HO6635 1 0  6 1  
Exon 3 - Exon 5 HO663509 - exon 4 6 
* = Relative abundance of transcripts identified by 5 'RACE and 3 'RACE reactions 
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Figure El: Specificity of antibodies as determined by o verexpression and blocking 
experiments. 
Newly generated isoform specific polyclonal antibodies detect bands at ~ 150 kDa for isoform 
1, and ~170 and ~50 kDa for isoform 2, in 16HBE and L-cells overexpressing isoform 1 or 2, 
while these bands were not detected using the control vector (eGFP) (A). Bands at ~170 kDa 
were completely blocked for isoformt I in I 6HBE ( 16H), L-cells overexpressing isoform 1 ( +) 
or asthma patient samples (Pl-P4), when the antibody was pre-incubated with peptide. For 
isoform 2 both the ~170kDa and ~50 kDa were diminished in L-cells over-expressing PCDHl 
isoform 2 and 16HBE, when the antibody was pre-incubated with immunizing peptide (B). 
NB=not blocked, FL=Full length. 
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Characterization of PCDH 1 in bronchial epithelium Figure E2: Isofonn 1 and isoform 2 protein expression in cultured PBECs. 
No or weak expression of PCDH I isoform I is observed for asthma patient submerged 
cultured PBECs (PI - P 19), while the positive controls ( +; L-cell overexpressing cells; 16H 
= 16HBE) give a clear signal (A). Low expression of PCDHJ isoform 2 was detected in 
cultured PBECs, as compared to 16HBE (B), while the 50kDa band was not detected in 
cultured PBECs. Arrows indicate the size of specific bands (~170kDa, isoform I and 2, 
~50KDa isoform 2) previously detected by blocking experiments. FL = full length isoforms. 
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Protocadherin-1 (PCDHJ) is a novel susceptibility gene for airway 
hyperresponsiveness, and is expressed in bronchial epithelial cells. Here, we asked how 
mouse Pcdhl expression is regulated in lung structural cells in vivo under physiologic 
conditions, in a house-dust mite driven mouse model of asthma, and in short-term cigarette 
smoke exposure models, both characterized by airway hyperresponsiveness. Pcdhl gene­
structure was investigated by Rapid Amplification of cDNA Ends. Pcdh 1 mRNA and protein 
expression was investigated by qRT-PCR, western blotting and immunohistochemistry using 
isoform-specific antibodies. We observed 87% conservation of the Pcdhl nucleotide 
sequence, and 96% conservation of the Pcdh 1 protein sequence between men and mice. We 
identified a novel Pcdhl isoform encoding only the intracellular signalling motifs. Airway 
epithelial cells expressed all Pcdhl isoforms, while airway smooth muscle only expressed this 
novel isoform. Epithelial Pcdh 1 protein expression was reduced in a chronic house dust mite 
induced asthma model, while its mRNA expression was induced in the resolution phase after 
house-dust mite challenges. Short-term cigarette smoke exposure also reduced Pcdhl mRNA 
expression in lung tissue (3 to 4-fold), while neutrophilia and airway hyperresponsiveness was 
induced. We conclude that Pcdhl is highly homologous to human PCDHJ, encodes two 
transmembrane proteins and one intracellular protein, with distinct expression patterns in 
airway epithelial and airway smooth muscle cells, and is regulated by house-dust mite and 
cigarette smoke exposures in vivo. 
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INTRODUCTION 
Asthma is a complex disease, caused by gene-gene and gene-environment interactions 
( I ). Many asthma susceptibility genes have been identified, several of which are expressed in 
the airway epithelium (2). The airway epithelium in asthma has a disrupted barrier function 
(3) and an impaired repair response upon injury (4,5) that might contribute to airway 
remodelling. In addition, the airway epithelium of asthmatics shows an enhanced immune 
response towards harmful agents (allergens or viruses) by secreting increased amounts of pro­
inflammatory mediators such as IL-33, CCL20, GM-CSF or TSLP (6-9). Polymorphisms in 
asthma susceptibility genes expressed by airway epithelial cells, affecting the level or 
regulation of their expression (10), might therefore contribute to both altered barrier function 
of airway epithelial cells and to enhanced induction of an immune response upon airway 
epithelial injury ( I I). 
Previously, we identified protocadherin-1 (PCDHJ) as a novel susceptibility gene for 
airway hyperresponsiveness (AHR) in asthma families (12). Interestingly, a strong linkage 
signal of PCDHJ with asthma and AHR was observed in families exposed to environmental 
tobacco smoke (ETS). PCDHJ encodes for two main isoforms: a 3 exon and a 5 exon isoform 
that are expressed in the airway epithelium (12). In addition a putative third isoform was 
identified that lacks exon l and part of exon 2 (13). Both main isoforms encode for a protein 
containing an extracellular domain with seven cadherin repeats, a transmembrane domain, and 
an intracellular domain containing several Serine and Tyrosine residues, that have been found 
to be subject to phosphorylation (14, 15). The third isoform only contains two extracellular 
cadherin repeats and, as for the long 5 exon isoform, an intracellular domain containing three 
intraceIIular conserved motifs (CM I-CM3), of which CM3 is the binding motif for protein 
phosphatase I alpha (PPla) (16,17). We previously reported complex splicing patterns of PCDH 1 regarding the expression of intracellular conserved motifs, and observed a marked 
upregulation of PCDHI during mucociliary differentiation of primary bronchial epithelial 
cells (13). 
In mouse, Pcdhl mRNA expression was identified in several adult tissues (brain, 
kidney, heart, lung and uterus), but highest expression was observed in lung (18). During 
mouse embryogenesis, Pcdhl mRNA expression in lung was restricted to mesenchyme and 
blood vessels, and was not detected in the bronchial epithelium. Similar to the human 
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situation, two main transcripts were identified in the mouse, as well as a variant displaying 
variation in expression of conserved motifs ( 16). 
As PCDHJ is a susceptibility gene for AHR and encodes an adhesion molecule that is 
expressed in the airway epithelium, we hypothesize that PCDHl plays a role in the barrier 
function and repair of the epithelium. Currently, detailed knowledge about Pcdh 1 expression 
in lung structural cells and its regulation by environmental exposures in vivo is unknown. 
Therefore, we aimed to investigate the expression and regulation of Pcdhl under basal, 
damaging and repair conditions in vivo in asthma and smoke exposure mouse models, known 
to be associated with AHR. 
MATERIAL AND METHODS 
Animal Models 
BALB/c mice (6 lo 8 weeks) were purchased from Charles River Laboratories 
(L' Arbresle-Cedex, France), housed in individually ventilated cages, kept under specific 
pathogen-free conditions and maintained on a 12h light-dark cycle, with food and water ad 
libilum. Experiments were approved by the Institutional Animal Care and Use Committee of 
the University of Groningen (The Netherlands), and carried out following (inter-)national 
welfare regulations. 
House Dust Mite (HDM) asthma models 
Mild HDM-model: Female BALB/c mice (n = 4 per group) were exposed intranasally 
to 25µg HDM extract (Greer Laboratories, Lenoir, NC, USA) or PBS in 10 µ1 volume once a 
week for three weeks, followed by a two week rest period, and two consecutive intranasal 
exposures (Figure 3A). Lung lobes were snap frozen for RNA or protein isolation, filled with 
Tissue-Tek™ diluted in PBS (1:1) (Sakura Finetek Holland BV, Zoeterwoude, the 
Netherlands) and slowly frozen to -80°C, or embedded in paraffin. 
Chronic HDM-model: Male BALB/c mice were exposed intranasally with 25µg of 
HDM extract (Greer) (n = 5) or PBS (n = 4) in 10  µ1 volume twice a week for five weeks as 
described previously (Figure 4A) ( 19). Lung lobes were embedded in paraffin for Pcdh 1 
immunohistochemistry, 24h after the last HDM exposure. 
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Cigarette smoke (CS) exposure models 
BALB/c mice were exposed to gaseous-phase CS from Kentucky 3R4F research 
reference cigarettes (Tobacco Research Institute, University of Kentucky, Lexington, USA). 
Each cigarette was smoked without filter in 5 minutes at a rate of 5 L/hr in a ratio with 60L/hr 
air using whole body exposure. Gaseous-phase CS was directly distributed inside 6-liter 
perspex boxes. In this study we employed two CS-exposure models: 
Sub chronic CS model: Female mice (n = 8 per group) were exposed to CS of 1-5 
cigarettes for 5 days or filtered air each morning and afternoon, using a peristaltic pump as 
described previously (20). Mice were sacrificed 2h after the last CS exposure (Figure 5A). 
Acute CS model: Male mice were exposed to CS of IO cigarettes (n = 8) in 1.5h or 
filtered air (n = 5), and were sacrificed 6h after the last CS exposure (Figure 6A). 
From all mice, Bronchial Alveolar Lavage (BAL)-fluid was isolated and the smallest 
lung lobe was stored at -80°C for RNA or protein isolation. BAL was obtained, by lavaging 
through a tracheal cannula with five I ml aliquots of saline of 37°C. Differential BAL cell 
counts (3 times 100 cells) were obtained from cytospin preparations stained with Diff-Quick 
(Merz & Dade A.G., Dudingen, Switzerland). 
Airway responsiveness (AHR) was assessed in a separate group of sub chronic 
exposed mice at day 5, by omitting the final smoke exposure (n = 8 smoke exposed, n = 8 air 
exposed). AHR was determined by measuring airway resistance in response to i.v. 
administration of increasing doses of methacholine (acetyl-b-methylcholine chloride, Sigma­
Aldrich, St. Louis, MO), using a computer-controlled small-animal ventilator (Flexivent; 
SCIREQ, Montreal, Quebec, Canada) as described previously (19). 
RNA purification, Rapid amplification of cDNA ends (RACE) and quantitative (q)RT­
PCR. 
RNA was isolated from 50-100 mg of mouse lung tissue homogenized in 1 ml of 
TriReagent (MRC, Cincinnati, OH). gDNA traces were removed enzymatically, followed by 
purification using RNeasy Mini Kit (QIAGEN). RNA concentration and integrity was 
determined by Nanodrop measurements (ND-I 000 spectrophotometer, lsogen Lifesciences, 
de Meern, Netherlands). 
RACE was performed on RNA purified from lung tissue according to the 
manufacturer' s  instructions (GeneRacer-RLM-RACE Kit, Invitrogen, Carlsbad, USA), and as 
described previously (13) using the primers described in Table 1. RACE was performed from 
Pcdh l exon I for 5' transcripts and from exon 3 for 3' transcripts. Furthermore, additional 
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5'RACE experiments from exon 3 were performed in order to identify a homolog of the 
putative human isoform 3 (13). PCR products were TOPO-cloned and Pcdhl transcripts were 
sequenced (StarSEQ®, Mainz, Germany) as described previously (13). Pcdhl mRNA and 
protein sequences were compared to human PCDHJ using ClustalW 
(http://www.ebi.ac. uk/Tools/msa/clustal w2/). 
Expression levels of Pcdhl transcripts were determined by qRT-PCR as described 
previously (13), using ABI primer-probe sets. In brief, two microgram of RNA was reverse 
transcribed in 20µ1 reaction volume using Omniscript™ reverse transcriptase (QIAGEN 
Benelux BV, Venlo, the Netherlands). Pcdhl exon 1-2 (Mm01264041_ml ,  Applied 
Biosystems Europe BV, Nieuwekerk AID IJssel, the Netherlands), Pcdhl exon 3-4 and Pcdhl 
exon m-1 B (Custom assays, Applied Biosystems, Table 1 for primer sequences) expression 
was determined relative to the most stable combination of four housekeeping genes (HPRTJ 
(Mm01545399_ml), Pgkl (Mm01225301_ml ), B2m (Mm00437762_ml ), Ipo8 
(Mm0 1255158_m 1 ), Applied Biosystems). Data was analyzed using SDS2.3 software by 
applying the !).!).Ct-method (Applied Biosystems User Bulletin 2). As four house-keeping 
genes were used, for normalization the best combination of house-keeping genes was 
determined by using the Norm finder applet (21 ). We calculated relative expression levels as 
follows: First the cycle threshold value (Ct-value) of the average of the combination of most 
stable house-keeping genes was subtracted from the Ct-values of our Pcdh I-assays (formula 
1 ). Next, we converted the !).Ct-value to expression level (EL; formula 2), and normalized the 
expression levels relative to the average of the control group (formula 3). In formulas: 1 ). 
!).Ctpc/Jlil = CtPCDHI - CtHKG-average; 2). ELPCDHI = 2-llCt
PCDHI
; 3). Relative EL = ELPCDHI I 
ELpcf)H I-control• 
Table 1: Pcdhl RACE and qPCR primer sequences 
Pcdhl RACE Sequence (5'-3') Corresponding GeneRacer primer Sequence (5'-3') 
primer 
5'RACE 301 Rev GAGGTCTCTGTGGTGAAAATGTCT GeneRacer 5' primer CGACTGGAGCACGAGGACACTGA 
5'RACE 1 62Rev GTICCTCTGGCACCTIGTATACTACC GeneRacer 5' nested primer GGACACTGACATGGACTGAAGGAGTA 
3'RACE FWI GCCCAGGAGCTGCAGGATCCAT GeneRacer 3' primer GTCGTCAACGATACGCTACGTAACG 
3'RACE FW2 GAAACACCCTCTAGCAAGTCATCCT GeneRacer 3' nested primer CGCTACGTAACGGCATGACAGTG 
5'RACE Ex3 Rev3 GCTGTGATGGATCCTGCAGCTCCT GeneRacer 5' primer CGACTGGAGCACGAGGACACTGA 
5'RACE Ex3 Rev2 ACTGGTGGCCGAGAAGGTGACA GeneRacer 5' nested primer GGACACTGACATGGACTGAAGGAGTA 
qPCR assay Forward (5'- 3') Probe (FAM-NFQ labelled) Reverse (5' -3 ') 
M- 1 8-Ex l CTCAGCATGCGCAGAAGAAAA ACTGTICTCCTGATICTGG CCTCAGAGGCCCCATCCT 
Ex2-Ex3 GAGCAGTACTCCGACTACAG CCAGCAAGCAGTIACCTCAC TAGAGGGTGTTICCGATICC 
Ex = exon; Rev = reverse; FW = Forward 
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Cloning and overexpression of Pcdhl isoform 3 in BEAS2B bronchial epithelial cells 
Cloning: The human DNA sequence corresponding to the isoform 3 sequence obtained by RACE PCR experiments, was amplified from the isoform 2 plasmid (pCMV-XL6-iso2, TC I 09554, Ori gene, Rockville, USA) with forward primer CCGCGAA TICA TICTCTTIGGTGTGGTGG and reverse primer CACTGGAGTGGCAACTIC by using Phusion TM High Fidelity PCR Kit (F-553S, Finnzymes, Fisher Scientific, Landsmeer, The Netherlands), followed by subcloning of the PCR product into the pCMV-XL6 expression vector (Origene, USA). The resulting pCMV­XL6-Pcdh l -Iso3 plasmids were sequenced (StarSeq Sequencing, Mainz, Germany). 
Overexpression: BEAS2B ceJls were grown as described previously (22), seeded into 24-well plates, and transfected at a confluency of 60-80% with 0.5µg of eGFP (expression control, pEGFP-C l ,  Westburg BV, Leusden, The Netherlands), fuJl-length Isoform 2 (pCMV­XL6-Pcdh l -iso2), or Isoform 3 plasmid (pCMV-XL6-Pcdh l -iso3), using Fugene HD transfection reagent according to the manufacturer's procedures (Roche Diagnostics, Al mere, the Netherlands). Cells were harvested 48h after transfection using leammli buffer (2x leammli: 4% SDS; 20% glycerol; I 0% P-mercaptoethanol; 0.004% bromphenol blue; 0. 1 25 M Tris HCI; pH6.8), boiled for 5 min, and analysed for PCDHI protein expression by western blotting using the antibody specific for the intracellular domain encoded by exon 4 (EP76, Figure I A) ( 1 3). 
Detection of Pcdhl protein expression levels by western blotting 
Protein isolation: Frozen lungs were homogenized in 5µ1/mg lysis buffer ( I % Triton­X I 00, l 50mM NaCl, 5mM MgC]z, I 0mM HEPES, I :500 Protease Inhibitor Cocktail (P8340, Sigma-Aldrich, Zwijndrecht, the Netherlands)) using a tissue homogenator (T l 0 basic, ULTRA-TURRAX, IKA ®, Staufen, Germany). Subsequently lung homogenates were boiled for I O  minutes with 2x laemmlli buffer and stored at -80°C. 
Western blotting: Lung tissue homogenates were separated on 7.5% acrylamide SDS­page gels (Bio-Rad Laboratories BV, Veenendaal, the Netherlands). Detection of Pcdh I protein was performed using antibodies that were designed against specific peptide sequences in the intracellular tail of both human PCDHI variants as described previously ( 1 3) (Figure 2A). These antibodies showed cross-reactivity with mouse Pcdhl due to high homology of the immunizing peptide sequences: (QPFQLSTPQPLPHPYH, EP78, 86% conserved; SPSPPEDRNTKTAPV, EP76, 1 00% conserved) (See Figure I A  for binding sites of antibodies). Antibodies were affinity column purified against immunizing peptides 1 1 3 
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(Eurogentec, Liege, Belgium), and were validated by blocking experiments using a pre­
incubation period of 30 min at 37°C with 1 Ox molar excess of immunizing peptides or H20. 
Pcdh 1 bands on western blots were visualized using Goat-anti-Rabbit-Peroxidase 
(GARPO, Daco, Heverlee, Belgium) as secondary antibody, and as tertiary step Rabbit-anti­
Goat-Peroxidase (RAGPO, Dako, Heverelee, Belgium) was used. Next, blots were incubated 
with Luminol-reagent, and subsequently analysed using Fuji Medical X-Ray films (Fuji Photo 
Film Gmbh, Germany), followed by densitometric analysis using Quantity One Software 
v4.6.2 (Bio-Rad), relative to the P-actin loading control (sc-47778, Santa-Cruz 
Biotechnology, Heidelberg, Germany). 
Immunohistochemistry 
Periodic Acid Schiff (PAS) staining was performed on 3µm thick paraffin sections. 
Eosinophils were detected by cyanide resistant eosinophil peroxidase reaction on 5 µm thick 
frozen lung sections (23). Pcdh 1 immunohistochemistry on paraffin embedded lung tissue 
was performed as follows: 3 µ m thick paraffin sections were deparaffinized and antigen 
retrieval was performed by 30 min incubation with Tris-EDT A buff er (10 mM Tris, 1 mM 
EDTA, pH=9.0) at 100°C. Pcdhl specific antibodies, GARPO, RAGPO and AEC (3 amino-9-
ethylcarbazole (Merck, Darmstadt, Germany)) were used to visualize Pcdh 1 protein. Tissue 
was counterstained with haematoxylin (Merck, Darmstadt, Germany). Images were obtained 
with Ce118 Olympus imaging software using an Olympus BX50 microscope with DP70 
camera. Pcdh 1 epithelial staining intensity was determined using ImageJ software 
(http://rsb.info.nih.gov/ij/). In brief, background intensity values were determined in open 
spaces in the airway. Next, airway epithelial staining was determined by specifically selecting 
the epithelial layer. Relative intensity values were obtained by subtracting the background 
intensity values from the epithelial intensity values. 
Statistical analysis 
Differences in mRNA or protein expression levels were statistically tested by Mann­
Whitney tests (GraphPad v4.0, La Jolla, USA). Differences in airway hyperresponsiveness 
between smoke-exposed and air-exposed mice were determined by testing for differences in 
the area under the curve (AUC) using GraphPad software. 
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RESULTS 
Pcdhl expression in the mouse lung 
To allow an accurate investigation of Pcdhl expression regulation in the mouse lung, 
we first determined the Pcdhl gene-structure by RACE experiments. Compared to the 
published mouse Pcdhl gene-structure (16), we detected two novel exons on the 5' end of 
Pcdhl ( exon m-1 b and m- lc, Figure I A), two novel exons on the 3' end ( exon 3b and exon 5), 
as well as major variation in exon 4, containing the conserved CM2-domain and PDZ-BS 
motifs (Figure IA). Exon 3b is a short 39 basepair exon encoding a premature stop codon, 
which is completely conserved between men and mice (See Table 2 for corresponding 
Genbank accession numbers). 
Table 2: Genbank accession numbers of novel Pcdhl transcripts 
RACE reaction Protocadherin-1 Sequence GenBank Accession number 
Mm 5'RACE exon I Exon m-lb  - I JK707005 
Mm 5'RACE exon I Exon m-lc  - I JK707006 
Mm 5'RACE exon I Exon m-lc  - I (short exon) JK707007 
Mm 3'RACE exon 3 Exon 3-3b-4 JK707008 
Mm 3 'RACE exon 3 Exon 4 including gap JK707009 
Mm 3 'RACE exon 3 Exon 4-5 JK707010 
Mm 5'RACE exon 3 Exon 2-3 (Isoform 3) JK70701 l 
Hs 3'RACE exon 3 Exon 3-3b-4-5 JK707004 
Mm = Mus musculus; Hs = Homo sapiens 
Remarkably, mouse Pcdhl exons had high homology to human exons resulting in a 
87% homology at the nucleotide level (Figure 1 A) and a 96 % homology on protein level 
(Supplementary Figure El). Previously we detected an isoform lacking several extracellular 
domains in human bronchial epithelial cells (13). We therefore performed 5'RACE 
experiments from exon 3 in mouse lung. Interestingly, we identified an additional transcript 
starting from within exon 2, containing a CTG Kozak-sequence (isoform 3, Genbank 
accession JK707011), and putatively encoding a protein product with an in-frame translation 
initiation at amino-acid no 870 of the full-length PCDHI isoform 2 protein (Genbank 
accession NP _115796). Overexpression of the corresponding 5' -truncated open reading frame 
in BEAS2B cells induced 40-and 50kD Pcdh 1 proteins. Both protein products were 
specifically detected by the EP76-antibody as intensity of these bands clearly diminished after 
blocking with immunizing peptide, and were not detected with the EP78 and EP209 
antibodies (Figure 1 B). These results show that in mouse lung a third, intracellular Pcdh 1 
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isofonn is expressed that does not contain the extracellular and transmembrane domains, but 
retains all intracellular domains also present in Pcdh 1 isofonn 2 (Figure 1 B). 
We next investigated basal expression of Pcdhl mRNA and protein levels in mouse lung 
tissue. We observed very low levels of Pcdhl using the exon m- lb/exon-1 specific qRT-PCR 
assay, while much higher expression levels of Pcdhl were detected using exon 1-2 and exon 
3-4 specific assays (Figure 2A). On western blot of whole lung homogenate, we observed two 
specific bands of 140-and 150 kD using a specific antibody generated against the intracellular 
tail of the Pcdhl isoform 1 (EP78, Figure 2B). In contrast, we observed a 50kD and 170kD 
bands using a specific antibody generated against the intracellular tail present in Pcdh 1 
isofonns 2 and 3 (EP76, Figure 2B). 
Immunohistochemical staining revealed expression of Pcdh 1 in the airway epithelium, 
using three antibodies that detect either intracellular (EP76 and EP78) or extracellular 
(EP209) Pcdh 1 domains (Figure 1 A and 2C). In addition, smooth muscle cells surrounding 
airways and blood vessels stained positive for Pcdh 1, but only with antibody EP76 (Figure 
2C). These results suggest that airway smooth muscle cells (ASMs) express an N-terminally 
truncated Pcdh I protein containing intracellular, but not extracellular domains, consistent 
with the novel isofonn 3. 
Figure 1: Pcdhl gene-structure and isof orms 
Two novel exons were detected at the 5 'end of PCDHJ, and one novel exon on the 3 'end of 
Pcdhl. Mouse Pcdhl exons share high homology with human PCDHJ exons. Corresponding 
isoforms (isoforms 1, 2 and putative isofomi 3) and their protein structures are depicted. Only 
isoform 2 and putative isoform 3 contain evolutionary conserved motifs (CMJ-3). Two 
antibodies were generated against sequences in the intracellular tail of both isoform 1 ( EP78) 
and isofonn 2 (EP76) of Pcdhl. An antibody directed against the extracellular domains of 
Pcdhl (EP209) was generated previously ( 12) (A). Western blot of lysates of BEAS2B cells 
overexpressing the open reading frame of Pcdhl isoform 3, using antibody EP76 for detection 
as indicated ( left hand panel) including a pre-incubation with the immunizing peptide 
( 'Peptide blocked ') as a control for specificity (right hand panel). Western blots using EP78 
and EP209 antibodies for detection are also included as indicated (B). eds = coding 
sequence; UTR = Untranslated region; SP = Signal peptide (amino-acid (aa) 1-57); EC = 
Extracellular Cadherin domain; TM = Transmembrane domain; CM = Conserved Motif; 
PDZ-BS = PDZ-domain Binding Site; EP209 = Binding site for antibody directed against the 
extracellular domain of Pcdhl; EP78 = Binding site for antibody directed against a specific 
intracellular sequence of isoform 1, encoded by exon 2; EP76 = Binding site for antibody 
directed against the intracellular domain present in isoforms 2 and 3 and encoded by exon 4; 
FL = full length. Genbank accession numbers of novel transcripts are provided in Table 2. 
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A Pcdh1  gene-structure 
Mouse 
Homology 
Mouse exons m-1a m-1b m-1c  2cds 
Size (basepair) 182 153 211 863 2280 
Human exons 1a Na 1 e/1f 1 2cds 
Size (basepair) 180 Na 195 863 2280 
Homology (%) 87 Na 73 87 89 
P rotein structure 
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Figure 2: Basal Pcdhl mRNA and protein expression, and localization. 
mRNA expression levels of exon m-lb, exon 1-2 and exon 3-4 containing transcripts in naive 
mouse lung of four mice (A). Western blot of mouse lung homogenate using the antibody 
directed against the intracellular domain of Pcdhl isoform 1 (EP78), and the antibody 
directed against the intracellular domain encoded by exon 4 of Pcdhl (isoform 2, EP76) (see 
arrows), with fJ-actin as loading control (B ). Immunohistochemical staining of Pcdhl on 
frozen sections using the 209-antibody and on paraffin sections using antibodies EP78 and 
EP76. PBS and IgG (isotype) were used as controls (C). ml = lung homogenate of mouse 
number 1; FL = full length. 
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Pcdhl expression levels in HDM driven asthma models 
Previously, we observed PCOHI expression in the human airway epithelium (12), and 
here we confirmed epithelial expression in the mouse lung. We aimed to identify whether 
Pcdh I expression is altered in house-dust mite (HOM) driven asthma models, as these models 
of asthma are induced by sensitisation through the airway epithelium, resulting in AHR, 
eosinophilic airway inflammation, goblet cell metaplasia and increased ASM-mass in the 
airways as well as the induction of HOM-specific IgE responses (24). We first employed a 3-
week HOM-exposure model based on Hammad and co-workers (25), which induced 
eosinophilic inflammation and goblet cell metaplasia in the airways (Figure 3A). To test 
whether Pcdh I was involved in subsequent repair, we allowed the mice to recover for 2 weeks 
followed by an additional 2 HOM exposures (exposure 4 and 5, Figure 3A) and another 
recovery period. In the control (PBS-exposed) groups terminated prior to (day 0) and at the 
end of the experiment (day 46), we observed a trend towards higher expression of exon 1-2 
(p=O. I I), and a significant higher expression of exon 3-4 (p<0.05) during the 7-week period 
of the experiment (Figure 3B). We observed no alterations in Pcdhl expression during the 
first 3 weeks of HOM exposure, during the two weeks of recovery thereafter, or during the 
second series of HOM exposures (Figure 3B). However, we observed a clear upregulation of 
Pcdhl mRNA expression between 7 and 14 days after the last two HOM exposures, for both 
exon 1-2 and exon 3-4 assays (HOM day 39 vs HOM day 46, p<0.05 for both assays) (Figure 
3B). Our design did not enable direct comparison to a control group at this time-point. Since 
Pcdhl expression levels of the control groups were higher at the end than at the start of this 
HOM-model, it is hard to conclude whether the marked Pcdhl expression difference reflects a 
reduced expression of Pcdhl during the two consecutive HOM exposures, or a strong 
induction of expression during the resolution phase thereafter. Furthermore, no differences in 
protein levels were detected between the different groups when analysed by western blot or 
immunohistochemistry (data not shown). Therefore, we performed a second experiment in 
which we compared Pcdh I expression between HOM- and PBS treated mice that had received 
a higher number of HOM exposures (Figure 4A). In this model we observed marked 
eosinophilic airway inflammation, airway remodelling and AHR as published previously ( I 9). 
Immunohistochemical staining for Pcdh I isoforms revealed strong staining in intact epithelial 
cell layers using isoform I and isoform 2/3-specific antibodies. In contrast, no (isoform I -
specific antibody) to low (isoform 2/3-specific antibody) staining was observed in remodelled 
airways characterized by goblet cell metaplasia (Figure 4B). 
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Figure 3: Expression of Pcdhl after HDM-exposure in the mild HDM-model 
In the mild HDM model mice are exposed to HDM (25µg in JOµl PBS) or PBS (control) once 
a week for three weeks, followed by a two week rest period and two consecutive exposures 
( exposures 4 and 5 ). After these two exposures two additional weeks of rest are included. This 
model is characterized by tissue eosinophilia and goblet cell hyperplasia (A). mRNA 
expression levels of Pcdhl exon 1 -2 and 3-4 were determined during HDM exposures ( closed 
symbols), compared to the control group (open symbols) (B). Wk =  week; HDM = house-dust 
mite; f = day at which mice are sacrificed; PAS = Periodic Acid Schiff-staining for mucous 
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Expression and regulation of Pcdhl in mouse lung 
To quantify the differences of airway epithelial Pcdhl expression between PBS and HDM­
exposed mice we next determined the mean intensity of Pcdhl expression in intact epithelial 
cell layers, not affected by goblet cell metaplasia. Pcdhl isoform 1 expression was the same in 
both groups while, in contrast, lower expression levels of Pcdhl isoform 2/3-specific staining 
was observed (p=0.03S) in HDM exposed mice when compared to PBS exposed controls 
(Figure 4C). These data indicate that in the active phase of HOM-induced airway 
inflammation, expression of Pcdhl isoform 2 and/or isoform 3 was lower in airway epithelial 
cells. 
Short term smoke exposure down regulates Pcdhl expression levels 
Given the initial linkage of PCDHJ to AHR and asthma in cigarette smoke exposed 
families defined by a significant smoking history of the asthma proband of more than 5 
packyears ( 12), we investigated whether Pcdhl expression was regulated in a sub chronic (5 
days) smoke exposure model (Figure SA). This model induced a neutrophillic influx into the 
airways (Figure SA), a feature of sub chronic smoke-exposure models (20, 26), as well as a 
trend towards AHR to methacholine (p=0.0S6, Figure SA). 
In CS-exposed mice, we observed significantly lower expression of Pcdhl transcripts 
encoding exon 1-2 (3.9 fold, p=0.0003) and exon 3-4 (3.3-fold, p=0.0003) in total lung 
(Figure SB). Next, we investigated whether this was reflected at the protein level in total 
mouse lung homogenate. No differences in Pcdhl isoform 1 protein levels were found, but a 
clear trend towards lower levels of the 170 kd Pcdhl isoform 2 protein band (p=0.052, 
Figure 5C and SD) was observed by western blot after 5 days of smoke exposure. 
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Figure 4: Expression of Pcdhl after HDM exposure in the 5-week HDM-model 
In this HDM model mice are exposed to HDM (25µg in JOµ[ PBS) or PBS (control) twice a 
week for 5 weeks as described previously (19) (A). Pcdhl protein expression levels are 
depicted of HDM-exposed airways with and without goblet cell metaplasia, and in PBS­
exposed airways, using EP78 and EP76 antibodies (B ). Pcdhl protein levels of EP78 and 
EP76-stainings were quantified in intact HDM exposed airways ( closed symbols) compared 
to PBS exposed airways (open symbols), by comparing the relative intensity levels. IgG­
isotype was used as control (C). Exp. = exposure; Wk =  week; HDM = house-dust mite; t = 
day at which mice are sacrificed. 
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Figure 5: Pcdhl expression levels decrease after sub chronic smoke exposure 
In the sub chronic smoke exposure model, mice were exposed to 1 and 3 cigarettes or air at 
day 1, followed by 5 cigarettes at day 2-5 or air. 2h after the last cigarette both smoke and air 
exposed mice were sacrificed. Neutrophils in the bronchoalveolar lavage fluid, and airway 
hyperresponsiveness to methacholine were determined. Error bars show Standard Deviation 
(A). Pcdhl exon 1-2 and 3-4 transcript levels were determined in lungs of air exposed (open 
symbols) and smoke exposed (closed symbols) mice (B). Pcdhl protein levels were determined 
by western blot of lung homogenate of air ( control) and smoke exposed mice. Pcdhl isoform 1 
( EP78-antibody ), full-length isoform 2 ( EP76-antibody) and 50kD ( EP76-antibody) levels are 
shown, with /3-actin as loading control (C). Densitometric quantification of Pcdhl expression 
levels of full-length isoform 1 and 2, and the 50kD fragment, relative to /3-actin ( D ). Cig = 
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To test whether this down regulation of Pcdh 1 expression levels was a direct effect of 
CS-exposure, we also analyzed Pcdh 1 expression shortly after an acute CS-exposure, in 
which no significant neutrophilic influx was observed (Figure 6A). Remarkably, already 6 
hours after CS-exposure, a 2-fold (p=0.006) decrease in exon 1-2 expression levels and a 1.6-
fold (p=0.03) decrease in exon 3-4 expression levels was observed (Figure 6B), suggesting 
that Pcdhl expression indeed is directly regulated by CS-exposure. This difference was not 
paralleled by a reduced lung Pcdhl protein expression at this time-point (Figure 6C and 6D). 
DISCUSSION 
In this study, we provide a full characterization of the expression pattern of a novel 
asthma and AHR susceptibility gene in the mouse lung, and its regulation in relevant in vivo 
models known to modulate AHR by direct effects on the airway epithelium. Here, we show 
that the mouse and human genes for Protocadherin-1 are highly homologous, both at the 
nucleotide and at the amino-acid level, validating the mouse as a relevant model to study 
Pcdh 1 function. As seen in human bronchial biopsies (12), Pcdh I is mainly expressed in the 
airway epithelium. In addition to the two annotated isoforms of Pcdh I that differ in their 
cytoplasmic signalling domains, we observed expression of a novel Pcdhl isoform, 
characterized by the lack of extracellular and transmembrane domains, whilst containing the 
intracellular domains also present in isoform 2. With immunohistochemistry, we found a 
staining pattern consistent with the presence of this novel isoform, specifically in smooth 
muscle cells surrounding the airways and venules in the lung. In the active phase of both 
house-dust mite and sub chronic cigarette smoke exposure models at the time of AHR, Pcdh 1 
expression levels were at the lowest. Specifically, epithelial Pcdh 1 protein expression was 
reduced after chronic exposure to house-dust mite in an asthma model, while in the resolution 
phase after house-dust mite exposure an induction of Pcdhl mRNA expression was observed. 
Interestingly, acute exposure of mice to CS induced a rapid and strong reduction of Pcdhl 
expression. 
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Figure 6: Pcdhl mRNA expression levels decrease after acute smoke exposure 
In the acute smoke exposure model, mice were exposed to 10 cigarettes, with a 20 min rest 
period in between, or air. Low numbers of neutrophils were observed in the lung after 6h (A). 
Pcdhl exon 1-2 and 3-4 mRNA expression levels were determined in the smoke exposed 
group (closed symbols) and compared to the air-exposed group (open symbols) (B). Western 
blot of Pcdhl isoform 1 (iso 1, EP78-antibody), isoform 2 (iso 2, EP76-antibody) and the 
50kD fragment ( EP76-antibody) in lung homogenate of mice exposed to smoke for 1 day 
(smoke) or air (control) ( C ). Densitometric quantification of Pcdhl expression levels of full­
length isoform 1 and 2, and the 50kD fragment, relative to /J-actin (D ). Cig = cigarette; f = 
time-point at which mice are sacrificed; CS = cigarette smoke. 
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When comparing the gene-structure of Pcdhl to human PCDHl ( 1 3), we observed a 
striking homology between the two; with 87% at the nucleotide level and 96% at the amino­
acid level (Figure I A, Supplementary Figure E I). Moreover, the low expression levels of 
alternative 5'exons (exon m-lb), the gap in exon 4 ( 1 3, 1 6) resulting in deletion of conserved 
CM2-domains, and the novel exon 5 are also conserved between man and mouse ( 13). In 
addition to the high level of conservation we obtained evidence for a third Pcdh I isoform that 
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CHAPTER 5 initiates transcription from within exon 2 and contains a CTG start-codon (27) within a conserved KOZAK sequence (Figure 1 A). Overexpression of this isoform induced expression of 40-and 50kD PCDHl proteins that were only detected by the antibody generated against the intracellular domain encoded by exon 4 also present in isoform 2 (EP76-antibody). ASMs stained positive only with this specific antibody. These results suggest that ASMs express a Pcdh 1 protein containing intracellular, but not extracellular cadherin repeats, consistent with a third isoform. Its function may involve cell signalling rather than cell adhesion, which will be subject of future investigations in human ASM cells. In contrast to ASM cells, this novel isoform was not conclusively expressed in airway epithelial cells, as shown in vivo using the combination of approaches employed by us. The 1 6HBE bronchial epithelial cell-line however, was shown to display a 50kd band on Western blot that could correspond to this novel isoform (13), but it might also represent a posttranslational modification of the full­length isoform 2 protein as has been observed for other protocadherins (28). Expression of Pcdh 1 during mouse development was previously investigated by RNA hybridizations using a probe specific for the three last extrace1lular domains and the transmembrane domain of Pcdh 1 (18). This probe covers Pcdhl isoforms containing the extrace1lular domains (isoform 1 and 2), but does not detect the newly identified intracellular isoform 3. Using this approach Pcdhl staining was observed in the parenchyma with a predominant positive staining for blood vessels, but no staining in the bronchi, up to the adult stage ( 18). This is in contradiction to our results where a clear bronchial epithelial staining, and a lack of blood vessel staining was found by immunohistochemistry using 3 independent antibodies. The smooth muscle layer surrounding the vessels stained positive by the isoform 2/3-specific antibody only, corresponding to expression of Pcdh I isoform 3. This 3rd isoform would have been missed by the probe used in the RNA hybridization study. The absence of airway epithelial expression of Pcdhl during development might be explained by the different developmental stages under scrutiny or differences in the sensitivity of the different techniques used to detect Pcdh 1 .  Clearly, more data with respect to the role of Pchd 1 in lung development is needed. The effect of genetic variation of the AHR susceptibility gene PCDHJ on its expression and regulation is currently unknown. We hypothesized that gene-variants are associated with alterations in PCDHl expression, either at the basal level or in response to relevant environmental stimuli, and analyzed the regulation of Pcdh 1 expression in mouse 126 
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models of experimental asthma, sensitized through the epithelium. In the mild HOM-induced 
asthma model, whole lung Pcdhl mRNA expression remained relatively stable during the 
active phase (i.e during HOM exposures), but increased in the recovery phase following 
exposures 4 and 5 (Figure 3). Given the slight increase of Pcdhl expression levels in time in 
the control groups over the course of this HOM-model, we cannot formally distinguish 
whether these data represent a repression of Pcdhl expression during the HOM exposures 
that extends into the first week after these exposures, or an increase in Pcdhl expression 
during the recovery phase at later time-points after the cessation of the HOM exposures. 
Furthermore we can not tell whether the observed differences in Pcdhl expression levels arise 
from changes in epithelial or ASM PcdhJ-expression levels, as previously changes in ASM­
mass were observed in HOM-exposed mice, as well (24). Nevertheless, the increase in Pcdhl 
expression levels is evident and suggests a role for Pcdh 1 in epithelial repair. Epithelial repair 
consists of several processes, including an immediate response with cell migration to restore 
the barrier, followed by an interim repair stage and a final phase of proliferation and 
differentiation (4). Based on our previous observation of an up regulation of PCDH I 
expression during mucociliary differentiation of airway epithelial celJs (13), we hypothesize 
that Pcdh I may play a role in this final phase of epithelial repair after repeated allergen 
exposures. To get a more detailed understanding of the expression of Pcdh 1 during the active 
phase of allergic asthma development, Pcdh 1 protein expression was investigated in our 
chronic HOM-driven allergic asthma model ( 19) in which the mice received a double number 
of HDM exposures and were sacrificed 24h after the last HOM exposure. Interestingly, in this 
model of ongoing allergic airway inflammation and remodelling, lower Pcdh I isoform 2 or 3 
protein levels were found in airway epithelial cells. These epithelial cells were located in 
airways that were devoid of goblet cell metaplasia. These results suggest that airway 
exposures to allergen do have impact on epithelial Pcdh I expression, although these effects 
are relatively mild and only apparent for Pcdh I isoform 2 and/or 3. 
In addition to chronic HOM exposure, CS-exposure also reduced Pcdhl expression 
levels, as determined in whole lung homogenate. Since loss of Pcdhl expression is already 
observed as early as 6 hours after CS-exposure, Pcdhl expression might in fact be regulated 
directly by CS-exposure as this time-point precedes significant influx of inflammatory cells in 
the airways. The human chromosomal region 5q31-33, containing PCDHJ , was previously 
l inked to AHR and asthma in 95 ETS exposed families. In this study, ETS exposure was 
defined by a significant smoking history of the proband of the asthma family. Associations of 
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PCDHJ gene-variants with AHR were further investigated in four populations of children 
exposed to ETS in utero or in early life. PCDHJ gene-variant rs3822357 was associated with 
AHR in ETS exposed children in one population only (12). 
Mice sub chronically exposed to smoke were hyperresponsive to methacholine (trend), 
which confirms other studies in smoke exposed mice (29) and guinea pigs (30). CS is known 
to impair the epithelial barrier function, and thereby induces permeability of airway epithelial 
cells, as evidenced by a decrease in electrical (31) or trans-epithelial (3) resistance. Epithelial 
ce11s are interconnected by tight-junctions (TJ) and adherens junctions (AJ). CS delocalizes 
the TJ adaptor molecule Z0-1 (32), and down-regulates several AJ adhesion molecules, 
including E-cadherin (33). The resulting loss of TJ-and AJ stability may subsequently lead to 
loss of barrier function of the epithelium. As PCDHJ was previously reported to have a role 
in cell-cell adhesion (34), the loss of PCDHl expression might contribute to the reduced 
epithelial barrier function induced by CS-exposure. Since PCDHJ is an AHR susceptibility 
gene, we hypothesize that these decreased Pcdh 1 levels contribute to a reduced epithelial 
barrier function or an altered repair process, thereby making subjects more susceptible to 
environmental insults, possibly leading to inflammation, remodelling and eventually AHR 
and asthma. Remarkably, in both the HOM-driven asthma model and the CS-exposure model, 
Pcdh 1 expression levels are relatively low at the time when AHR is observed. Future 
mechanistical studies will assess the contribution of Pcdh 1 expression levels to AHR. 
In conclusion, our data show that Pcdhl is strongly conserved between mouse and 
man. Furthermore, our data are the first to show that Pcdh 1 expression is strongly regulated 
by CS-exposure, while its regulation in HOM-driven models of in experimental allergic 
asthma is less pronounced, but present. Future studies on the function of Protocadherin-1, 
using novel knockout and/or transgenic approaches, and its interaction with environmental 
factors such as HDM and/or CS exposure will provide novel insights into the origins of 
airway hyperresponsiveness and asthma. 
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SUPPLEMENTARY DATA 
Supplementary Figure El: Human PCDHJ and mouse Pcdhl protein homology 
Alignments of human 
PCDH I and mouse 
Pcdhl protein 
isof orms I and 2 was 
performed using 
Clustal W software. 
Homology of EP78 
and EP76 immunizing 
peptides is depicted in 
the marked boxes. 
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CHAPTER 6 
ABSTRACT 
Protocadherin- 1  (PCDH J) and Mothers against decapentaplegic homo log 3 (SMAD3) 
are novel asthma associated genes. PCDH I encodes for two transmembrane molecules with 
seven extracellular cadherin repeats, and one intracellular isoform containing conserved 
signalling domains that are shared with one of the transmembrane isoforms. PCDHl belongs 
to the 8 1  family of non-clustered protocadherins and displays weak adhesion activity. PCDHl 
and SMAD3 are proposed to interact on protein level, suggesting that they may act in a novel 
pathway associated with asthma. We aimed to identify whether PCDHI is a candidate 
molecule for intracellular signalling by investigating the subce11ular localization of PCDHI 
isoforms and their interaction with SMAD3 in 16HBE bronchial epithelial ce11s. The 
subcellular localization of PCDHI protein products was investigated in l 6HBE culture 
supernatant, cytoplasmic, and nuclear/membrane fractions, and by immunofluorescent 
microscopy using four PCDHl specific antibodies targeted at both extracellular and 
intracellular domains. An interaction with SMAD3 was investigated by co­
immunoprecipitation in PCDH I pull-downs using PCDHl isoform- 1 and isoform-2/3 specific 
antibodies. We identified a novel 1 20kD soluble PCDH I protein product (sPCDHl ), and a 
series of novel intrace11ular 52, 50, 48 and 37kD protein products. Isoform 1 showed a 
punctuate supra-nuclear localization, while a cytoplasmic filamentous staining pattern was 
detected for isoform-2/3 that concentrated around the nucleus. Furthermore, an interaction of 
both PCDHI isoforms 1 and 2 with SMAD3 was identified by SMAD3 co­
immunoprecipitation in PCDHI pu11-downs and vice versa, at endogenous levels in 16HBE 
ce11s. We conclude that PCDHI may contribute to signalling by its soluble extracellular 
sPCDHI isoform and via intracellular protein products that reside at the nuclear membrane. 
Furthermore, by identifying the interaction of both PCDHI isoforms with SMAD3 we 
physically connect two asthma associated genes to act in a shared pathway. 
1 34 
PCDH I isoforms interact with SMAD3 
INTRODUCTION 
Asthma is a chronic disease of the airways, affecting up to 300 million individuals 
world-wide (I). Asthma is a complex disease, characterized by gene-gene and gene­
environment interactions (2). Recent genetic studies have led to the discovery of novel, 
replicated asthma loci such as ORMDL3/GSMDL, /LJRLJI/Ll8Rl, TSLP/WDR36, IL-33, and 
SMAD3 identified by genome wide association studies (3), and ADAM33 (4), NPSRJ (5) and 
PCDHJ (6) by positional cloning. Although these discoveries likely identify genes associated 
with important mechanisms in asthma, it has been difficult to assign these novel genes to 
distinct pathways, with notable exceptions being IL33 - IL J RLI  signalling (7), and the 
NPSR 1 - Tenascin C interactions (8). Two of these novel asthma genes, Protocadherin-1 
(PCDHJ) and Mothers against decapentaplegic homolog 3 (SMAD3), were proposed to 
interact on protein level based on yeast-2-hybrid screens (9, 10). This suggests that PCDHI 
and SMAD3 might act in a third pathway identified by unbiased genetic screens in asthma. 
SMAD3 is widely expressed in many cell types including epithelial, mesenchymal and 
immune cells (11, 12). Upon TGFB or Activin (Act) activation (13), the constitutive active 
type II TGFB or Act - Receptor kinases form a complex with and subsequently phosphorylate 
the type I receptors, such as TGFB Receptor I (TGFBRI) or Activin Like Kinase (ALK) 
receptors. Subsequently, these type I receptors phosphorylate SMAD3 C- terminally. 
Phosphorylated SMAD3 binds to SMAD4, translocates to the nucleus, and induces gene­
transcription (14). 
PCDHI belongs to the 81-protocadherin subfamily of the cadherin superfamily of 
adhesion molecules, and is expressed in the airway epithelium (6) where its levels are 
upregulated during mucociliary differentation (15). PCDHJ encodes for two full-length high 
molecular weight isoforms (isoform I of 150kD, isoform 2 of l 70kD), both containing seven 
extracellular cadherin repeats (ECs), and a third isoform (isoform 3 of approximately 50kD) 
that lacks 5 or all ECs and thus mostly consists of intracellular domains (15) (Figure I). The 
intracellular domains of isoforms 2 and 3 are characterized by the presence of three conserved 
signalling motifs CMI-3. Whereas the putative interaction partners of CMI and 2 are 
unknown, CM3 is the binding domain for protein phosphatase I alpha (PPI a) (16), a 
phophatase implicated in lung development ( 17). 
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PCDH1 may function as an adhesion molecule, but displays only weak adhesion 
activity (18). Despite its proposed interactions with downstream molecules like PPl a.  and 
SMAD3 the possibility that PCDHl performs other functions like intracellular signalling has 
not been investigated. Adhesion molecules may perform signalling functions, by (a) clustering 
with signalling receptors, (b) binding cytoskeleton organizing molecules, (c) interacting with 
intracellular signal transduction proteins, or ( d) by translocating to the nucleus to affect gene­
transcription (reviewed in (19)). Extracellular domains of (proto)cadherins may be shed by 
metalloproteases, followed by cleavage of the intracellular domain by presenilins, as was 
described for E-cadherin (20) and y-Protocadherins (21). In addition, transcriptional or 
translational regulation may lead to the expression of isoforms that only encode extracellular 
domains (as was shown for PCDHl 5, (22)) or lack extracellular domains (as was reported for 
PCDHl and PCDH15  (15, 22)). Altogether, the subcellular localization of PCDHl isoforms 
may provide a first clue into its potential signalling functions. We hypothesize that PCDHl 
can contribute to intracellular signalling. Therefore we determined the subcellular localization 
of PCDHl isoforms, and their interaction with a known downstream signalling molecule, 
SMAD3, in bronchial epithelial cells. 
MATERIAL AND METHODS 
Cell-culture 
The human bronchial epithelial cell line I 6HBE 140- ( 16HBE) was cultured in Eagle 
minimum essential medium (EMEM) supplemented with 10% fetal calf serum (PCS; 
Biowhittaker, Verviers, Belgium) on collagen (PureCol, !named, Santa Barbara, California, 
USA) and bovine serum albumin (A331 l -1 00G, Sigma-Aldrich, Zwijndrecht, The 
Netherlands) coated T25-flasks as described previously (23). In order to generate a time-range 
with increasing confluency of l 6HBE cells, 7* 105 cells were seeded in T25-flasks at day 0, 
and harvested after 24h (day 1), 72h (day 3) and 120h (day 5) in duplicate. In total three 
independent replicate experiments were performed. 
Measurements of PCDHl in 16HBE culture supernatants 
I 6HBE supernatants were concentrated with Amicon Ultra-2 Centrifugal Filter Units 
with Ultracel- I OkD membrane (Millipore BV, Amsterdam Zuidoost, The Netherlands), 
according to the manufacturers' instructions. In brief, 2 ml of supernatant of confluent 16HBE 
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cells cultured without serum for 24 or 48h in T25-flasks, or control EMEM-medium, was 
applied to the insert of the I 0kD cutoff Ami con column and centrifuged at 4000g for 20 min. 
The concentrated supernatant was recovered and centrifuged in the inverted column at I 000g 
for I min. The volume of the concentrate was determined, followed by boiling for 5min with 
the corresponding volume of 5x Leammli buffer (0.3M Tris-HCI pH 6.8, 50% glycerol, 25% 
P-mercaptoethanol, I 0% sodium dodecyl sulphate (SOS), 0.2% bromophenol blue), and 
stored at -20°C until further use. This experiment was repeated three times. 
Preparation of nuclear/membrane extracts from 16HBE epithelial cells 
Nuclear/membrane extracts were obtained according to the protocol of Schreiber and 
co-workers (24). All steps were performed on ice or at 4°C. In brief, I 6HBE bronchial 
epithelial cells were washed with PBS and scraped in ice-cold PBS with protease inhibitor 
cocktail ( I :500, P8340- I ML, Sigma-Aldrich). The cell-pellet was carefully resuspended and 
incubated for 15 min in 400 µI ice-cold buffer A (IOmM HEPES pH 7.9; IOmM KCI; 0. lmM 
EDTA; 0. lmM EGTA, lmM OTT, Protease inhibitor cocktail (1:500)). Then Nonidet P-40 
(NP40, Sigma Aldrich) was added and incubated for 10 sec to swell the cells followed by 
collection of the cytoplasmic fraction. After centrifugation at 13000rpm ( I 7982g) for 30 sec 
the pellet containing the nuclear fraction, precipitated membranes and DNA was washed 
twice with buffer A to remove remaining cytoplasmic contaminants. Nuclear proteins were 
extracted by a 15 min incubation with 50 µ1 ice-cold buffer C (20mM HEPES pH 7.9; 0.4M 
NaCl; lmM EDTA; lmM EGTA, l mM DTT, Protease inhibitor cocktail (1:500)), followed 
by centrifugation for 5 min at I 3000rpm. The remaining cell-pellet or insoluble fraction was 
discarded. Protein concentration of extracts was determined using the Micro-BCA kit (Pierce, 
Thermo Fisher Scientific; Perbio Science BV, Etten-Leur, The Netherlands). Equal protein 
amounts (5-10 µg) were loaded on 10% acrylamide SOS-page gels for western blotting. 
Purity of nuclear and cytoplasmic fractions was confirmed by staining for HDAC2 (nuclear 
protein, 3602-100, BioVision, Mountain View, USA) and a-tubulin (cytoplasmic protein, 
T6199-200UL, Sigma-Aldrich, Zwijndrecht, The Netherlands) in both fractions. PCDHI 
levels in fractions were compared to levels of E-cadherin, an adherens junction protein (HJ 08, 
Santa-Cruz Biotechnology, Heidelberg, Germany). Potential plasma membrane contamination 
was assessed by staining for the presence of the Anti-alpha I Sodium Potassium ATPase 
(Plasma membrane marker, ab7671, Abeam, Cambridge, United Kingdom). 
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Western blot detection of PCDHl 
To detect the extracellular domains of PCDHl by western blotting two antibodies 
were used: the extracellular cadherin repeat 1 (ECl )-domain antibody (amino-acid 62-170, 
H00005097-M01, Abnova, Taiwan) and the EC7-domain antibody (EP209 polyclonal 
antibody; immunizing peptide DIAGPEYERSKQRG+C, (6)). To detect the intracellular 
domains of PCDHI by western blotting or immunoprecipitation two polyclonal antibodies 
were used: the isoform-1 antibody (EP78, immunizing peptide QPFQLSTPQPLPHPYH) and 
the isoform-2/3 antibody (EP76, immunizing peptide SPSPPEDRNTKTAPV+C) (15). 
Location of the peptides recognized by the individual antibodies is schematically depicted in 
Figure 1. PCDHI proteins present in concentrated culture supernatants and nuclear and 
cytoplasmic fractions were detected by western blotting as described previously (15). In brief, 
protein samples were separated on 10% acrylamide SOS-page gels (Bio-Rad Laboratories, 
Veenendaal, The Netherlands), transferred to nitrocellulose membranes for PCDHI detection 
and visualized by ECl -domain, EC7-domain, isoform-1 and-2/3 antibodies, with Goat anti­
Rabbit and Rabbit-anti-Goat-Horseradish Peroxidase (HRP, Daco, Beverlee, Belgium) 
detection antibodies. Blots were incubated with Luminol, and subsequently analysed using 
Fuji Medical X-Ray films (Fuji Photo Film Gmbh, Germany). 
Immunofluoresence 
16HBE bronchial epithelial cells were seeded on coverslips (5* 104 cells per coverslip), 
grown to full confluency and fixed in 4% paraformaldehyde and 0.1 % glutaraldehyde in PBS 
for 20 min and afterwards with 50nM ammonium chloride in PBS for 5 min to quench free 
aldehyde groups (PCDH l isoforms 1 and 2 staining), or in ice-cold methanol (Claudin-3, Life 
Technologies Ltd, Paisley, United Kingdom) for 20 min. Next, cells were incubated with 
blocking buffer (10% normal goat serum or 1 % BSA in PBS) for 20 minutes. Primary 
antibodies (PCDHl isoform-1 ab (1 :50), isoform-2/3 ab (1 :20), EC7-domain ab (1 :200) or 
Claudin-3 (1 :50) diluted in PBS with 0.1 % BSA) or PBS with 0.1 % BSA (negative control) 
were applied for 60 min. Finally, goat anti-rabbit Alexa Fluor 488 conjugate (green 
fluorescence, Life Technologies Ltd) was used as a secondary antibody to visualize PCDHl 
or Claudin-3 immunoreactivity, while nuclei were counterstained with Hoechst 33342 (blue 
fluorescence, Molecular Probes, Life Technologies Ltd). Fluorescence staining was detected 
by Confocal Microscopy using a Leica SP5 Confocal microscope. 
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Immunoprecipitation (IP) of PCDHl and SMAD3 proteins Confluent 1 6HBE cells (T25-flask) were scraped in ice-cold Mammalian Protein Extraction Reagent buffer (M-PER, Pierce, Thermo Fisher Scientific) with protease inhibitor cocktail ( I  :250; Sigma-Aldrich), and lysed at 4°C using an orbital shaker. The lysate was pre­centrifuged to remove insoluble proteins and pre-cleared by incubating with Protein-G agarose beads (Pierce, Thermo Fisher Scientific) to reduce non-specific binding of proteins to fresh beads at a later stage. Next, I µg of isoform-specific PCDHI antibody (isoform- 1 or 2/3) or 2 µ I  of SMAD3 antibody (04- 1 035, Millipore) was added per 1 00 µ1 lysate, and incubated overnight at 4°C to bind PCDHI or SMAD3 proteins. The immune complexes were precipitated after 3h incubation with fresh Protein-G agarose beads, and washed thoroughly with PBS. As a control, lysate was incubated at the same time without PCDHI or SMAD3 antibody followed by incubation with fresh Protein-G agarose beads. The bound immune complexes or control beads were boiled in 5x Laemmli buffer to elute proteins and used for western blotting purposes. Immunoprecipitated proteins were separated on SOS-PAGE gels and blotted to nitrocellulose membranes for PCDH I detection as described before, or transferred to PDVF membranes for SMAD3 detection using the SMAD3 detection antibody C67H9 (Cell-Signalling Technology, Bioke, Leiden, The Netherlands). Antibodies used for detection of immunoprecipitated proteins of approximately 50kD were first biotin-labelled using the EZ-link Sulfo-NHS-LC-Biotin kit (Thermo Fisher Scientific), followed by detection using Streptavidin-HRP (R&D Systems Europe Ltd, Oxon, United Kingdom) as secondary step, in order to prevent interference of the 50kD heavy-chain IgG molecules. 
Quantification of protein levels Protein intensity levels (/) were quantified by densitometric analysis using Quantity One 4.6.2 software (Bio-Rad). a.-Tubulin was used as a marker for the cytoplasmic fraction, while HDAC2 was used as a marker for the nuclear fraction. The relative contamination of cytoplasmic (Cyto) proteins in the nuclear (Nucl) fraction (a), and nuclear proteins in the cytoplasmic fraction (b) was calculated as follows: 
a(%) = 
Ia-1ub11/i11 Nucl x 1 00; b(%) = IHDAC2Cyto x 1 00 
(I a-111b11ti11 Cyto + I a-111h11ti11 Nucl) (I HDAC2 Nucl + I HDAC2 Cyto) 1 39 
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RESULTS 
Detection of soluble PCDHl in 16HBE tissue culture medium 
We previously identified PCDHl proteins of 150kD (isoforrn 1), 170kD (isoforrn 2) 
and ~50kD (isoforrn 2 or 3) PCDHI protein products in whole cell-lysate of primary 
bronchial epithelial cells and 16HBE bronchial epithelial cells (15). Here, we aimed to 
identify the presence of PCDHl proteins in tissue culture supernatants, using ECl and EC7-
domain antibodies (abs) (directed against extracellular PCDHl domains) and isoforrn 1 and 
2/3 abs (directed against intracellular PCDHl domains) respectively (see Figure 1). 
Figure 1: PCDHl isoforms and epitopes of detection antibodies 
Schematic overview of both mRNA and protein structures of PCDHJ isoforms 1, 2 and 3. The 
potentially phosphorylated Serine (S) and Tyrosine (Y) residues are located in the constant 
shared region of all isoforms. Conserved motifs (CM) encoded by exon 3 and 4 are present 
only in isoforms 2 and 3. Epitopes of PCDH 1 antibodies are depicted. SP = signal peptide, 
EC = extracellular cadherin repeat, TM = transmembrane domain, PDZ-BS = PDZ-domain 
binding site. 
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37kD fragments (both isoform-1 and 2/3 abs) and a 50kD fragment (isoform-2/3 ab) 
were detected in tissue culture medium of I 6HBE cells (Figure 2). The 37kD fragments were 
confirmed to be specific after peptide pre-incubation of the abs, while the 50kD fragment was 
non-specific (results not shown). Interestingly, a clear I 20kD protein product was detected 
using the antibody directed against the ECl -domain of PCDHI, that appeared as early as 4 
hours after incubation of confluent I 6HBE epithelial cells with fresh serum free tissue culture 
medium. No full-length PCDH I isoforms were detected in tissue culture medium of l 6HBE 
cells (Figure 2). These results may suggest that PCDH I is actively being shed, resulting in the 
presence of a soluble 120kD PCDH I isoform (sPCDHJ )  that contains extracellular but not 
intracellular domains. Furthermore it may suggest that PCDH I is secreted, resulting in 37kD 
proteins only containing intracellular domains of isoform I or isoforms 2/3. 
Figure 2: Detection of PCDHJ isoforms in 16HBE culture medium 
Concentrated 16HBE supernatants were screened for the presence of PCDH 1 protein 
products using EC7-domain, isoform-1, isoform-2/3 and EC-1 domain antibodies (upper 
panels). The appearance of sPCDHJ was determined in a time-range using the £Cl -domain 
antibody (lower panel). Equal volumes of concentrated supernatant were loaded in each lane. 
16H = 16HBE cell-lysate, EM = EMEM control medium, Pl = Passage 1, P2 = Passage 2, 
FL = full-length, sPCDHJ = soluble PCDHJ, 50kD = 50kD PCDHJ protein product. 
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Localization of PCDHl isoforms in subcellular fractions 
We next investigated the relative presence of PCDH1 isoforrns in cytoplasmic and 
nuclear/membrane fractions of confluent I 6HBE epithelial cells. We were able to efficiently 
separate the cytoplasmic fraction from the nuclear/membrane fractions as evidenced by the 
detection of I .0% of the cytoplasmic protein a-tubulin in the nuclear/membrane fraction, and 
of 9. I% of the nuclear protein HDAC2 in the cytoplasmic fraction (Figure 3A). This implies 
that the nuclear/membrane fraction consists of approximately 99% nuclear/membrane proteins 
with 1 % cytoplasmic protein contamination, while the cytoplasmic fraction consists of 90.9% 
cytoplasmic proteins with 9. 1 % nuclear protein contamination. We detected full-length 
PCDHl isoforrns 1 and 2 proteins both in nuclear/membrane and cytoplasmic fractions 
(Figure 3). In addition, using the isoforrn 2/3-antibody we detected multiple low molecular 
weight PCDHl protein bands (50, 48 and 37kD) that were exclusively present in the 
nuclear/membrane fraction, and one low molecular weight PCDHl band (52 kD) that was 
present in both nuclear and cytoplasmic fractions (Figure 3A). The specificity of the Ab 
staining for these fragments was confirmed by blocking of the signal by pre-incubation with 
immunizing peptides (Figure 3B). 
Previously we observed an increase m expression levels of the full-length 1 50kD 
isoforrn 1 and 170kD isoforrn 2 PCDH 1 proteins with epithelial differentiation (15). 
Therefore, we investigated whether the expression of the 37-52kD PCDH1 protein products 
Figure 3: Detection of PCDHJ isoforms in 16HBE subcellular fractions 
Cytoplasmic and nuclear/membrane fractions were screened for the presence of PCDHJ 
protein products using isoform-1 and isoform-2/3 antibodies. The relative contamination of 
cytoplasmic and nuclear proteins in the corresponding fractions was calculated using 
HDAC2 (nuclear marker) and a-tubulin (cytoplasmic marker) expression levels. Equal 
protein amounts were loaded in each lane (A). The specificity of the detected PCDHJ protein 
products was determined by blocking experiments by pre-incubation of isoform-1 and 
isoform-2/3 antibodies with immunizing peptides (B). T = total 16HBE cell lysate, CJ  = 
cytoplasmic fraction 1, C2 = cytoplasmic fraction duplicate, N 1 = nuclear fraction 1, N2 = 
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and the 150kD isofonn I and 170kD isofonn 2 PCDHI proteins change over time with 
increasing confluence of I 6HBE ce11s, since this bronchial epithelial ce11 line is known to 
increase cell-cell contacts during growth and forms adherens and tight-junctions (23). To this 
end, we compared subce11ular distribution of PCDH I proteins between I 6HBE at low 
confluence (20% confluent; day 1 ), at sub-confluence (80% confluent; day 3) and full 
confluence (day 5) (Figure 4A). The I 50kD isofonn I PCDHI protein was present in both 
cytoplasmic and nuclear/membrane fractions at low levels, and did not consistently change 
over time (Figure 4). In contrast, levels of full-length isofonn 2 and the low molecular weight 
band at 52kD increased in the cytoplasmic fraction towards day 5 (Figure 4B). In the 
nuclear/membrane fraction we observed a stable level of full-length isofonn 2 PCDH I 
protein. The low-molecular weight bands in the nuclear fraction display variable levels of PCDHI proteins, with the exception of 48 and 37kD fragment bands that decrease from day 1 
towards day 5 (Figure 4B). Remarkably, total full-length PCDHl protein levels seem to 
Figure 4: Detection of PCDHI isoforms in 16HBE subcellular fractions o ver time 
The change in expression of full-length 150kD isoform 1 (isoform-1 ab, n=2), full-length 
170kD isoform 2, and 37-52kD protein products (isoform-2/3 ab, n=3) and both full-length 
PCDHJ proteins (EC7-domain ab, n=3), in cytoplasmic and nuclear/membrane fractions 
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were determined with increasing confluence, with low confluence at day 1 (DJ), 
subconfluence at day 3 (D3), and high confluence at day 5 (DS). Representative images of 
16HBE confluency are shown. HDAC2, a-tubulin, NaK-ATPase, and E-cadherin were used as 
nuclear, cytoplasmic, membrane and adherens-junction markers respectively. Equal protein 
amounts were loaded in each lane (A). Expression levels of full-length JSOkD, 1 70kD, 37-52 
kD and total full-length PCDH 1 protein products were quantified in both fractions ( B ). T = 
total 16HBE cell-lysate, Iso-1 = isoform 1, Iso-2 = Isoform 2, FL = full length. 
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PCDHl isoforms interact with SMAD3 decrease over time both in nuclear and cytoplasmic fractions as evidenced by immunoblotting using the EC-7 domain antibody (Figure 4A and B). 
Immunofluorescence localization of PCDHl isoforms In order to determine the exact subcellular localization of the PCDHI isoforms, we next investigated their localization by immunofluorescence staining, using confluent 16HBE monolayers. The negative control showed no cellular staining (Figure 5A). PCDHI Isoform 1 (isoform-1 ab) showed a punctuate cytoplasmic immunostaining distributed over the entire cell (xy-plane), that is not localized at the plasma-membrane. Interestingly, an orthogonal cross-section of the16HBE monolayer revealed a supra-nuclear staining, suggesting that isoform 1 localizes to the apical part of the cell (xz-plane) (Figure 5C, D). PCDHI isoforms 2 and/or 3 (isoform-2/3 ab) showed an even distribution over the cell, with no apparent supra­nuclear localization. A higher magnification revealed a dense filamentous staining, with a concentration of signal at the nuclear membrane (Figure 5E, F). Staining of both full-length PCDHI isoforms 1 and 2 (EC7-domain ab) revealed a combination of punctuate and filamentous staining patterns (Figure 5G, H). The localization of both isoforms was not coincident with Claudin-3, a tight-junction molecule that localized to cell junctions at the plasma-membrane (Figure 5B). Clearly, isoform 1 and 2/3 show a distinct localization pattern in 16HBE bronchial epithelial cells. 
Figure 5: Localization of PCDHl isoforms in confluent 16HBE monolayers Immunofluorescent staining of 16HBE epithelial cells without primary antibody (negative control) or with Claudin-3 antibody (positive control), followed by detection with secondary goat anti-rabbit Alexa Fluor 488 conjugate antibody (A, B ). Immunofluorescent stainings of 16HBE epithelial cells for PCDHJ isoform 1 (C, D), isoform 2/3 (E, F) or both full-length isoforms (EC7-antibody) (G, H), followed by detection with secondary goat anti-rabbit Alexa Fluor 488 conjugate antibody. Shown are images taken at low magnification including x-y, x­z and y-z sections (left panels (C, E, G); the x-z and y-z orthoganol sections for the lines indicated on the x-y sections are shown on the left and bottom of each image), or at high magnification in x-y plane (right figures (D, F, H)). Scale-bar represents a size of 50µm. 145 
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Control stainings 
A Negative control • Low magnification 
PCDH1 stainings 
C lsoform 1 (EP78 antibody) - Low magnification 





B Positive control Claudin-3 - High magnification 
D lsoform 1 - High magnification 
F lsoform 2/3 - High magnification 
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PCDHl isoforms interact with SMAD3 
SMAD3 is a novel asthma gene encoding a signal transduction protein that is localized 
both to the cytosol and nucleus of epithelial cells (25). Previously, SMAD3 was identified as a 
PCDH I interacting protein using overexpression yeast-2-hybrid (Y2H) systems (9, 10). To 
determine whether PCDHI interacts with SMAD3 at endogenous levels in airway epithelial 
cells, we performed immunoprecipitation (IP) of PCDH I proteins using isoform-1 and 
isoform-2/3 abs, followed by detection of PCDH I and SMAD3. Detection of a specific 
150kD PCDH I isoform I protein band indicated that we were able to IP the endogenous 
protein from the l 6HBE cell lysates (Figure 6A). Next we immunoprecipitated PCDHI 
isoform I, and determined whether SMAD3 (molecular weight of ~54kD) does co-IP with 
PCDHI. Indeed, we detected low levels of SMAD3 in the PCDH I isoform I IP (Figure 6B). 
Importantly, biotinylated SMAD3 specific antibody did not detect 50kD heavy-chain IgG 
molecules (Supplementary Figure EI). To further validate the interaction between PCDH I 
isoform I and SMAD3, we also immunoprecipitated SMAD3 and tested for co-IP of PCDHI. 
SMAD3 was successfully immunoprecipitated from l 6HBE cell lysates (Figure 6C). Using 
the isoform-1 specific antibody, we detected the PCDHI isoform I protein of 150kD in the 
SMAD3 immunoprecipitate (Figure 6C), which was blockable after pre-incubation of the 
isoform-1 antibody with immunizing peptide (Figure 6D). These results suggest that PCDH I 
protein isoform I interacts with SMAD3 at endogenous levels in l 6HBE celJs. 
Figure 6: Detection of SMAD3 after immunoprecipitation of PCDHl isoform 1 
Immunoprecipitation of PCDHJ isoform 1 protein from 16HBE cell-lysate using the isoform 1 
antibody. Specificity of isoform I detection was indicated by pre-incubation of the isoform 1 
antibody with immunizing peptide. The arrow depicts the location of the isoform 1 protein 
band (A). Immunoprecipitation of isoform 1 and; detection using the isoform 1 antibody (left 
panel); detection of SMAD3 using the SMAD3 antibody (right panel) (B). 
Immunoprecipitation of SMAD3 using the SMAD3 IP antibody and; detection with SMAD3 
detection antibody (left panel); detection of PCDHJ using the isoform-1 antibody (right 
panel) (C). Specificity of PCDHJ isoform 1 detection after SMAD3 immunoprecipitation was 
confirmed by blocking experiments of isoform 1 antibody with immunizing peptides (D ). 
Control-IP = IP procedure pe,formed without primary antibody; HC = heavy chain; IP = 
immunoprecipitation; sup = supernatant; iso-1 = isoform 1; ab = antibody. 
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In order to determine whether PCDHl isoform 2 also interacts with SMAD3, we 
additionally performed IP-experiments using the isoform-2/3 ab. Detection of specific full­
length PCDHl isoform 2 protein band indicated that we were able to successfully IP the 
endogenous protein from l 6HBE cell lysates (Figure 7 A). Next, we tested whether SMAD3 is 
co-immunoprecipitated with PCDHJ isoform 2 from l 6HBE cells. As shown in Figure 7B, 
we clearly identified a SMAD3 band in the PCDHl isoform 2 IP. In order to validate the 
interaction between SMAD3 and PCDH 1 isoform 2, we also performed SMAD3 IPs, and 
tested whether PCDHJ isoform 2 would co-IP from the 1 6HBE cell lysates with SMAD3. We 
could clearly IP SMAD3 from l 6HBE cells (Figure 7C). As expected, PCDHJ isoform 2 
could readily be detected in the SMAD3 IP (Figure 7C). Specificity of isoform 2 bands was 
confirmed by peptide pre-incubation of the biotin-labelled isoform-2/3 ab (Figure 7D). These 
results confirm the protein-protein interaction of PCDHl isoform 2 with SMAD3 at 
endogenous levels in l 6HBE cells. 
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Figure 7: Detection of SMAD3 after immunoprecipitation of PCDHJ isoform 2 
Immunoprecipitation of full-length PCDH 1 isofonn 2 protein from 16HBE cell-lysate using 
the isofonn-2/3 antibody, and detection with both isoform-2/3 (left panel) and EC7-domain 
(middle panel) antibodies. Specificity of isofonn 2 detection was proven by pre-incubation of 
the isoform-2/3 antibody with immunizing peptide (right panel). The arrow depicts the 
location of the isofonn 2 protein band (A). Immunoprecipitation of isofonn 2 and; detection 
of isofonn 2 using isofonn-2/3 antibody (left panel); detection of SMAD3 using the SMAD3 
detection antibody (right panel) (BJ. Immunoprecipitation of SMAD3 using the SMAD3 IP 
antibody and; detection with SMAD3 detection antibody (left panel); detection of PCDHJ 
isofonn 2 (iso-2) using the isofonn-2/3 antibody (right panel) (C). Specificity of PCDHJ 
isoform 2 detection after SMAD3 immunoprecipitation was confirmed by blocking 
experiments of isoform-2/3 antibody with immunizing peptides (D). IP 
immunoprecipitation; sup = supernatant; iso-2 = isofonn 2; ab = antibody. 
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PCDH 1 is a bronchial hyperresponsiveness (BHR) and asthma gene of unknown 
function, and is associated with bronchial epithelial cell differentiation ( 15). Here, we 
investigated whether PCDHI can participate in intracellular signalling, by determining the 
subcellular localization of PCDHI isoforms and their interaction with SMAD3. Our main 
results include (i) the identification of a novel soluble PCDHl protein product (sPCDHI) of 
120kD in the culture supernatant that contains extracellular cadherin repeats, and novel 
secreted 37kD protein products containing intracellular domains; (ii) the identification of 
intracellular isoform 2 or 3 PCDHI protein species of 52, 50, 48 and 37 kD containing 
conserved motifs, that may reside in the cytoplasmic (52kD) or nuclear/membrane 
compartments (52, 50, 48 and 37 kD); and (iii) the detection of a cytoplasmic supra-nuclear 
localization of full-length isoform 1, and a filamentous staining pattern for isoforms 2 and/or 
3 that concentrated around the nucleus. Finally (iv), we confirmed an interaction of both 
PCDHI isoforms 1 and 2 with SMAD3 at endogenous levels in airway epithelial cells, thus 
physically linking two novel asthma genes, implicating that these act in a single pathway. 
This is the first report describing the existence of a PCDH 1 protein product that is free 
in solution and not anchored to the cell membrane. We detected this 120kD sPCDHl product, 
containing EC-domains in cell-free 16HBE culture supernatants. The 120kD sPCDHI may 
arise from shedding of the full-length isoforms from the plasma membrane by the proteolytic 
activity of metalloproteases such as ADAMs or MMPs, as this mechanism has been observed 
previously with ADAMIO for E-cadherin (20), y-protocadherins (26), and Protocadherin-12 
(PCDH12, (27)). Alternatively, the 120kD sPCDHI may be translated from a novel mRNA 
transcript, as was previously observed for PCDHI 5 (22). However, in our own RACE 
experiments in bronchial epithelial cells from asthma patients, we have not found evidence for 
the presence of such an mRNA transcript for PCDHI (see Chapter 4). The function of the 
sPCDHI fragment is currently unknown, although two possibilities can be envisioned: (i) 
disruption of homophilic PCDHI interactions, thereby weakening cell-cell contacts, and/or 
(ii) induction of signalling through PCDHI and related 81-protocadherins, or perhaps 
cadherin family members, thereby initiating a cellular response. In support of the first 
possibility, it is of interest to compare this finding to the function of soluble E-Cadherin 
fragments (sECad). sEcad was shown to participate in cell-migration (28) by homophilic 
binding to the E-cadherin/�-catenin complex, followed by the disruption of cell-cell adhesion 
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of E-cadherin molecules (29). With respect to the second possible function, several studies 
have shown that protocadherins can form heterophilic adhesion complexes by interacting in 
cis with cadherins (PCDHI 9 - N-cadherin (30), Arcadlin (rat PCDH8 ortholog) - N-cadherin 
(31), Pcdhl/Pcdh7/Pcdh9 (zebrafish) - N-cadherin (32)). Here, they either co-operate through 
heterophilic adhesion (30) or abrogate adhesion (3 I). As these interactions were identified 
with artificial fusion proteins in overexpression systems, future studies will need to determine 
whether soluble protocadherins also exist in vivo and can perform these functions. Altogether, 
based on these studies we suggest that sPCDH I may positively or negatively influence 
PCDH I function or the activity of other (proto)cadherins by homo or -heterophilic 
interactions with adhesion complexes in the extracellular compartment. 
In the intracellular compartment we observed the presence of several small molecular 
weight PCDH I proteins of 52, 50, 48 and 37kD, carrying the conserved signalling domains 
also found in full-length isoform 2. These intracellular PCDHI protein products may also 
arise from translation of alternatively spliced mRNA transcripts, similar to the third isoform 
of Pcdhl we identified by RACE in mouse lung tissue (see Chapter 5), or from 
posttranslational mechanisms such as proteolytic cleavage of the intracellular tail of the full­
length isoform 2 of PCDHI. This latter process has been described for y-protocadherins (26), 
and Protocadherin-12 (PCDHI 2, (27)), where ADAMI O and y-secretase-mediated cleavage 
resulted in the release of one soluble extracellular product and two similar sized intracellular 
products. One intracellular fragment was membrane-bound and was generated by ADAMIO 
processing of full-length y-protocadherin or PCDH 12. This fragment served as substrate for y­
secretases to generate a second cytoplasmic fragment (26, 27). The largest of the four 
intracellular PCDHI fragments, the 52kD fragment, was present in both the cytoplasmic and 
the nuclear/membrane compartment. The presence of the 52kD fragment in the 
nuclear/membrane fraction was paralleled by an increase of the 52kD fragment in the 
cytoplasmic fraction, with highest expression at day 5 in a I 6HBE confluency model. As we 
previously identified a putative isoform 3 of a similar size ((15), Chapter 5), we therefore 
hypothesize that the cytoplasmic 52kD fragment corresponds to this novel isoform and may 
translocate from cytoplasm to the nucleus. Alternatively, as tyrosine and serine 
phosphorylation sites were detected in the shared region of PCDH I isoforms I, 2 and 3 (33, 
34 ), the 52kD fragment may arise due to phosphorylation of the processed 48kD fragment in 
the cytoplasm (see Figure 8). Furthermore, we detected slightly smaller 50kD, 48kD and 
37kD fragments. For PCDH I six lysine residues were identified in the constant shared region 
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of PCDHl isofonns 1, 2 and 3 that may be targeted for ubiquitination, and subsequent 
breakdown by the proteasome (35). This proteasomal breakdown of full-length PCDHl 
proteins may generate several smaller PCDHl protein products. The 50kD, 48kD and 37kD 
fragments of PCDH 1 are most abundant in the nuclear/membrane fraction. Our approach did 
not enable us to separate nuclear and membrane compartments. However, using 
immunofluorescence and confocal imaging, we confirmed the presence of PCDHl isoforms 2 
and/or 3 in the cytoplasm, and at the nuclear membrane, but not in the nucleus itself. 
Interestingly, PCDHl isoform I localized to the apical compartment of 16HBE cells, and thus 
shows a distinct localization from isoforms 2/3. As isoform I also lacks CMs 1-3 and a PDZ­
BS motif present in isoforms 2/3, these results suggest that these isoforms may mediate 
different signalling functions. Previously, it was shown for y-protocadherins that the 
cytoplasmic fragment may translocate to the nucleus, but was mostly rapidly degraded by the 
protcasome (21). We speculate that similar processing may take place for PCDHl :  the 170kD 
full-length PCDHI isoform 2 may be subject to metalloprotease and y-secretase processing, 
resulting in soluble l 20kD sPCDH I and membrane bound 50kD and 48kD fragments. The 48 
kD fragment may reside at the nuclear membrane, where it is rapidly degraded by the nuclear 
protcasome (35, 36), resulting in 37kD and sma1ler breakdown products (see Figure 8 for a 
schematic overview). Further experiments are planned in our laboratory to investigate this 
possibility. 
Figure 8: Model of interaction of PCDHI isoforms with SMAD3 
Schematic overview of the hypotheses regarding the processing of PCDHJ isoforms and their 
interaction with SMAD3. PCDHJ extracellular (sPCDHJ) and intracellular protein products 
( 37-52kD) may arise by shedding ( depicted by scissors), alternative splicing ( depicted by iso3 
transcription in nucleus) and I or phosphorylation events ( depicted by ( P)) ( left panel). Once 
generated, the sPCDH I fragment resides in the extracellular compartment, while the 
intracellular 48-52kD fragments may either stay in the cytoplasm or translocate to the 
nucleus or nuclear membrane (middle panel). PCDHJ isoforms may bind to SMAD3 using the 
SMAD3 binding element (SBE) present in the constant shared region of all isofonns. This 
interaction may take place either in the cytoplasm or in the nucleus to affect SMAD3 
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Our time-range model of 16HBE is characterized by an increase in confluence that is 
associated with a strong rise in transepithelial resistance and the build-up of adherens and 
tight junctions, for which the junctional adhesion complex plays a critical role (23, 37). The 
formation of adhesion complexes is paralleled by the translocation of junctional adhesion 
molecules, like E-cadherin and Z0-1, from the cytosol to the membrane (38). Protocadherin-1 
has been shown to mediate weak cell-cell adhesion (18), suggesting a possible role as 
adhesion molecule. We therefore compared PCDHl isoforms 1 and 2 levels with E-cadherin 
levels in our fractions. To our surprise we did not observe a decrease in E-cadherin levels in 
both fractions, but rather an increase over time, suggesting that E-cadherin expression levels 
are upregulated with increasing 16HBE confluency (Figure 4A). Levels of PCDHl isoform 2 
increased in the cytoplasmic fraction but remained constant in the nuclear/membrane fraction, 
while isoform 1 levels did not show a clear trend for in- or decrease in both fractions. 
Remarkably, total full-length isoform levels (EC7-domain ab) decreased over time in 
nuclear/membrane and cytoplasmic fractions (Figure 4). We cannot fully explain the 
discrepancies between the different levels detected by these PCDHl antibodies, although we 
acknowledge that part of the PCDH 1 proteins may appear in the discarded insoluble fraction. 
Interestingly, we observed an apical localization of PCDHl isoform 1 but not isoform 2 
proteins by confocal microscopy. Furthermore, both isoforms 1 and 2 showed a staining 
pattern different from claudin-3, a tight junction molecule (Figure 5). The apical compartment 
is a separate compartment from adherens and tight-junction membrane-proximal 
compartments (39). We therefore conclude that PCDHl isoforms localize differently than 
adherens and tight junction molecules like E-cadherin and Claudin-3. We hypothesize that 
PCDHl isoform 1 localizes to the apical compartment of the cell over time, which after 
fractionation resides in the insoluble fraction, and that, together with a slight increase in 
cytoplasmic levels and constant nuclear levels of PCDHl isoform 2, therefore total isoform 
levels decrease. Further experiments will be performed directed at immunohistochemical 
localization of PCDHl isoforms during mucociliary differentiation. 
We are the first to show a direct interaction of PCDHl with SMAD3 at endogenous 
levels in a bronchial epithelial cell line. Since both genes are associated with asthma in 
genetic studies, we propose that the PCDH1/SMAD3 interaction constitutes a novel pathway 
in asthma development. We identified this interaction with both PCDHl isoforms. Therefore 
the SMAD3 binding element is probably located in the shared, constant region of isoforms 1 
and 2, just below the transmembrane-domain, and not in the conserved signalling domains 
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unique to isoforms 2 and 3. This shared element is also present in the novel isoform 3, and 
contains several serine and tyrosine residues that have been found to be phosphorylated (33, 
34) consistent with participation in signal transduction (see Figure 8). 
SMAD3 is an intracellular molecule that translates extracellular signals generated by 
TGFB I and activin-A (I 3) into specific gene-transcription by binding to SMAD4, followed by 
nuclear translocation (14 ). The gene transcriptional profile induced by TGFB I is associated 
with epithelial to mesenchymal transition (EMT) of several epithelial cell-types (40). During 
EMT adhesion molecules like E-cadherin are down-regulated, while a smooth muscle actin is 
upregulated to induce a migratory mesenchymal cell-type that produces extracellular matrix 
components (40). Interestingly, EMT was shown to be more severe in cultured asthmatic 
airway epithelial cells than in epithelial cells of healthy controls, and was shown to be 
dependent on SMAD3 (41). Previously we observed a clear association of PCDHI mRNA 
and protein expression levels with mucociliary differentiation of bronchial epithelial cells. A 
differentiated cellular phenotype requires the establishment of adherens and tight-junctions, 
structures which are abrogated in EMT to induce cellular migration (40). We hypothesize that 
PCDHI inhibits SMAD3 signalling, either in the cytoplasm, where it can inhibit activation or 
translocation of SMAD3, or in the nucleus where it may act as a transcriptional co-repressor 
(42). Thereby EMT is prevented and the expression of junctional proteins needed for a 
differentiated phenotype is maintained. 
SMAD3 may additionally play a role in wound healing, as several studies showed that 
knock-down or knock-out of SMAD3 increased the re-epithelialization rate and subsequent 
wound healing of the skin of mice (43, 44). Interestingly, in a skin keratinocyte wounding 
model PCDHl was upregulated during wound-healing (45). Furthermore, we previously 
showed that PCDHl is upregulated during epithelial differentiation (15). Therefore, it is 
tempting to speculate that increased PCDHI expression levels can inhibit SMAD3 signalling 
and thereby increase wound-healing or epithelial repair. 
Altogether, by interacting with SMAD3, PCDHl may play a role in EMT or epithelial 
repair. Dysfunction of the PCDHl / SMAD3 pathway in the asthmatic airway epithelium may 
lead to increased EMT and exaggerated repair responses in asthma. Thereby these genes may 
co-operatively contribute to remodelling of the asthmatic airways. 
We also need to consider some limitations of our study. We detected 50, 48, and 37kD 
fragments in the nuclear fraction, but this fraction also contains membrane proteins. The 
complementary fluorescence staining revealed a nuclear membrane localization that may 
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origin both from isoforms 2 and 3. Therefore, we are unable to identify the exact location of 
the 50, 48, and 37kD fragments. We are confident that these protein fragments orginate from 
PCDHl ,  but we acknowledge that their identity needs to be revealed by proteomic analysis. 
We did identify an endogenous interaction of both PCDHl main isoforms with SMAD3. But 
as these interactions were detected in the 16HBE bronchial epithelial cell-line, we need to 
confirm these results in primary bronchial epithelial cells, and test whether this is different 
between those of asthmatics patients and healthy controls. We detected low SMAD3 protein 
levels after precipitation of Protocadherin-1 protein complexes, and vice versa. This might 
indicate that the interaction between PCDHI and SMAD3 is either temporal or weak, or only 
involves part of the total protein pool available within the cells. Furthermore, the localization 
of the interaction is unknown. Therefore, we need to determine the relevance of this 
interaction using functional assays, like SMAD3 reporter assays, and during cellular transition 
processes like EMT, mucociliary differentiation, and epithelial repair. Furthermore, we 
suggest elucidating the localization of the interactions using co-localization studies. 
In conclusion, we identified that besides cell-cell adhesion, PCDHl may function as a 
signalling molecule. PCDH I may participate in signalling by its 120kD sPCDHI isoform, and 
via intracellular 48-52kD protein products that may participate in nuclear gene-transcription. 
Furthermore we identified an interaction of PCDHI isoforms with SMAD3. Thereby we 
physically connect two asthma genes, and provide a new potential mechanism for asthma 
pathogenesis. 
REFERENCES 
1 .  Braman SS. The global burden of asthma. Chest. 2006 Jul; 1 30( 1 Suppl):4S- 1 2S. 
2. Koppelman GH. Gene by environment interaction in asthma. Curr Allergy Asthma Rep. 2006;6(2): 1 03- 1 1 .  
3 .  Ober C,  Yao TC. The genetics of asthma and allergic disease: A 2 1 st century perspective. Immunol Rev. 
201 1 ;242(1 ): 1 0-30. 
4. Van Eerdewegh P, Little RD, Dupuis J ,  Del Mastro RG, Falls K, Simon J ,  et al. Association of the 
ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002;4 1 8(6896):426-30. 
5. Laitinen T, Polvi A, Rydman P, Vendelin J ,  Pulkkinen V, Salmikangas P, et al. Characterization of a 
common susceptibility locus for asthma-related traits. Science. 2004;304(5668):300-4. 
6. Koppelman GH, Meyers DA, Howard TD, Zheng SL, Hawkins GA, Ampleford EJ, et al. Identification of 
PCDHl  as a novel susceptibility gene for bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2009; 
1 80( I 0) :929-35. 
7. Liew FY, Pitman NI ,  Mcinnes 18. Disease-associated functions of IL-33: The new kid in the IL- 1 family. 
Nat Rev Immunol. 20 1 0; 1 0(2): 1 03- 1 0. 
8 .  Orsmark-Pietras C, Melen E,  Vendelin J ,  Bruce S,  Laitinen A, Laitinen LA, et al . Biological and genetic 
interaction between tenascin C and neuropeptide S receptor I in allergic diseases. Hum Mo! Genet. 2008; 
1 7( 1 1  ): 1 673-82. 
9 .  Colland F ,  Jacq X, Trouplin V, Mougin C,  Groizeleau C,  Hamburger A, et  a l .  Functional proteomics 
mapping of a human signaling pathway. Genome Res. 2004; 1 4(7): 1 324-32. 
10. Rua! JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, et al. Towards a proteome-scale map 
of the human protein-protein interaction network. Nature. 2005 ;437(7062): 1 1 73-8. 
156 
PCDH l isoforms interact with SMAD3 
1 1 . Luukko K, Ylikorkala A, Makela TP. Developmentally regulated expression of Smad3, Smad4, Smad6, and 
Smad7 involved in TGF-beta signaling. Mech Dev. 200 1 ;  I O I  ( 1 -2):209-1 2. 
1 2. Elyaman W, Bassil R, Bradshaw EM, Orent W, Lahoud Y, Zhu B, et al . Notch receptors and Smad3 
signaling cooperate in the induction of interleukin-9-producing T cells. Immunity. 20 1 2;36(4):623-34. 
1 3 . Kariyawasam HH, Semitekolou M, Robinson DS, Xanthou G. Activin-A: A novel critical regulator of 
allergic asthma. Clin Exp Allergy. 20 I I ;4 1 ( 1 1  ) : 1 505- 1 4. 
14. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: Differential roles and regulation of Smad2 and 
Smad3 in TGF-beta signaling. J Cell Biochem. 2007; I O  I ( I ) :9-33. 
I 5 .  Koning H, Sayers I ,  Stewart CE, de Jong D, Ten Hacken NH, Postma DS, et al. Characterization of 
protocadherin- 1 expression in primary bronchial epithelial cells: Association with epithelial cell 
differentiation. FAS EB J. 20 1 2;26( I ):439-48. 
1 6. Yanhalst K, Kools P, Staes K, van Roy F, Redies C. Delta-protocadherins: A gene family expressed 
differentially in the mouse brain. Cell Mol Life Sci. 2005 ;62( 1 1 ) : 1 247-59. 
1 7 . Hormi-Carver KK, Shi W, Liu CW, Berndt N. Protein phosphatase I alpha is required for murine lung 
growth and morphogenesis. Dev Dyn. 2004;229(4) :79 1 -80 1 .  
1 8. Sano K ,  Tanihara H ,  Heimark RL, Obata S ,  Davidson M ,  S t  John T, et al . Protocadherins: A large family of 
cadherin-related molecules in central nervous system. EMBO J. I 993; 1 2(6):2249-56. 
1 9. Cavallaro U, Dejana E. Adhesion molecule signalling: Not always a sticky business. Nat Rev Mol Cell Biol. 
20 1 I ;  I 2(3) :  I 89-97. 
20. Maretzky T, Reiss K, Ludwig A, Buchholz J ,  Scholz F, Proksch E, et al . ADAM IO mediates E-cadherin 
shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl 
Acad Sci U S  A. 2005 28; 102(26) :9 1 82-7. 
2 1 .  Haas IG, Frank M, Veron N, Kemler R. Presenilin-dependent processing and nuclear function of gamma­
protocadherins. J Biol Chem. 2005;280( 1 0) :93 1 3-9. 
22. Rouget-Quermalet V, Giustiniani J ,  Marie-Cardine A, Beaud G, Besnard F, Loyaux D, et al. Protocadherin 
1 5  (PCDH 1 5): A new secreted isoform and a potential marker for NKtr cell lymphomas. Oncogene. 
2006;25( 1 9):2807- 1 1 . 
23. Heijink IH, Brandenburg SM, Noordhoek JA, Postma DS, Slebos DJ, van Oosterhout AJ. Characterisation 
of cell adhesion in airway epithelial cell types using electric cel l-substrate impedance sensing. Eur Respir J .  
20 I 0;35(4):894-903. 
24. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini­
extracts', prepared from a small number of cells . Nucleic Acids Res. 1 989; 1 7( 1 5):64 1 9. 
25 . Nicolas FJ, De Bosscher K, Schmierer B, Hill CS. Analysis of smad nucleocytoplasmic shuttling in living 
cells. J Cell Sci. 2004; I I 7(Pt I 8):4 1 1 3-25. 
26. Reiss K, Maretzky T, Haas IG, Schulte M, Ludwig A, Frank M, et al. Regulated ADAM I 0-dependent 
ectodomain shedding of gamma-protocadherin C3 modulates cell-cell adhesion. J Biol Chem. 2006; 
28 1 (3 1 ) :21 735-44. 
27 . Bouillot S, Till et E, Carmona G, Prandini MH, Gauchez AS, Hoffmann P, et al. Protocadherin- 1 2  cleavage 
is a regulated process mediated by ADAM I O  protein: Evidence of shedding up-regulation in pre-eclampsia. 
J Biol Chem. 20 I I ;286( 17) :  15 I 95-204. 
28. Ryniers F, Stove C, Goethals M, Brackenier L, Noe V, Bracke M, et al. Plasmin produces an E-cadherin 
fragment that stimulates cancer cell invasion. Biol Chem. 2002;383( 1 ): 1 59-65. 
29. Noe V, Willems J, Vandekerckhove J, Roy FY, Bruyneel E, Maree! M. Inhibition of adhesion and induction 
of epithelial cell invasion by HA V-containing E-cadherin-specific peptides. J Cell Sci. 1 999; 1 1 2 ( Pt I )(Pt 
I ) : 1 27-35. 
30. Emond MR, Bis was S, Blevins CJ, Jontes JD. A complex of protocadherin- 1 9  and N-cadherin mediates a 
novel mechanism of cell adhesion. J Cell Biol. 20 1 1 ;  1 95(7): 1 1 1 5-2 1 .  
3 1 .  Yasuda S ,  Tanaka H ,  Sugiura H ,  Okamura K ,  Sakaguchi T, Tran U ,  et al. Activity-induced protocadherin 
arcadlin regulates dendritic spine number by triggering N-cadherin endocytosis via TAO2beta and p38 MAP 
kinases. Neuron. 2007;56(3):456-7 1 .  
32. Blevins CJ , Emond MR, Biswas S ,  Jontes JD. Differential expression, alternative splicing, and adhesive 
properties of the zebrafish delta 1 -protocadherins. Neuroscience. 20 1 1 ;  1 99:523-34. 
33. Rush J ,  Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, et al. Immunoaffinity profiling of tyrosine 
phosphorylation in cancer cells . Nat Biotechnol. 2005;23( I ):94- 1 0  I .  
34. Dephoure N ,  Zhou C, Yillen J ,  Beausoleil SA, Bakalarski CE, Elledge SJ, et al . A quantitative atlas of 
mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008; 1 05(3 1 ): 1 0762-7. 
35. Kim W, Bennett EJ , Huttlin EL, Guo A, Li J, Possemato A, et al . Systematic and quantitative assessment of 
the ubiquitin-modified proteome. Mol Cell .  20 1 1 ;44(2):325-40. 
36. von Mikecz A. The nuclear ubiquitin-proteasome system. J Cell Sci. 2006; I I 9(Pt I 0): 1 977-84. 
157 
CHAPTER 6 
37. Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K, et al. CFTR expression and chloride 
secretion in polarized immortal human bronchial epithelial cells .  Am J Respir Cell Mal B iol. 1994; 1 0( 1 ) :38-
47. 
38. Nawijn MC, Hackett TL, Postma OS, van Oosterhout AJ, Heijink IH. E-cadherin: Gatekeeper of airway 
mucosa and allergic sensitization. Trends Immunol . 20 1 1 ;32(6) :248-55. 
39. Schuck S, Simons K. Polarized sorting in epithelial cells : Raft clustering and the biogenesis of the apical 
membrane. J Cell Sci .  2004; 1 1 7(Pt 25):5955-64. 
40. Hackett TL. Epithelial-mesenchymal transition in the pathophysiology of airway remodelling in asthma. 
Curr Opin Allergy Clin Immunol. 201 2; 1 2( 1 ) :53-9. 
41 . Hackett TL, Warner SM, Stefanowicz D, Shaheen F, Pechkovsky DY, Murray LA, et al. Induction of 
epitheli al-mesenchymal transition in primary airway epithelial cel ls from patients with asthma by 
transforming growth factor-beta 1 .  Am J Respir Crit Care Med. 2009 1 5 ;  1 80(2): 1 22-33.  
42.  Vandewalle C, Comijn J ,  De Craene B, Vermassen P, Bruyneel E, Andersen H, et  a l .  SIP 1/ZEB2 induces 
EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res. 2005;33(20):6566-
78. 
43. Flanders KC, Major CD, Arabshahi A, Aburime EE, Okada MH, Fuji i  M, et al. Interference with 
transforming growth factor-beta/ Smad3 signaling results in accelerated healing of wounds in previously 
irradiated skin. Am J Pathol. 2003; 1 63(6):2247-57. 
44. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mize) DE, et al. Mice lacking Smad3 show 
accelerated wound healing and an impaired local inflammatory response. Nat Cell B iol. I 999; 1 (5):260-6. 
45. Fitsialos G, Chassot AA, Turchi L, Dayem MA, LeBrigand K, Moreilhon C, et al. Transcriptional signature 
of epidermal keratinocytes subjected to in vitro scratch wounding reveals selective roles for ERK 1 /2, p38, 
and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem. 2007 I 8 ;282(20): 1 5090- 1 02. 
158 
PCDH I isoforms interact with SMAD3 
SUPPLEMENT ARY DA TA 
Supplementary Figure El: Specificity of Biotin-labelled SMAD3 antibody 
The SMAD3-detection antibody was biotin-labelled to prevent detection of IgG-molecules at 
50kD size. No non-specific IgG-band was detected in the lane where only antibody ( lane 7, 
ab) was loaded, proving that no IgG-molecules are being detected using the SMAD3-
detection antibody. This implies that SMAD3 is detected after immunoprecipitation of PCDH 1 
isoform 2 at 50kD (lane 2). IP=immunoprecipitation, x = empty lane, Ab = IgG antibody. 
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Summary, Discussion and Future Perspectives 
CHAPTER 7 
OVERVIEW Major advances in asthma genetics have resulted in the identification of many novel asthma susceptibility loci. In order to further characterize the contribution of these genes to asthma pathogenesis, functional studies are required. This thesis describes the results of our investigations into the expression and regulation of Protocadherin-1 (PCDHJ), a novel gene associated with bronchial hyperresponsiveness and asthma. In this chapter we first summarize the data of Chapters 2 to 6 of this thesis, followed by the interpretation of our findings. Finally, we provide suggestions for future research. 
SUMMARY In Chapter 2 we describe the discovery of PCDH 1 as a novel gene for bronchial hyperresponsiveness (BHR) and asthma, and provide a basic characterization of its expression pattern. First linkage analysis was performed to identify the gene(s) responsible for the association of the chromosomal region 5q3 l-33 with asthma and BHR (1 ). Interestingly, a strong linkage signal was detected in families exposed to environmental tobacco smoke (ETS). Further fine-mapping of a 250kb region surrounding the marker that was most strongly associated with BHR resulted in the identification of PCDHJ . The observed association of PCDHJ with BHR was replicated in seven populations from the Netherlands, the United States and the United Kingdom, both in subjects with asthma and in the general population. We investigated the PCDHJ mRNA expression pattern in a range of cell types, and identified high mRNA and protein expression in primary bronchial epithelial cells and the 16HBE bronchial epithelial cell line, while low mRNA expression levels were found in fibroblasts and peripheral blood mononuclear cells. The expression of Protocadherin-1 isoforms in bronchial epithelial cells was confirmed on protein level and in human lung tissue, and suggests a role for PCDHI in the epithelial barrier. Together our data identify PCDHJ as a novel susceptibility gene for BHR, both in the asthmatic and general populations. As BHR is a hallmark of asthma, PCDH 1 may thereby influence asthma susceptibility via BHR. Thus, for the first time we implicate a member of the 81-protocadherin family in BHR and asthma. In Chapter 3 we aim to identify whether PCDHJ polymorphisms previously associated with asthma also associate with eczema. Asthma and eczema have a common 162 
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genetic background, but also disease specific genetic factors exist (2). PCDH 1 is located on 
chromosome 5q3 I, a region linked to both asthma and eczema ( I). We report an association 
of one PCDHJ polymorhism Ala514Thr (rs3822357) with eczema in one birth cohort, 
whereas a second polymorphism, the insertion deletion polymorphism IVS3-I 16 associates 
with eczema in two independent birth cohorts. 
Eczema is a disease of the skin, characterized by local inflammation, itching, redness, 
and increased trans-epidermal water loss (3). To interpret a shared genetic susceptibility of 
asthma and eczema, it is of interest to compare the epithelial barrier of the airways and the 
skin. The skin barrier is built up by a skin-specific epithelial cell type, the keratinocyte, while 
the airway epithelial barrier is built up by bronchial epithelial cells. The skin epithelium forms 
two separate barriers. The first barrier is the stratum corneum, consisting of multiple layers of 
keratinocytes without nuclei (corneocytes), and protects from dehydration and injury (4). 
Below the stratum corneum several layers of intact keratinocytes form the second physical 
barrier by close attachment via tight junctions (5), and they control the passage of water, ions 
and solutes, and microbes and viruses. In contrast to the skin, the airway epithelium has only 
one barrier: stratified ciliated epithelial cells that are closely attached via adherens and tight 
junctions and connect with the basal epithelial cell layer. Stratified epithelial cells form an ion 
selective barrier, and a size selective barrier against inhaled environmental agents (6). A 
defect in these skin and airway wall barriers may be an underlying cause of eczema and 
asthma. Indeed, several eczema susceptibility genes have been identified that are expressed in 
the stratum corneum, the first barrier, including Filaggrin (FLG), (7); and small proline rich 
protein 3 (SPRR3, (8), or in the keratinocytes, the second barrier, including Claudin-1 ,  (5). 
FLG and SPRR3 are located in the epidermal differentiation complex (EDC) locus on 
chromosome I q2 I .3. The EDC family of genes is involved in correct maturation and 
cornification of the skin barrier (8). Claudin-I is a structural tight junction protein, and its 
down regulation may induce loss of tight junction function and facilitate increased entry of 
microbes or viruses (5). Furthermore, a recent GWAS meta-analysis has identified OVOLJ as 
an eczema gene that is involved in the regulation and differentiation of the male germinal 
epithelium and epidermal tissues (9). Thus several susceptibility genes for eczema are 
identified that may play a role in the formation and integrity of the skin barrier. 
In Chapter 3 we show that PCDHJ polymorphisms associate both with eczema and 
asthma. Moreover, we report that PCDHJ mRNA and protein isoforms are expressed in 
keratinocytes and bronchial epithelial cells. Thus, we propose that PCDHI has a function in a 
pathway that contributes to both asthma and eczema. Interestingly, !LI RLJ, a gene encoding 
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the IL-33 - receptor, is also associated with both eczema (10) and asthma (11). As IL-33 is an 
alarmin that is produced by both keratinocytes and bronchial epithelial cells (12), the IL1RL1-
IL33 pathway constitutes a novel disease associated pathway at the interface of structural 
(keratinocytes, bronchial epithelial cells) and immune cells. 
We speculate that variation in shared genes like PCDHJ and ILJRLJ may contribute 
to the observed barrier defects (PCDHJ), and changes in IL l RL l -IL-33 signalling (/LJRLJ) 
in both diseases, while variation in diseases specific genes contribute to eczema and asthma 
separately. Further genetic studies will have to replicate our findings on PCDHJ and to 
identify the function of PCDHI in both skin and airway epithelium. 
In Chapter 4 we perform an in-dept analysis of PCDH 1 expression levels in cultured 
and ex vivo primary bronchial epithelial cells of asthma patients, and in differentiated 
bronchial epithelial cells of healthy subjects. We identify complex alternative splicing 
patterns of PCDHJ. First, we report novel 5'exons that differ between the two main isoforms 
of PCDHJ, suggesting alternative promoter usage. In addition, a CpG-Island is detected that 
surrounds exon 1 A. Second, we show the identification of a transcript that lacks five 
extracellular cadherin repeats (ECs), and only contains two ECs, the transmembrane domain 
and the intracellular domains, and named it isoform 3. The intracellular tail of PCDHl 
isoform 2 is characterized by three conserved motifs (CMI-3) and a C-terminal PDZ-domain 
binding site (PDZ-BS). Third, we report of novel transcripts that lack the CM2 domain and 
PDZ-BS and thus may have other intracellular signalling properties than isoforms that express 
all conserved intracellular domains. These studies show that PCDHI is subject to complex 
splicing patterns. 
Importantly, we identify a clear association of PCDHJ mRNA and protein expression 
levels with epithelial differentiation of primary bronchial epithelial cells. This association of 
PCDHJ expression levels with epithelial differentiation may not only be specific to bronchial 
epithelial cells, but also to primary cells in the skin, the keratinocytes. This is supported by 
observations on PCDH 1 mRNA expression in two keratinocyte datasets. First, PCDH 1 
mRNA expression was 5.5-fold upregulated during confluence induced differentiation of 
normal human keratinocytes (13). Second, PCDHJ mRNA was higher expressed in the more 
differentiated suprabasal keratinocytes, compared to progenitor-like basal keratinocytes (14). 
We conclude that PCDHI is regulated during epithelial differentiation, but its exact function 
in differentiated epithelia needs further investigation. 
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Discussion and Future Perspectives In Chapter 5 we aim to identify the in vivo regulation of Pcdhl in mouse lung by environmental exposures that increase BHR in experimental mouse models, and that are known risk factors for asthma development, such as housedust mite (HDM) ( 1 5) and cigarette smoke (CS) exposure (I 6). We investigate the regulation of Pcdh I by HDM and CS in HOM-induced asthma models and acute and sub chronic CS-exposure models. To this end, we first assessed homology on the gene and mRNA transcripts between human PCDHJ and mouse Pcdhl. We identified a remarkably high homology between mouse Pcdhl and human PCDH I ,  both on RNA and protein level, and confirmed the existence in mice of a third isoform encoding intracellular domains (mouse isoform 3). The high similarity of PCDHI in mice and men may indicate that PCDH I performs an important function that has been conserved during evolution ( 1 7). In our chronic HDM exposure model we detected slightly lower PCDHI protein expression levels after HDM exposure. Especially in airway epithelial cell layers that had undergone goblet cell metaplasia upon HDM exposure almost no PCDH I staining was observed ( Chapter 5). In addition, we observed an upregulation of PCDH 1 mRNA expression levels in the recovery phase after housedust mite exposure. These results may suggest that HDM down regulates PCDHI expression levels and that PCDHI expression is induced in the repair phase. In our CS-exposure mouse model, we observed that CS-exposure resulted in a direct and clear down regulation of PCDH I expression levels in mouse lung. CS-exposure is known to affect the epithelial barrier by decreasing cell-cell contacts ( 1 8). We propose that subjects exposed to environmental tobacco smoke may, in the presence of susceptible PCDHJ alleles, develop BHR and asthma, due to downregulation of PCDH I and epithelial adhesion molecules and a subsequent impaired epithelial barrier function. In Chapter 6 we investigate whether PCDH I could act as a signalling molecule by identifying the subcellular localization of its protein isoforms and its interaction with SMAD3. Since PCDHI does not appear to be a classical adhesion molecule as its adhesion properties are weak ( I 9) or not detectable (20), it is important to consider alternate functions, such as signalling functions. PCDHl isoforms I ,  2, and 3 contain conserved tyrosine and serine residues in their intracellular tail that may be phosphorylated (2 I ,  22). Furthermore, conserved motifs (CMJ -3) and a PDZ-binding site are present in the intracellular tail of isoform 2, motifs that are shared with isofonn 3. Importantly, two yeast-2-hybrid studies using protein overexpressions suggest an interaction between PCDHl and SMAD3 (23, 24). Therefore, we were interested whether PCDHI may play a role in downstream signalling, by 1 65 
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assessing PCDHI isofonn expression in the extracellular and intraceIIular compartments, and 
i ts interaction with SMAD3. We detected a novel extraceI ular soluble PCDHl protein 
product (sPCDHl ), and multiple intracellular protein products ( Chapter 6), that may play a 
role in signaIIing. Further proteomic analysis is needed in order to identify the origin of these 
protein products. 
Interestingly, we observed an interaction of both PCDHl isofonns 1 and 2 with 
SMAD3, suggesting that PCDHl can act as a signalling molecule. SMAD3 has been identified 
as an asthma gene by the genome-wide meta-analysis from the GABRIEL consortium (11). 
SMAD3 is a key downstream molecule in the TGF�-pathway, and is a critical factor for 
epithelial to mesenchymal transitions (EMT) and epithelial repair responses (25). The 
asthmatic epithelium is more sensitive to TGF�-induced EMT than epithelium of healthy 
controls (in vitro, (25)), but no evidence for EMT in airways of asthmatic patients has yet 
been identified (26). However, a recent in vivo study showed that prolonged exposure of the 
mouse airway to HDM induces an increase in epithelial derived mesenchymal cells in mouse 
airways, a finding paraIIeled by an increase in TGF� in the broncheoalveolar lavage fluid. 
This may suggest that airway epithelial cells of mice exposed to HDM undergo EMT and 
indicate a possible role for TGF� in this process (27). We propose that PCDHI may inhibit 
TGF�-induced EMT by interacting with SMAD3. Interestingly, several in vivo studies 
showed that knock-out of SMAD3 in mice resulted in an increased skin wound repair (28, 
29). As we observed a physical interaction between PCDHI and SMAD3, we propose that the 
sensitivity towards TGF�-signalling is decreased in the normal situation due to high PCDHl 
expression levels in differentiated epithelial ceIIs. It is tempting to speculate that PCDHI 
levels are dysregulated in a disease situation (i.e. asthma or eczema), followed by an increased 
sensititity towards TGF�-signaI ing, and a chronic epithelial repair phenotype. 
In conclusion, the physical interaction between the proteins encoded by two asthma 
susceptibility genes implicates the existence of a novel pathway in asthma pathogenesis in 
which these two proteins play a central role. 
DISCUSSION 
When we integrate the findings of Chapters 2 to 6, we can discern four main topics for 
further study; the relevance of 8 1-protocadherins in asthma, epigenetic regulation of 
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protocadherins, PCDH I signa11ing and potential functions of PCDHl related to asthma 
development. 
The role of 31-protocadherins in asthma 
We identified PCDHJ as a novel susceptibility gene for BHR and asthma. PCDH I 
belongs to the ci l -protocadherin sub-family, consisting of PCDH I, PCDH7, PCDH9 and 
PCDH 11, within the cadherin superfamil y of adhesion molecules. The ci 1-protocadherin 
family is part of the non-clustered protocadherin family, characterized by the presence of 
seven extrace11ular cadherin repeats (30). ci 1-protocadherin genes display a high level of 
alternative splicing, resulting in isoforms that encode alternative cytoplasmic domains (31 ). 
ci 1-protocadherin family members are expressed in a range of tissues, such as brain, heart, 
liver, kidney and lung (32, 33). Interestingly, a recent GWAS meta-analysis suggested two 
other ci 1-protocadherins, PCDH7 and PCDH9, to be associated with lung function in asthma 
patients (34). Furthermore, PCDHI ,  PCDH7 and PCDH9 are upregulated during epithelial 
differentiation in an air liquid interface culture model (35, 36). These studies suggest that 
multiple members of the ci 1-protocadherin family expressed in airway epithelial cells may 
play a role in asthma susceptibility or severity as they are associated with two ha11marks of 
asthma: BHR and lung function. This supports further research into the exact role of the <> 1-
protocadherins in airway epithelial cell differentiation and asthma. 
Epigenetic regulation of Protocadherin-1 
We identified a strong linkage signal of PCDHJ with BHR in families exposed to 
environmental tobacco smoke compared to unexposed families (37). In addition, we observed 
a decrease of Pcdhl expression levels after cigarette smoke exposure in mice, as early as 6 
hours after exposure. Of note, PCDHJ gene exon IA is situated in a CpG-Island that may be 
methylated and that is conserved between man and mouse. Therefore the mechanism behind 
the decrease in Pcdhl expression levels may encompass epigenetic changes induced by 
cigarette smoke, or constitute a direct transcriptional effect. Interestingly, differential 
methylation of another protocadherin, PCDH20, was observed in DNA isolated from sputum 
ce11s of asthma subjects who smoke compared to healthy smokers (38). These results suggest 
that methylation of J-Protocadherin gene promoters may be a mechanism to regulate their 
expression levels. The regulatory effects of methylation, and the effects of cigarette smoke 





PCDHl may perform intrace11ular signalling at different cellular compartments. 
Initia1Iy two main isoforms of PCDHl were identified in the airway epithelium; a short 3 
exon isoform and a long 5 exon isoform that additionally encodes an intracellular domain 
with conserved motifs (CMl -3, PDZ-BS). We investigated whether the two main transcripts 
and potential novel transcripts were expressed in bronchial epithelial cells. We confirmed the 
expression of the two main isoforms in bronchial epithelial cells and identified mRNA 
transcripts that lack the conserved motif CM2 and / or PDZ-BS, and thereby may influence 
signal transduction or its localization, as PDZ-BS can provide anchorage for PDZ-domain 
molecules for apical sorting (39). Furthermore we detected an isoform that lacks 5 (human 
isoform 3) or a11 (mouse isoform 3) extrace11ular cadherin repeats. These isoforms encode 
signalling domains and may directly be involved in downstream signalling. 
Previously, research has shown that adhesion molecules like E-cadherin, and y­
protocadherins can be shed by metalloproteinases like A Disintegrin And Metalloproteinase 
I O  (ADAMI O) and further proteolytically processed by y-secretases (40, 41). Shedding of E­
cadherin resulted in the generation of extrace11ular soluble E-cadherin (sEcad), while y­
secretase processing yielded intracellular C-terminal fragments. Extrace11ular sEcad was 
shown to stimulate migration of epithelial cells by inhibiting E-cadherin mediated adhesion 
complexes (40), while the intracellular E-cadherin fragment was shown to bind to �-catenin 
thereby inhibiting its signalling (42). y-Protocadherins were also shed by ADAMl O  (41). The 
resulting intrace11ular y-protocadherin protein products were shown to reside in the nucleus to 
induce gene transcription ( 41 ). Therefore, besides by generating alternative transcripts with 
different signalling domains, we hypothesize that PCDHJ may also be subject to post­
translational processing by ADAMs and y-secretases, possibly resulting in intracellular 
protein products that may participate in signalling. Indeed, we identified a soluble (s)PCDHl 
in the culture supernatant of 16HBE bronchial epithelial ce11s, and a series of intrace11ular 
protein products in cytoplasmic and nuclear/membrane fractions. But as we previously 
discovered transcripts that lack extracellular domains (human and mouse isoform 3) the 
intracellular protein products may as well arise from alternative splicing. Alternatively, as 
conserved lysine residues were identified in the shared constant region of PCDHl isoforms 1, 
2 and 3 that may be ubiquitinated (43), these fragments can as well be generated by 
proteasomal breakdown. The function of the extrace11ular and intracellular protein products 
for PCDH 1 is unknown. The presence of these fragments in different cellular compartments 
may implicate that they participate in signalling, but as it is unsure whether these fragments 
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are generated by ADAM/MMP-processing, alternative transcription or proteasomal 
breakdown, the exact mechanism remains to be elucidated. 
In Chapter 6 we identified that PCDHI interacts with SMAD3. This is the second 
confirmed PCDHI interacting protein, besides Protein Phosphatase I a (PPI a) (3 1 ). The 
interaction of PCDHI with PPla  is isoform specific, since PPla  interacts with the conserved 
CM3-motif, only present in PCDHI isoforms 2 and 3. In contrast, the PCDHI-SMAD3 
interaction is detected for both isoform I and 2, and therefore is thought to occur via the 
constant shared domain of isoforms I and 2 containing conserved serine and tyrosine residues 
that can be phosphorylated (2 I, 22). 
Altogether, PCDH I may perform signalling functions at three different levels; I) by 
alternative splice-variants that express different signalling domains or lack extracellular 
cadherin-repeats, 2) by intracellular protein products potentially generated by post­
translational processing, and 3) by interacting with downstream signalling partners like PPI a 
and SMAD3. 
Potential implications of PCDHl functions: role in adhesion, differentiation, EMT, 
and/or repair 
In our first characterization of PCDHI expression in the airway epithelium, we 
observed expression specifically at the apical sites of ciliated bronchial epithelial cells, but not 
in basal undifferentiated cells (37). Based on its expression pattern in the airway epithelium 
and observations that PCDHI may perform (weak) adhesion functions (19), we hypothesized 
that PCDH I may influence the epithelial barrier function. Protocadherin-I contains several 
apical localization signals. First, a PDZ-domain binding site was detected (44), which may 
provide anchorage for transport to the apical domain. Second, five N-glycosylation sites have 
been predicted (http://www.cbs.dtu.dk/services/NetNGlyc/) which can function as apical 
localization signals (45). Interestingly, several other protocadherins also display apical 
localization, like y-protocadherins (46), protocadherin-LKC/PCDH24 (47), and mu­
protocadherin/CDHR5 (48). The function of the apical localization is currently unknown, but 
may include a role in the apical adhesion complex and / or the establishment of cell polarity. 
The asthmatic epithelium is characterized by a decreased epithelial barrier function, 
and a lowered expression of junctional molecules, like Z0-1 and E-cadherin. The 
aforementioned protocadherins did not show co-localization with junctional molecules such 
as Z0-1. Our immunofluorescent localization studies on PCDHI in a bronchial epithelial cell­
line showed a punctuate supra-nuclear apical staining pattern for PCDH I isoform I, while 
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isoform 2 displayed a cytoplasmic filamentous staining pattern that concentrated around the 
nucleus. Furthermore their localization was different from Claudin-3, a tight-junction marker. 
We acknowledge that we need to determine the specificity of these PCDHJ stainings by 
PCDH 1 knockdown and overexpression studies. Nevertheless, these results suggest that the 
role of PCDHl is not consistent with a function in adhesion complexes. What other functions 
could PCDHJ perform besides cell-cell adhesion functions? We have described a correlation 
of PCDHJ expression levels with differentiation of bronchial epithelial cells (36), and as 
previously mentioned, similar results were obtained for PCDH7 and 9 in ALI cultures using 
micro-arrays (35), suggesting that 81-protocadherins are highest expressed in ciliated 
bronchial epithelial cells. Indeed, from immunohistochemistry in mouse lung tissue we 
specifically identified expression of Pcdhl in terminally differentiated ciliated epithelial cells, 
but no staining in goblet cells. Furthermore studies from model-organisms like Xenopus, 
Drosophila and mouse embryos regarding the function of protocadherin-othologs showed that 
protocadherins can coordinate tissue morphogenesis and cell-polarity (49, 50), but their 
function in human cells remains to be determined. Therefore, from these observations we can 
speculate that PCDHl is not involved in ce11-ce11 adhesion by a role in the apical adhesion 
complex, but rather acts in epithelial polarization or differentiation. Additional support for 
this stems from our investigations of PCDH 1 as a candidate signalling molecule, as we 
observed an interaction of PCDHl with SMAD3. SMAD3 is implicated in several processes 
like epithelial to mesenchymal transition (EMT) and wound repair (51 ). These processes are 
closely related as they are paralleled by transient loss of terminal differentiation of the 
epithelial cell and the (partial) adaptation of a more mesenchymal phenotype (EMT) (26), 
followed by migration of cells to the injured area and restoration of cell-cell contacts and 
barrier function. Finally a re-adaptation state is initiated that results in terminal differentiation 
of the cells (wound repair) (52). 
PCDHJ may play a role in several stages of this process. First, PCDHJ may influence 
EMT by interacting with SMAD3. During TGF�-induced EMT, the expression of adhesion­
molecules like E-cadherin is down-regulated, while mesenchymal markers like a-smooth 
muscle actin, vimentin and fibronectin are upregulated. The activation of gene-transcription 
during the EMT process is dependent on the transcription factor SMAD3, and results in a 
migratory mesenchymal phenotype (25). We propose that PCDH J levels are decreased in an 
asthmatic individual with susceptible PCDHl alleles, a process followed by an increase in 
free SMAD3 and subsequent increase in TGF�-signalling, resulting in a chronic epithelial 
repair phenotype. Interestingly, besides TGF� the related family member Activin-A may as 
170 
Discussion and Future Perspectives 
wen signal via SMAD3. Activin-A is upregulated directly after epithelial injury, and is 
considered a potent inducer of epithelial repair (53). The exact role of Activin-A in the airway 
epithelium is just beginning to be discovered, but we speculate that by interacting with 
SMAD3, PCDH I may as well influence Activin-A induced epithelial repair. 
Second, PCDH I may play a role in the final stage of epithelial repair: terminal 
differentiation of migrated epithelial ce11s. After migration of epithelial cells to a wounded 
area, residing epithelial ce11s need to obtain a terminal differentiated phenotype, such as a 
ciliated cell, in order to form a functional protective barrier. During epithelial differentiation 
there is an increase in PCDH I expression levels. The increased PCDHI expression levels may 
result in a decrease of SMAD3 protein levels that may participate in TGFB-signalJing, and 
therefore opposite transition processes (EMT) are halted. It is tempting to speculate that in the 
airway epithelium of asthma subjects with susceptible PCDHJ a11eles PCDHI levels are 
dysregulated. As a consequence, an undifferentiated phenotype is maintained, characterized 
by a decreased build up of adherens and tight junctions. Together with a dysregulated TGFB­
or Activin-A signa1 Jing, this may result in a chronic epithelial repair phenotype and a 
weakened epithelial barrier. Subsequently, a weakened epithelial barrier may lead to an 
increased entrance of environmental factors like allergens and pathogens, thereby 
continuously activating the immune system leading to a chronically inflamed airway (54), and 
increased smooth muscle mass due to hypertrophy and/or hyperplasia of the smooth muscle 
layer that may contribute to BHR and asthma. 
In conclusion, PCDHJ is genetically associated with BHR, asthma and eczema. 
PCDH 1 is highly expressed in differentiated bronchial epithelial cells, while its expression 
levels are lower in goblet cells or undifferentiated epithelial cells. Combined with 
observations using immunofluorescence localization studies, we show that PCDH I is not 
associated with cellular adhesion complexes and may rather be involved in polarization or 
differentiation of airway epithelial cells. In addition PCDH 1 may act as a signaJling molecule 
as several intracellular protein products were identified that may be generated by 
ADAM/MMP processing or alternative splicing, and as it interacts with SMAD3. By 
influencing TGFB-induced SMAD3 signalling PCDHI may play an important role in EMT, 
wound repair and differentiation. 
How can we integrate our current knowledge on PCDH I function into our 
understanding of asthma? The epithelial barrier is compromised in asthma (55), which may in 
part be due to PCDH I dysregulation, and may lead to an increased access of inhaled allergens 
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to the immune system promoting allergic sensitisation. Furthermore due to the weakened 
airway epithelium barrier function, the airway epithelium of asthma patients responds 
differently to environmental exposures like cigarette smoke, housedust mite, and viruses 
compared to healthy subjects by producing increased amounts of pro-inflammatory cytokines 
(6). Together with an increased availability of inhaled allergens this may lead to priming of 
the immune system towards a Th2-dominated allergic response and progression to a 
chronically inflamed phenotype. Environmental cigarette smoke or housedust mite exposure 
down regulate PCDHI expression levels, potentially via epigenetic mechanisms, whereas the 
effect of viral exposures on PCDHI expression remains unknown. Thereby these 
environmental factors may further compromise the epithelial barrier function, rendering 
subjects more susceptible for injuries. This may activate the EMTU, which may lead towards 
a continuous repair phenotype (52). Changes of the airway epithelium from a ciliated towards 
a goblet cell phenotype may lead to excessive mucus production, and airway narrowing (54). 
Components of structural cells of the airway (ECM deposition by (myo)fibroblasts and 
epithelial cells) and of immune cells (cytokines, growth factors) in the airway may induce 
hypertrophy and / or hyperplasia of the smooth muscle layer, leading to increased smooth 
muscle mass (56). As we identified expression of Pcdh 1 in mice airway smooth muscle cells, 
the role of Pcdh 1 in the increase in smooth muscle cell mass needs further investigation. 
Subjects with a specific genetic susceptibility in genes encoding epithelial factors (for 
example PCDHJ) or immune functions may thus in combination with an increased exposure 
to harmful agents or physical stress (i.e. environment), eventually develop BHR and asthma 
(see Figure I ). If this is a basic mechanism underlying the initiation of asthma, future 
therapeutic interventions may be targeted at restoring the ciliated epithelial phenotype, to 
create a more stable epithelium that maintains a proper barrier function protective towards 
foreign agents, allergens included. Specifically, provided that PCDHI -SMAD3 signalling is 
impaired in the asthmatic epithelium, we speculate that stabilizing the PCDH1-SMAD3 
interaction may decrease EMT or increase the repair potential of epithelial wounds and thus 
create a protected, differentiated epithelial phenotype. Future research is needed into the 
function of PCDHl ,  SMAD3, and their interaction in asthma pathogenesis. 
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Figure 1: Model: Cigarette smoke and House-dust mite exposure changes epithelial barrier 
by modulation of Protocadherin-1 expression levels 
The epithelial barrier of the large airways consists of mainly basal and ciliated bronchial 
epithelial cells, located on top of the basement membrane (BM). Epithelial cells express 
PCDHJ, which localizes to the apical site just below the brush border (apically localized, 
marked in blue). Cigarette smoke (CS) exposure may down-regulate PCDHJ and junctional 
adhesion molecules, thereby de-differentiating epithelial cells. House-dust mite (HDM) 
exposure may injure the epithelial layer or induce the formation of goblet cells (pink color), 
with no or low PCDHJ expression, and results in excessive mucus in the airway. Due to a 
dysregulated interaction of PCDHJ with SMAD3 in asthmatic subjects with susceptible 
PCDHJ-alleles, epithelial repair remains unfinished and epithelial cells may in addition go 
into epithelial mesenchymal transition (EMT). The resulting migrating myofibroblasts (Myo) 
produce extracellular matrix components (ECM). Altogether, this may lead to airway 
epithelium with a continuous repair phenotype, and a subsequent weakened epithelial barrier. 
The weakened epithelial barrier may result in increased sensitization of the immune system. 
Together with increased cytokine and growth factor production by asthmatic epithelial cells 
this may lead to a chronic inflammatory response that is partly Th2-mediated. Components of 
structural cells of the airway (ECM) and immune cells (cytokines, growth factors) may induce 
hypertrophy and I or hyperplasia of the smooth muscle layer. Together with an excessive 









:::z_; � PCDH1?  
Recent genome wide association studies identified 16 asthma loci with genome wide 
significance (57). This thesis provides a first characterization of a novel gene for BHR and 
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asthma with a yet unknown function, Protocadherin-1. The technical advances in the 
development of whole genome sequencing and parallel total RNA sequencing of lung tissue 
and its separate cell types like epithelial cells and smooth muscle cells will reveal novel 
disease associated genes and their corresponding transcriptome in the near future. Research 
into epigenetics will additionally identify another level of gene-regulation, which then needs 
to be combined into an integrative genomics approach towards asthma (58). 
An increasing number of asthma susceptibility genes are being identified. There is 
now a need for the scientific community to prioritize functional genetic investigations of these 
susceptibility genes. These genes can be different per population, as US and Japanese GW AS­
studies have identified population specific loci, like PYHINJ for afro-americans (59), and 
USP38-GABJ locus for the Japanese population (60). Moroever, a specific gene may be 
important in a certain subphenotype of asthma, e.g. BHR for PCDHJ, or childhood onset 
asthma for ORMDL3 I GSDMB (61). In general we propose the following procedures after 
identification of a novel asthma gene (see Table I): 
Table I: Strategy for functional analysis of a novel disease associated gene 
Step Action Required tools / experiments 




Generate and optimize toolbox Analyze expression in range of cell-types Identify transcripts and protein isoforms, and investigate differences between healthy and disease, that may be regulated by the susceptibility SNPs (q RT)-PCR assays, Overexpression plasmids, siRNA, antibodies, ELISAs Model cell-lines, primary cells and tissues - Model cell-lines, primary cells and tissues - Identify eQTLs (62) in relevant cells and/or tissues 





Determine effect of environmental exposures on gene expression I function Investigate how gene-variants modulate gene function Perform protein i nteraction and pathway analysis Investigate effect of modified gene-function with environmental exposures on previously identified (step 8) pathways modulation of epigenetic signatures In vivo: KO and gene overexpressing mice Genetic epidemiological studies CS, HDM, particulate matter exposures i n  cell-lines, mouse-models SNP specific functional assays Immunoprecipitation, micro-arrays, proteomics -qPCR/antibodies for siRNA / overexpressions: cell-systems -KO and overexpression mouse models -micro-array exposed vs non-exposed 
10. Identify and intervene upon dysfunctional pathways Therapeutic i ntervention 
eQTL = expression Quantitative Trait Locus (62); KO = knock-out ;  CS = cigarette smoke ; HDM = House-dust 
mite 
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When we apply these steps to the research in the function of PCDHI, we can suggest 
several next steps: 
We determined PCDHI expression levels in asthma subjects, but were not able to 
correlate PCDH I genotypes to gene-expression (identify eQTLs) due to a low number 
of available cells/tissue from asthma subjects. An important first step is to investigate 
how and if PCDHI non-coding (promoter) gene-variants induce changes in PCDHI 
mRNA or protein expression levels, and perhaps gene methylation, by screening a 
larger population of epithelial cells from healthy and asthmatic subjects. 
We suggest to investigate the function of PCDH I by siRNA experiments (in vitro) and 
KO-studies (in vivo). Outcomes of main interest are adhesion, epithelial polarization, 
differentiation and wound repair. 
KO and Pcdh I isoform specific overexpression mouse models should be employed in 
order to investigate whether there is a changed sensitivity towards allergic 
sensitisation, asthma and BHR development, both with and without environmental 
exposures like HOM and CS. 
We observed a down-regulation of Pcdhl expression levels by CS in vivo. Therefore, 
further investigations into potential epigenetic regulation are needed. 
The significance of the PCDH I - SMAD3 interaction should be further investigated. 
Specifically it should be investigated whether PCDHI inhibits or stimulates TGFB 
induced SMAD3-signalling. Furthermore it should be investigated whether PCDHI is 
involved in Epithelial to Mesenchymal Transition (EMT) or wound repair. 
It is unknown whether PCDH I is involved in other signalling pathways. Therefore co­
immunoprecipitation experiments should be performed to confirm interactions with 
proposed interactors like PP la and to identify potential novel interaction partners. 
As more protocadherin family members are associated with asthma or lung function 
we propose that the complete family of 8-protocadherins should be characterized in 
asthma and BHR. 
Future investigations into the role of 81-protocadherins, specifically PCDH I may reveal novel 
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Astma is een chronische ziekte van de luchtwegen, die gekenmerkt wordt door een 
ontstekingsreactie en blijvende veranderingen in de structuur van de luchtwegen. Astma 
patienten ondervinden periodes van hoesten, piepende ademhaling, en kortademigheid. 
Daarnaast hebben astmapatienten een overgevoeligheid van de luchtwegen (bronchiale 
hyperreacitiviteit) voor factoren zoals rook of mist, of voor allergenen zoals huisstofmijt. 
Verder kan een venninderde doorgankelijkheid van de luchtwegen door samentrekken van de 
spieren rondom de luchtwegen, zwelling van het slijmvlies en/of de productie van veel slijm 
(mucus) leiden tot hevige aanvallen van benauwdheid. Astma wordt vaak gekenmerkt door 
een allergische reactie tegen specifieke gei"nhaleerde stoffen, de zogenaamde allergenen. Bij 
het eerste contact met deze allergenen worden cellen van het afweersysteem geactiveerd, die 
onder andere afweerstoffen aanmaken die deze allergenen specifiek herkennen, en eraan 
kunnen binden. Deze antistoffen zijn de zogenaamde IgE-antilichamen en nestelen zich op 
mestcellen in de longen. Bij hernieuwd contact worden deze allergenen gebonden aan de lgE­
antilichamen op de mestcellen. Hierdoor worden de mestcellen geactiveerd, wat leidt tot de 
uitscheiding van vele stoffen zoals histamine. Histamine zorgt ervoor dat spiercellen rondom 
de luchtwegen samentrekken, wat kan leiden tot Iuchtwegvernauwing en de eerder genoemde 
symptomen van benauwdheid. Continue blootsteIIing aan de allergenen kan een chronische 
ontstekingsreactie van de luchtwegen veroorzaken, wat kan leiden tot blijvende veranderingen 
van de structuur van de Iuchtwegen. 
Astma is een complexe ziekte die wordt veroorzaakt door een combinatie van 
genetische factoren en omgevingsfactoren zoals allergenen en sigarettenrook. De genetische 
factoren die een rol spelen bij astma zijn maar ten dele bekend. De genetische infonnatie 
opgeslagen in het DNA van iedere lichaamscel, <lat bestaat uit een combinatie van de letters 
of basen A C T  en G, verschilt van persoon tot persoon. Uit voorgaande studies is bekend dat 
de gevoeligheid om astma te ontwikkelen deels genetisch is bepaald: door verschiIIen in het 
DNA hebben sommige mensen meer kans om astma te ontwikkelen dan andere mensen. Om 
te achterhalen welke verschillen in het DNA nu bijdragen aan een grotere kans op astma 
worden er vele genetische onderzoeken gedaan, zoals associatie studies. Deze studies 
bekijken of bepaalde stukken DNA overerven binnen families, oftewel geassocieerd zijn met 
de ziekte. Ze wijzen dus bepaalde regionen aan waar genen liggen die mogelijk astma of een 
van de kenmerken van astma zoals bronchiale hyperreactiviteit kunnen veroorzaken. 
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Vervolgens wordt onderzocht of DNA variaties in bepaalde genen vaker voorkomen bij 
mensen met astma dan bij gezonde mensen. In de Nederlandse populatie is op deze manier 
Protocadherine-1 ontdekt als nieuw gen voor bronchiale hyperreactiviteit en astma. De 
functie van dit gen en het corresponderende eiwit is grotendeels onbekend. Het doe] van dit 
proefschrift is dan ook om de rol van Protocadherine-I (PCDH I) bij de ontwikkeling van 
astma te onderzoeken. 
In hoofdstuk 2 beschrijven we de ontdekking van Protocadherine-1 als een nieuw 
gevoeligheidsgen voor bronchiale hyperreactiviteit en astma. Eerst werden associatie studies 
uitgevoerd om te ontdekken welke DNA regio's overerven met astma en bronchiale 
hyperreactiviteit in de Nederlandse populatie. Er werd een regio op het vijfde chromosoom 
gevonden die specifiek overerfde met astma en bronchiale hyperreactiviteit. Er was zelfs een 
sterkere associatie met astma van dit stukje DNA in families die waren blootgesteld aan 
sigarettenrook. Omdat dit een groot stuk DNA betreft waar meerdere genen liggen is het in 
meer detail verder onderzocht. Dit werd gedaan door een systematisch onderzoek van 
bekende basepaar veranderingen van het DNA (bijvoorbeeld een A naar een C of een G naar 
een T) in dit gebied. Er bleek dat bepaalde basepaar veranderingen gelegen in het 
Protocadherine-1 gen vaker voor kwamen bij astma patienten dan bij gezonde mensen. Deze 
associatie van PCDHJ met astma werd bevestigd door genetische studies in populaties uit 
Engeland en de Verenigde Staten. Met deze studies werd aangetoond dat het Protocadherine-
1 gen is geassocieerd met astma. Dit betekent dat een bepaalde variant van dit gen meer 
voorkomt bij mensen met astma, terwijl een andere variant van dit gen meer voorkomt bij 
mensen die geen astma hebben. 
Protocadherine-I behoort tot de familie van adhesiemoleculen. Deze moleculen zorgen 
ervoor dat naast elkaar gelegen cellen met elkaar verbonden blijven. Protocadherine-I heeft 
een relatief zwakke adhesie functie, dus het blijft onduidelijk of adhesie de enige functie van 
PCDH I is. We hebben vervolgens onderzocht in welke celtypes van de long PCDHI eiwit 
moleculen aanwezig zijn. PCDHI eiwit moleculen komen vooral voor in cellen van de 
luchtwegbekleding, zogenaamde epitheelcellen, en specifiek aan de bovenkant (apicaal) van 
deze cellen (Figuur I A). Epitheelcellen vormen de eerste barriere tegen ingeademde stoffen, 
zoals allergenen (bv graspollen, huisstofmijt), luchtvervuilingen en ziekteverwekkers. 
Adhesiemoleculen zorgen ervoor dat deze cellen sterk tegen elkaar aanliggen. Onze 
hypothese is dat PCDHI bijdraagt aan het in stand houden van deze barriere, en dat een fout 
in het PCDHI gen of eiwit een zwakkere barrierefunctie tot gevolg heeft, zodat allergenen en 
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ziekteverwekkers gemakkelijker kunnen binnendringen. Dit zou uiteindelijk kunnen leiden tot 
een verhoogde gevoeligheid voor het ontwikkelen van bronchiale hyperreactiviteit en astma, 
al speelt daar ook de omgeving nog een belangrijke rol in (zoals door blootstelling aan de 
allergenen en ziekteverwekkers). 
Zoals eerder genoemd hebben we bepaalde gebieden op het DNA gevonden waar 
genen liggen die astma en bronchiale hyperreactiviteit kunnen veroorzaken. Deze studies zijn 
ook uitgevoerd voor de huidziekte eczeem. Een regio op chromosoom 5 (5q31-33), waarin 
ook PCDHJ ligt, is zowel geassocieerd met astma en bronchiale hyperreactiviteit, als met 
eczeem. In hoofdstuk 3 hebben wij daarom onderzocht of basepaar veranderingen van 
PCDHJ die eerder geassocieerd waren met astma en BHR ook associeren met eczeem. Dit 
hebben we onderzocht in twee verschillende populaties waar vanaf de geboorte het ontstaan 
van eczeem gevolgd is, en ook DNA afgenomen is (KOALA en PIAMA geboorte cohorten). 
Ecn drie basenparen deletie (IVS3-116) van het PCDHJ-gen bleek zowel in PIAMA als in 
KOALA geassocieerd te zijn met eczeem. Eczeem is een ziekte van de huid. Als de huid 
wordt vergeleken met ccn stenen muur, waarin de stenen de verschillende cellen van de huid 
voorstellen, dan is bij eczeem het cement tussen de stenen verzwakt of verdwenen. Hierdoor 
is de barrierefunctie verminderd en is er een grotere doorlaatbaarheid voor mogelijk 
gevaarlijke stoffen van buitenaf. Dit manifesteert zich uiteindelijk in een allergische jeukende 
huidreactie. PCDHl komt ook voor in huid-epitheelcellen. Wij denken dat PCDH I zoals bij 
astma, ook bij eczeem kan bijdragen aan de integriteit van de huidbarriere, en zo aan de 
gevoeligheid voor het ontwikkelen van de aandoening. 
Uit onderzoek van hoofdstuk 2 is gebleken <lat PCDHl tot expressie komt in cellen 
van de luchtwegbekleding. Het gen protocadherine-1 is gelokaliseerd op het vijfde 
chromosoom. Een gen is een stuk DNA <lat bestaat uit exonen en intronen. De exonen 
bevatten de code die nodig is om eiwit moleculen te maken en wordt ook wel coderend DNA 
genoemd. De intronen bevatten vaak regulerende DNA codes en zijn niet coderend voor een 
eiwit. Om eiwitmoleculen van een bepaald gen te maken zijn eerst sjablonen nodig die de 
DNA code naar eiwit productiefabrieken brengen. Deze sjablonen zijn zogenoemde 
messenger RNAs (mRNAs) en zijn exacte kopieen van de coderende DNA sequenties, 
behalve <lat de letter T door een U vervangen is. Dit afschrijven van de DNA sequentie naar 
mRNA sequentie wordt ook wel transcriptie genoemd (zie Figuur IA). De mRNAs komen 
uiteindelijk aan in de eiwit productiefabrieken. De bouwstenen van eiwitten zijn aminozuren, 
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Nederlandse Samenvatting waarvan er 20 verschillende bestaan. Aminozuren kan je verge]ijken met de kra1en van een ketting. Een combinatie van drie mRNA basen (bijvoorbee]d AUG) staat voor een aminozuur of kraal . Zo wordt het hele mRNA molecuul in de fabriek vertaald naar een eiwit-molecuul en worden de bijbehorende aminozuren aan elkaar gekoppeld, wat resu]teert in een ketting van aminozuren. Dit proces wordt ook wel trans]atie genoemd (zie Figuur IB). De ketting van aminozuren kan gezien worden als een lange streng. Deze ketting wordt uiteindelijk nog in elkaar gevouwen om tot het uiteindelijke eiwit mo1ecuul te komen, wat resulteert in een eiwit­molecuu] met verschillende de1en die ieder een eigen functie hebben, de functionele domeinen. De expressie van een gen refereert dus naar de aanwezigheid van mRNA of eiwit moleculen waarvoor dat gen codeert in een bepaa]de eel. Van PCDHJ waren twee mRNA varianten bekend; een variant met 3 exonen (variant I )  en een variant met 5 exonen (variant 2). Beide varianten coderen voor een eiwit met zeven extrace11ulaire domeinen, terwij] de extra 2 exonen van variant 2 coderen voor geconserveerde intrace11ulaire domeinen die niet aanwezig zijn in de drie exon variant van het PCDHJ mRNA. De extracel1ulaire domeinen Jijken sterk op de domeinen van adhesiemoleculen, terwijl de functie van intrace11ulaire domeinen tot nog toe onbekend is. In hoofdstuk 4 hebben we onderzocht of er nieuwe of veranderde mRNA varianten van PCDH 1 tot expressie komen in epitheelce11en van astma patienten. Verder hebben we onderzocht wat er met de expressie niveaus van PCDHI gebeurd tijdens de uitrijping van luchtwegepitheelce11en (differentiatie) die wordt bereikt door de epitheelce11en tijdens weefse1kweek in het Jaboratorium bloot te ste11en aan lucht, net zoals <lat in het Jichaam gebeurt. Hierbij hebben we een aantal interessante observaties gedaan. Ten eerste vonden we nieuwe exonen aan de 5' kant van het 
PCDHJ-gen ('Jinks' van exon I :  voor het begin van het gen) die verschillend gebruikt worden door isovorm I en 2. Dit kan er op duiden <lat de twee varianten verschillend geregu]eerd worden. Ten tweede vonden we varianten die geconserveerde intrace11ulaire domeinen missen. Ten derde vonden we een nieuwe variant dat exon I en een deel van exon 2 mist en daardoor slechts twee extrace11ulaire domeinen en de intracellu]aire domeinen tot expressie brengt. Deze isovorm hebben we isovorm 3 genoemd. De hierboven beschreven resultaten geven de complexiteit van het PCDHJ gen weer, en tonen verschi11ende niveaus aan waarop 
PCDHJ gereguleerd kan worden (Figuur I B). Een belangrijke bevinding van hoofdstuk 4 was <lat zowel de mRNA als eiwit expressieniveaus van PCDHI toenamen tijdens het uitrijpen (differentiatie) van Juchtweg epitheelce11en. Dit zou kunnen betekenen <lat PCDHI een belangrijke rol speelt tijdens <lit proces, maar verder onderzoek is nodig om de exacte rol van PCDH 1 tijdens differentiatie te bepa]en. 1 83 
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Astma is een ziekte dat zowel door genetische als omgevingsfactoren veroorzaakt 
wordt. Bekend is wel, dat blootsteIIing aan omgevingsfactoren zoals sigarettenrook en 
huisstofmijt een versterkte hyperreactiviteit bij astmapatienten geven. PCDHJ blijkt in ons 
onderzoek bovendien sterker geassocieerd met bronchiale hyperreactiviteit en astma in 
families die zijn blootgesteld aan sigarettenrook, dan in families die niet zijn blootgesteld aan 
sigarettenrook. Daarom hebben we in hoofdstuk 5 onderzocht of PCDHI gereguleerd wordt 
door sigarettenrook en huisstofmijt in verschillende muismodellen. Eerst hebben we de muis 
en humane protocadherine-1 genen vergeleken. We vonden een erg hoge overeenkomst tussen 
mens en muis PCDHI, zowel op mRNA als op eiwit niveau. Bovendien vonden we in de 
muizenlong ook een derde isovorm, die alleen het intracellulaire stuk bevat dat gedeeld wordt 
met isovorm 2. Onderzoek van muis Pcdhl kan dus een goed model zijn van het menselijke 
PCDHJ. 
Vervolgens hebben we de invloed van huisstofmijt blootsteIIing op Protocadherine-1 
cxpressie onderzocht. Op ons laboratorium is een huisstofmijt muismodel voor astma 
gcvalideerd. Onder invloed van directe huisstofmijt toediening in de luchtwegen van de muis 
vcranderen de epitheelccllen in de muizcnlong naar slijmbeker ccllen die mucus produceren. 
Bovcndien vindt er een ontstekingsrcactic plaats en ontwikkelen de muizen luchtweg 
hyperreactiviteit. Wij vonden een verlaagde protocadherine-1 eiwitexpressie in de luchtwegen 
van de muis die blootgesteld waren aan huisstofmijt. Na een rustperiode van twee weken 
waarin geen huisstofmijt was toegediend zagen wij weer een toename van Pcdhl mRNA 
expressie niveaus. Dus: blootsteI ing aan huisstofmijt kan Protocadherine-1 expressie in de 
luchtwegen verlagen, dat later weer toeneemt in de herstelfase van het epitheel. Muizen die 
zijn blootgesteld aan sigarettenrook krijgen een ontstekingsreactie in de longen en 
ontwikkelen ook luchtweg overgevoeligheid. Wij zagen een directe afname van Pcdhl 
mRNA expressie in de longen van muizen die waren blootgesteld aan sigarettenrook. Een 
Iangere blootstelling zorgde voor een verdere verlaging van deze expressieniveaus. 
Sigarettenrook kan de epitheliale barriere verzwakken door het verbreken van de contacten 
tussen cellen. Wij stellen voor dat mensen die zijn blootgesteld aan sigarettenrook en die 
drager zijn van base-veranderingen in het PCDHJ-gen, uiteindelijk bronchiale 
hyperreactiviteit en astma ontwikkelen door een verlaging van de expressieniveaus van 
PCDHI en epitheliale adhesiemoleculen dat leidt tot een verlaagde barrierefunctie. 
Protocadherine-1 behoort tot de familie van adhesiemoleculen. Omdat Protocadherine-
1 een relatief zwakke adhesiefunctie heeft, is het de vraag of PCDHI ook nog andere functies 
uitoefent. In twee studies is beschreven dat het PCDH1 eiwitmolecuul mogelijk een fysieke 
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interactie aangaat met de signaalmolecuul SMAD3. SMAD3 is een molecuul dat s ignalen 
doorgeeft van membraangebonden Transforming Growth Factor � (TGF�) - receptoren, die 
geactiveerd zijn door de groeifactor TGF�, naar de kem van de eel. In de kem activeert 
SMAD3 de transcriptie van verschillende genen. Daardoor kunnen processen plaatsvinden 
zoals: (1) herstel van epitheel na schade en, (2) de verandering (!ransitie) van een �pitheelcel 
naar een bindweefsel of spiercel (mesenchymale eel) die uit de epitheellaag kan migreren 
(EMT). Verder is gebleken dat SMAD3 een rol kan spelen in differentiatie van epitheelcellen. 
In hoofdstuk 6 vragen we ons af of PCDH I ook als signaal molecuul zou kunnen 
functioneren. Daarom hebben we de lokalisatie van PCDH I isovormen in verschillende 
compartimenten van de bronchiale cellijn I 6HBE onderzocht en hun fysieke interactie met de 
signaalmolecuul SMAD3. We vonden een nieuw eiwitproduct van PCDH1 dat wordt 
uitgescheiden door de epitheelcellen (sPCDH 1 ). Dit eiwitproduct heeft geen intracellulaire 
domeinen en bestaat dus alleen uit extracellulaire domeinen. Verder vonden we een reeks 
kleinere eiwitproducten die alleen uit intracellulaire domeinen bestaan. Het mechanisme dat 
verantwoordelijk is voor het ontstaan van deze extracellulaire sPCDHl en intracellulaire eiwit 
producten is onbekend. Ten eerste kunnen deze producten zijn ontstaan door het knippen van 
de complete isovormen I en / of 2 door specifieke knipenzymen zoals metalloproteases. Ten 
tweede is het een mogelijkheid dat deze eiwit fragmenten zijn ontstaan door altematieve 
transcriptie, zoals voor isovorm 3. Als laatste bestaat de mogelijkheid dat deze eiwitproducten 
zijn ontstaan door afbraak van de complete isovormen I, 2 en / of 3 (Figuur 1 C). Omdat een 
deel van de intracellulaire eiwitfragmenten specifiek naar de kemmembraan lokaliseren, 
zouden ze bij kunnen dragen aan signalering. Het mechanisme achter het ontstaan van deze 
fragmenten en de mogelijke signaleringsfuncties behoeft verder onderzoek. 
In hoofdstuk 6 hebben we ook onderzocht of PCDH 1 een fysieke interactie aangaat 
met SMAD3 in de 16HBE cellijn. Door PCDHJ met een specifiek antilichaam uit de cellen te 
vissen vonden we dat SMAD3 meekwam met het 'opgeviste' PCDH1. Via deze procedure 
vonden we zowel een interactie van beide isovormen van PCDH 1 met SMAD3 als andersom. 
Dit is bewijs voor een directe interactie tussen SMAD3 en PCDH1, en opent nieuwe 
mogelijkheden voor onderzoek naar de functie van het PCDH1 eiwit. Door een interactie aan 
te gaan met SMAD3 zou PCDHJ het herstel van een beschadigde epitheellaag, of de transitie 
van epitheelcellen naar migrerende mesenchymale cellen (EMT) en differentiatie van 
epitheelcellen kunnen bei'nvloeden, allemaal processen die worden gereguleerd door de 
groeifactor TGF�. Het herstel van een beschadigde epitheellaag (wand) bestaat uit 
verschillende fasen. Ten eerste zullen de gezonde epitheelcellen die de wand omringen 
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moeten de-differentieren. Hierbij verliezen deze cellen hun functie als epitheelcel en 
verkrijgen ze een migrerende functie. Dit proces is vergelijkbaar aan EMT. Vervolgens 
kunnen ze zich gaan verplaatsen naar de plaats van de wond. Uiteindelijk moeten deze cellen 
weer di fferentieren om weer een functionele epitheelcel te vormen. PCDHl zou een rol 
kunnen spelen in al deze fases van epitheel herstel . Wij gaan uit van de hypothese dat mensen 
met astma die drager zijn van basepaar veranderingen van het PCDH 1 gen een verminderd 
functioneren of verlaagde expressieniveaus van PCDHl hebben. Daardoor worden proeessen 
als adhesie en differentiatie ontregeld, zodat het epitheel sleeht herstelt na schade en 
epitheelcellen niet goed differentieren. Dit kan leiden tot een epitheellaag die als het ware in 
een reparatiefase blijft hangen. Vervolgens raakt de epitheelbarriere verzwakt, wat 
uiteindelijk kan leiden tot bronehiale hyperreaetiviteit en astma. 
Concluderend, Protoeadherine- 1 is een gen dat zowel geassoeieerd is met astma als 
met eezeem. PCDHI komt hoog tot expressie in de bekledende eellen van de luehtwegen: het 
luehtwegepitheel. De transcriptie van PCDHI resulteert in versehillende mRNA varianten, 
waarbij grote versehillen zijn waargenomen in de expressie van sequenties die eoderen voor 
de intraeellulaire domeinen. Verder nemen de expressieniveaus van PCDHl toe tijdens het 
ui trijpen (de differentiatie) van epitheelcellen. Blootstelling van muizen aan 
omgevingsfaetoren zoals huisstofmijt en sigarettenrook verlaagt de expressie van PCDHI in 
de longen van muizen. PCDHI eiwit isovormen zijn ontdekt zowel buiten de eel 
(uitgeseheiden) als in de kem van de eel . Verder heeft PCDHI een fysieke interaetie met 
SMAD3 . Deze resultaten kunnen er op duiden dat PCDHI niet alleen een adhesiemoleeuul is, 
maar ook funetioneert als een signaleringsmoleeuul. Wij denken dat, door middel van de 
interaetie met SMAD3 en door het indueeren van expressieniveaus gedurende differentiatie 
van het epitheel, PCDH I een rol kan spelen in het herstel en de differentiatie van het 
luehtwegepitheel. In mensen die drager zijn van base veranderingen in het PCDHI gen, zou 
een verminderde funetie van PCDHI dus kunnen leiden tot een ontregeld herstel en 
ontwikkeling van het epitheel. Dit kan leiden tot een zwakkere epitheelbarriere, waardoor 
allergenen en andere omgevingsfaetoren gemakkelijker kunnen binnendringen en vervolgens 
een ehronisehe allergisehe reaetie veroorzaken, wat uiteindelijk kan leiden tot bronehiale 
hyperreactiviteit en astma. Ons uiteindelijke doel is om medicatie te ontwikkelen die gerieht 
is op het herstel van de PCDHI funetie waarmee de epitheelbarriere gestabiliseerd kan 
worden en weer volledige beseherming biedt. 
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Figuur 1: Ovenicht PCDHJ expressie, gen, mRNA en eiwit isovormen 
De luchtwegen in onze longen zijn bekleed met epitheelcellen, waarin Protocadherine-1 tot 
expressie komt. Elke eel heeft een celkem waarin het DNA zeer goed opgevouwen is (A). Het 
genomisch DNA (gDNA) bestaat uit verschillende genen die aangezet kunnen warden door 
een promoter. Elk gen bestaat uit exonen (zwarte box) en tussengelegen intronen. Bij 
transcriptie van het PCDHJ gen warden de vijf PCDHJ exonen afgeschreven in verschillende 
volgordes (transcriptie). De intronen warden later verwijderd, wat resulteert in drie PCDHJ 
mRNA varianten (B). Vervolgens warden de verschillende varianten weer vertaald naar eiwit 
isovormen (translatie). Deze eiwit moleculen kunnen mogelijk nog verder gemodificeerd 
warden, wat zau kunnen Leiden tot uitgescheiden PCDHJ (sPCDHJ) en intracellulaire 
producten (C). 
A. Longen: / Luchtweg epitheelcellen 
B. gDNA: 
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Dankwoord 
Het proefschrift is eindelijk klaar ! Voor mij is dit een afsluiting van een periode met 
vele hoogte maar ook enkele dieptepunten. Na het overlijden van mijn broer stond mijn ]even 
even stil... .. Na weer opgekrabbeld te zijn gebeurde drie jaar later aan het eind van mijn aio­
periode het ondenkbare. Mijn vader werd ziek en overleed .... Ik wil iedereen bedanken die mij 
en mijn familie gesteund heeft tijdens deze moeilijke periodes. Daarnaast waren er gelukkig 
ook veel mooie periodes. Gedurende mijn promotie heb ik veel leuke mensen ontmoet en 
prettig mee samengewerkt, zowel in binnen als buitenland. Natuurlijk wil ik iedereen 
bedanken, maar het zijn er teveel om op te noemen en het kan voorkomen dat ik vergeet 
iemand te vermelden. 
Het begon a11emaal in maart 2007, toen ik vanuit Wageningen hier naar Groningen 
kwam. Na eerst tijdelijk forens te zijn geweest, door te reizen vanaf mijn ouderlijk adres in 
Leeuwarden, vond ik uiteindelijk een kamer niet ver van het UMCG, dus lekker dicht bij het 
lab. Als eerste wil ik Debora bedanken voor het inwerken in het Protocadherine-1 labwerk. Je 
hebt me wegwijs gemaakt op de verschillende kweeklaboratoria. Daardoor heb ik veel 
opgestoken en met name over de wispelturigheid van onze I 6HBE cellijn. Resultaten 
gebaseerd op al je primaire kweekwerk zijn uiteindelijk mooi gepubliceerd in FASEB Journal. 
Mijn eerste werkkamer zat vlak na de brug. Dries, Benoit, Hadi & Soheila, bedankt 
voor de alle gezelligheid op de kamer. We wisten niet dat we daar weg moesten totdat ze 
plotseling in onze muren gingen boren en het bleek dat ze onze kamer gingen halveren. 
Ondertussen ben ik begin 2008 naar Nottingham University in Engeland gegaan om de 
techniek RACE te leren. Thanks for the warm welcome, Ian and Ceri. Lee, Janie, Emily, Asif, 
Imran and Javier, thanks for the nice time and parties in Nottingham, and the holiday at Ibiza. 
Terug gekomen in het UMCG verhuisden we naar de kamer die uitkeek op het 
personeelsrestaurant. Helaas was hier geen directe frisse lucht. Inmiddels zaten we daar met 
zes mensen, omdat Benoit was vertrokken en Dennie en Sijranke er bij waren gekomen. Oat 
bleek teveel omdat de warmte gegenereerd door deze hardwerkende aio's en de computers 
niet kon worden afgevoerd. Uiteindelijk zijn Hadi & Soheila naar een andere kamer verhuisd. 
Met Dennie en Dries heb ik nog veel lol beleefd op deze kamer. Dennie, de volgende keer als 
we je vastplakken aan de stoel zetten we je toch echt voor de kamer van de prof neer ! 
We hadden inmiddels een grote groep aio's op het lab. Roland zat op een andere 
kamer, maar ik denk dat we een aantal prachtige fietstochten hebben beleefd. Ik was blij dat 
ik jouw achterwiel kon volgen de zaterdagochtend vroeg op weg naar de Winsumer 
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Wierdentocht, want ik voelde de vrijdagborrel nog wel l We hebben toch maar mooi veel 
tocrtochten gefietst met Hans, Maaike en Renee. De vrijdagavondborre1 s1aan we zeker niet 
over. Deze labborrel werd eerst de laatste vrijdag van de maand gehouden in de Stadtlander, 
maar met Jan hebben we toendertijd besloten om de frequentie op te hogen naar een keer per 
week. Gelukkig waren er altijd wel slachtoffers te vinden die meegingen, zoals Irene, Harold, 
en de moleculaire farrnacologen Reinoud en Tonio, en later Eef. Het was gezellig discussieren 
en borrelen met iedereen. Zulke barrels zijn een goede afwisseling van het labwerk, zoals ook 
de woensdag - snackdag. Met Marco, Harold, Uilke, en de aio' s gezellig het broodje 
hamburger met kerrie-saus bij Cafe Prins naar binnen werken. Vervolgens gingen we 
noodgedwongen naar de wat minder hygienische brandgevaarlijke Chinese snackbar. 
Inmiddels had Debora ons lab verlaten en is Uilke het PCDHl -team komen 
versterken. Uilke, ik hoop dat je veel van me hebt opgestoken. Samen hebben we vele 
muizenlongen tot snot verholpen, en vele long coupes gekleurd en intensiteiten 
gekwantificeerd. Dat was niet altijd het leukste werk. Hopelijk wordt dit werk binnenkort nog 
gcaccepteerd voor publicatie. Ik denk dat we een goed duo vormden, natuurlijk bedankt 
hicrvoor en voor hct zijn van mijn paranimf. Machtcld en Wim bedankt voor de hulp met het 
interpreteren van de long kleuringcn. Later kwamen ook Mariska en Brigitte ons PCDHI­
team versterken. Mariska, bedankt voor het runnen van de vele westerns. Brigitte, wij hebben 
wat korter samen gewerkt, maar erg bedankt voor je hulp aan met name mijn laatste 
experimente1e hoofdstuk. 
De analisten op het lab wil ik natuurlijk ook bedanken: Jacobien, Simone, Lisette, 
Yo-Theo, Marnix, Marco, Harold, Janneke (wel Liwadders blijven praten hoor!), en uiteraard 
ook de diagnostiekers. Peter en Harold natuurlijk ook bedankt voor de plezierige werksfeer op 
het DNA lab. Dat maakte het opwerken van al die kolonies altijd een stuk gezelliger. Een 
persoon die nog niet in dit rijtje staat, maar specifiek bedank is Renee. Ik ben heel blij dat ik 
jou ben tegen gekomen en dat je mijn vriendin wilt zijn. Je was en bent mijn steun en 
toeverlaat. We hebben dieptepunten meegemaakt, maar gaan zeker nog vele mooie dingen 
beleven samen ! 
Natuurlijk wil ik ook mijn vrienden uit Leeuwarden bedanken. Jurjen, Jan en Frans, 
bedankt voor de gezelligheid tijdens de stapavondjes. Frans bedankt voor je vriendschap en de 
dinsdagavonden met gezellig eten, voetbal kijken en biertjes drinken. Ik ben blij dat je mijn 
paranimf wilt zijn ! Verder was er een welkome ski-afwisseling tijdens de slappe Nederlandse 
winters. Als schaatsende Fries wist ik niet of ik het echt leuk zou vinden, maar na de eerste 
vakantie was ik direct verkocht. John, Eline, en Jan, bedankt voor de leuke vakanties. 
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In de loop van de tijd kwamen er nieuwe aio's bij op verschillende projecten. 
Daardoor werd de kamerruimte wat krap, en omdat ik bovendien niet veel labwerk meer ging 
doen verhuisde ik naar de kamer in het Triade-gebouw, het terrein van Neomi. Neomi, sorry 
dat je geen harde muziek meer kan draaien, maar natuurlijk bedankt voor de gezellige tijd 
daar en de lunch met een overheerlijk soepje. Met Nicole heb je er weer een goede 
kamergenoot bij. Als jullie de strenge winters daar overleven komen er vast nog veel mooie 
IL IRL I publicaties. 
Natuurlijk wil ik ook de aio's die ik korter heb meegemaakt bedanken, Maaike, veel 
succes binnenkort in Southampton, en Laura en Daan met de immunotherapie en DAMPs. 
Verder wil ik natuurlijk de afdeling kinderlongziekten bedanken voor hun steun: Eric, Ewoud, 
Elianne, Bart, Christine, Hilde, Janette, bedankt. Natuurlijk ook de studenten Tanja en Olaf 
bedankt voor jullie bijdrage aan Protocadherine-1. Verder iedereen bij de GRIAC en Genetics 
meetings bedankt voor de input. Olga, ik hoop dat ik niet te vervelend werd met het vragen 
naar de biologische betekenis van de gevonden associaties. Marjan Kerkhof bedankt voor je 
hulp met de analyses van PCDH I en eczeem. 
Ook wil ik de leescommissie, bestaande uit Prof. John Holloway, Prof. Pieter Hiemstra 
en Prof. Frans van Roy bedanken voor hun tijd en aandacht aan de beoordeling van dit werk. 
Verder wil ik ook de sponsors van dit proefschrift bedanken. 
Dan zijn we nu aangekomen bij mijn begeleiders. Martijn, de hoeveelheid commentaar 
die je geeft op een manuscript is volgens mij omgekeerd evenredig met de hoeveelheid wijn 
in de fies ! 1k verheugde me altijd op de 100+ comments .... Zeker is dat de artikelen er stukken 
beter van werden. Dirkje en Antoon, bedankt voor jullie input tijdens alle besprekingen en 
jullie commentaar op de artikelen ! Dirkje, ik vind het erg jammer dat je niet bij de promotie 
kan zijn, maar wens je natuurlijk veel plezier op je sabattical. Uiteraard wil ik ook Gerard 
bedanken. Zonder jou was het PCDH I project er waarschijnlijk niet geweest. Jouw drive om 
dit gen functioneel te karakteriseren heeft altijd motiverend gewerkt. Het was altijd plezierig 
samenwerken. Bedankt ook voor het begrip en de ondersteuning in de moeilijkere periodes 
van mijn aio-periode. Dit heeft mij erg geholpen. 
Als Iaatste wil ik mijn familie bedanken. Mero, Boukje, Chris, Judith, Renee, we 
hebben samen deze moeilijke periodes doorgemaakt. De komende tijd zal ook niet altijd 
gemakkelijk zijn, maar met elkaar slaan we ons er wel doorheen ! 
Zo komt een bijzondere periode tot zijn einde. Al met al hoop ik dat iedereen de 
samenwerking met mij ook prettig vond. Het ga jullie allemaal goed! 
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